

**1) Definitions<sup>1</sup>**

**Substance Use Disorder (SUD):** uncontrolled use of a substance leads to adverse consequences (e.g. health, or problems at work, school or home). More severe SUDs are may be called addictions.

**Addiction's 4Cs:** LOSS of **control** over substance use WITH **craving** &/or **compulsive** use which is **continued despite consequences**.

**Dependence, physical:** a state of adaptation resulting in drug class-specific **withdrawal symptoms** upon abrupt dose reduction, decreasing drug levels or antagonist administration.

**Detoxification-managing acute withdrawal:** treatment to remove the physiological effects of the addictive substances (protocols).

- **Social Detox:** managed & engaged in recovery; 3-10+ day stay.

- **Brief Detox:** ~24 hour observation; not medically managed.

**Harm Reduction:** measures to ↓adverse health, social, economic consequences of SUD, to individuals, families & communities without necessarily requiring abstinence or cessation of drug use.

**Tolerance:** ↓effect of a drug over time, or ↑dose required for effect.

⇒ **Tolerance & physical dependence should not be confused with addiction.** Addiction is characterized by compulsive use of a substance or preoccupation with obtaining it despite evidence that continued use causes harm (physical, emotional, social, economic).<sup>2</sup>

**2) A Sampling of Statistics (CTADS 2017<sup>3</sup>; CADUMS 2011/12; PHAC 2021)**

- Prevalence, past 1yr: any tobacco (18%), e-cigarette (3%); illegal drugs (3%), cocaine (2%), ecstasy (1%), hallucinogens (1%); problematic psychoactive use to get high or other (i.e. opioid, stimulant, tranquilizers & sedatives, 5%).
- The **rate of drug use** cocaine or crack, speed, ecstasy, hallucinogens (including saliva) or heroin **by youth 15-24 yrs** is much higher (6.5%) than reported by adults ≥25 yrs (1.2%).
- 72% of non-medical opioids used by students were obtained from home.<sup>4</sup>
- The **prevalence of harm** 4x higher among youth aged 15 to 24 yrs (5.5%) than adults aged 25+ yrs (1.4%). (Age adjusted mortality ↑ 5x in urban SUD <sup>Boston</sup> <sup>5</sup>)
- {Harm related to social life, health, work, studies, employment, financial, legal, housing, learning.}
- ~10% report drugs/alcohol as reason for 1<sup>st</sup> ever sexual intercourse.<sup>6</sup>
- **Opioid toxicity deaths:** over 5yrs 2016-2020, there were 21,174. In 2020, half also involved stimulants. An ↑89% was seen during the COVID-19 pandemic.<sup>57</sup>
- Factors: ↑ toxicity of drug supply, ↑ isolation/stress; ↓ access to services

**3) Principles of SUD Treatment<sup>7</sup>**

- 1) No single tx is appropriate for all; concomitant medications are useful for many; tx needs to be readily available
- 2) **For success, attend to multiple needs, not just drug use**
- 3) Assess for medical, family, vocational, social & legal services
- 4) Ensure adequate time in treatment (≥3 months)
- 5) Arrange for counselling & behavioural tx
- 6) Integrate tx for those with mental disorders
- 7) Acute detoxification is only the 1<sup>st</sup> stage of tx
- 8) Tx does **not** need to be voluntary to be effective
- 9) Drug & alcohol use monitoring should be ongoing
- 10) Assess for HIV/AIDS, HBV, HCV, etc., & counsel re. harm reduction
- 11) Expect a long-term, life-long recovery process with relapses
- 12) Individualize support programs, e.g. self-help & spiritual

**Life worth living, without using!**

**4) SUD Screening: CAGE-AID, AUDIT, Other e.g. SASSI<sup>8</sup>**

**C** – Have you ever felt a need to **Cut down** or **Change** your drinking/drug use?

**A** – Do you get **Annoyed** when others criticize your drinking/drug use?

**G** – Have you ever felt **Guilty** about your drinking/drug use for any reason?

**E** – **Eye-opener:** Have you ever felt the need for a drink/drug use early in the morning to steady nerves, decrease hangover or withdrawal?

When assessing a patient's answers to the above questions: one YES suggests caution; ≥ 2 YES suggests strong caution/need for vigilance.

<b>AUDIT: questions to assess alcohol use<sup>9</sup></b>	0	1	2	3	4
1) How often do you have 1 drink containing alcohol?	0	≥monthly	2-4x/mo	2-3x/wk	4+ x/wk
2) How many drinks do you have on a typical day?	1-2	3-4	5-6	7-9	10+
3) How often do you have 4+ drinks on one occasion?	0	< 1/mo	1/mo	1/wk	~daily
4) How often last year were you not able to stop drinking?	0	< 1/mo	1/mo	1/wk	~daily
5) How often last year did you fail to do what was expected?	0	< 1/mo	1/mo	1/wk	~daily
6) How often last year have you needed a drink in the morning?	0	< 1/mo	1/mo	1/wk	~daily
7) How often last year have you had a feeling of guilt after drinking?	0	< 1/mo	1/mo	1/wk	~daily
8) How often last year have you not remembered the night before?	0	< 1/mo	1/mo	1/wk	~daily
9) Have you/someone else been injured as a result of drinking?	No		Yes, not this yr.		Yes, this yr
10) Has a relative, friend or doctor been concerned about your drinking?	No				
<b>Total score: 0-7=low risk; 8-15=at risk; ≥16 likely problems</b>					

**Single Question Screen:** ⇒ How many times in the past year have you used an illegal drug or prescription med for nonmedical reasons?

**History** – Use a non-judgmental, non-stigmatizing approach:

Ask first about socially acceptable drugs: caffeine, nicotine  
Ask next about CBD & alcohol, specifically beer & wine; quantity used.  
Then ask about high-potency cannabis, & illicit drugs. Don't rely on intuition!

⇒ Are illicit drugs available at school/work? What triggers craving?  
⇒ Do you have any close friends who sometimes use drugs?

Obtain collateral information from family & friends as necessary;  
confirm patient history & assess for recent behaviour changes.

Ask re. weight loss, sleep disturbance, impotence, gambling, porn.

**Physical findings (intoxication, withdrawal, other):**

- Evidence of associated infections, hepatitis, HIV, oral thrush
- Needle marks, including hidden sites; STDs; pupil size, ↑HR, runny nose, watery eyes, sweating, slurred speech, yawning, unsteady gait
- Lab: LFTs, HBV/HCV/HIV & drug screens (e.g. UDT as at bottom of page)

**5) RED Flags – Aberrant Rx Drug Use<sup>10,11</sup>**

**Consider: Brief Intervention/Discontinuation/Referral if...**

1. Prescriptions from multiple physicians (check prescription profile)
2. Frequent visits to emergency room requesting drugs of abuse
3. Requests from patients outside local area! Check picture ID!
4. Stolen, modification or tampering of prescriptions
5. Polypharmacy with CNS depressants, habituating substances
6. Forgery, selling, stealing, or using other persons' medications
7. Injecting oral or chewing long-acting formulations

**Reassess Regimen &/or Treatment Agreement if...**

1. Rapid ↑ in doses e.g. opioid especially if ≥ 90mg morphine equivalent in CNCP
2. Frequent early refills, excuses for running out of, or losing Rx's
3. Aversion to concurrent recommended non-opioid tx or UDT
4. Request for brand-name vs generic & short vs long-acting meds
5. Missed follow-up visits, lack of adjunct analgesic refills

**6) Adopting a Continuum of Care Approach for Substance Use Disorders<sup>12</sup>**

CONTINUUM OF CARE	HARM REDUCTION	Screening	Identify those who may be at risk
		Assessment	Diagnose, assess severity, & intensity of tx needs
		Brief Interventions <i>Ask, Assist, Advise</i>	Provide harms info; explore motivation to change
		Special Access Clinics	Option of specialist involvement when needed
		Community Outreach	Education, harm reduction resources, referrals, outreach programs
		Withdrawal Management	Interim pharmacological & psychological supports
		Pharmacological Interventions	Sometimes an option to help achieve desired outcomes in SUD
		Psychosocial Interventions	CBT, contingency management, counselling
		Recovery, Sustaining Wellness & Ongoing Care	Ongoing supports, formal & informal, to help change lifestyle & behaviour

**A SUD is a chronic disease. Patients with a SUD will require acute & ongoing intervention. A continuum of care approach supports patients in accessing various levels & intensities of care over time. An effective team approach is often the critical factor toward a successful outcome.**

**Best Practices (Adapted)<sup>13</sup>**

- 1) The individual experiencing harm should determine ultimate **goal** of treatment (e.g. safer use, substitution therapy, abstinence, etc.) with input from provider
- 2) **Determine treatment plan together.** Offer stepped care with least intensive services first (collaborate; offer menu of options)
- 3) Assess, address, coordinate all wellbeing components
- 4) Ensure services are **culturally, trauma & gender informed**
- 5) **Reduce stigma** to overcome major recovery barriers
- 6) Peer-engaged and peer-led services help with trust
- 7) Enhance outcomes by being **recovery-oriented**

💡 **Harm Reduction Measures (See chart)**

**1) Address risks for other diseases** (e.g. HIV, Hep C, syphilis)<sup>14</sup>

- a) screening, b) needle distribution & exchange programs, c) vaccinations, d) counselling regarding risky behaviours, e) safer smoking options, f) referral, related services g) oral hygiene

**2) Educate regarding responding to overdose** (including recommending take-home naloxone; [see chart](#))

**3) Inform re supervised consumption services when available**

**A non-judgmental attitude is a key for success!**

**Emerg Presentation & Possible Causes:** • **Unresponsive:** hypoglycemics, opioids, EtOH, cyanide, CO, tranquilizers, hydrocarbons, barbs. • **Seizures:** hypoglycemics, amphetamines, cocaine, hallucinogens, anticonvulsants, TCAs, PCP, mescaline. • **Hyperthermia:** salicylates, Ecstasy, atropine, phenytoin. • **Hypothermia:** EtOH, opioids, sedative/hypnotics, TCAs, barbs, CO

**Links:** WHO: [http://www.who.int/topics/substance\\_abuse/en/](http://www.who.int/topics/substance_abuse/en/); Medline Plus: <http://www.nlm.nih.gov/medlineplus/substanceabuseproblems.html>; AAFP: <http://familydoctor.org/familydoctor/en/diseases-conditions/opioid-addiction/treatment.html>; National Institute on Drug Abuse: <http://www.nida.nih.gov/>; Community Learning Network (CLN): [http://www.cln.org/themes/substance\\_abuse.html](http://www.cln.org/themes/substance_abuse.html); Opioid & Stimulant Identification pics: <sup>16</sup>

**Links-CDN:** Canadian Centre on Substance Abuse (CCSA): <https://www.ccsa.ca/>; CAMH: <http://www.camh.net/>; SK link<sup>17</sup> **Pregnancy/Lactation:** <http://www.camh.net/pregnancy/>; National Anti-drug Strategy: <http://www.nationaldrugstrategy.gc.ca/index.html>; Éduc'alcool: <http://www.educalcoool.ca/en/>; RxFiles AUD link: <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-Alcohol-Use-Disorder.pdf>

**Responding to aberrant behaviour:** Do not debate the motive; rather get agreement that such behaviour is problematic. Then delve into the root cause of the problem.  
**Do's:** Educate - Celebrate Success - Encourage - Implement Non-drug Approaches e.g. for insomnia - Prescribe Exercise & Healthy Eating - Find Support Groups

💡 **Urine Drug Screening (UDS):** to monitor medication compliance & identify/manage SUD risks.

- **Immunoassay:** rapid, inexpensive & preferred for initial screening. **Chromatography:** ↑\$, delay but ↑ accuracy.
- Assess drug causes for false positives. • Ensure proper collection technique & integrity of specimen.
- Goal is to improve patient care & communication, NOT to police!!! Discuss unexpected results with patient.
- Is prescribed drug there? Are any non-prescribed drugs there? • [See UDS chart](#)
- If issues identified, advise of consequences, tighten boundaries, refer to addiction service/specialist when necessary

Drugs/Substances of Abuse & slang terms		Signs/Symptoms: Overuse/Health Concerns		Management & Treatment Options; Comments <sup>18,19</sup>					
Opioid/Opiate	<b>Cannabinoids</b> <sup>20</sup> {THC = delta-9-tetrahydrocannabinol}	⇒ euphoria, impairment learning & reaction time, ↑ accidents MVA; panic, confusion, ↓ balance, coordination; ↑ HR, ↓ BP <sup>orthostatic</sup> , ↑ appetite		<b>Acute intoxication:</b> 1-3 hour; similar to alcohol; changes in mood, perception & fx ↑ accidents can persist					
	<b>Hashish</b> dried hemp flower resin - boom, hash, hemp	Synthetic: ↑ psychosis risk; renal synthetic		<b>Withdrawal syndrome:</b> anger, anxiety, irritable, insomnia, etc. Peak ~2-6 days ⇒ CBT & supportive tx					
	<b>Marijuana</b> dried hemp - dope, grass, joints, pot, weed	↑ potency = ↑ risk		Legal cannabinoids for medical use: ⇒ consider if indicated: see <a href="#">RxFiles Cannabis Chart</a> <sup>21</sup>					
	<b>cannabis</b> blunt/shatter/budder/crumble; concentrates (↑ potency = ↑ risk) {may be "spiked" with cocaine, meth, methylphenidate; pesticides} ganja	⇒ <b>assoc. problems:</b> physical, psych, financial, legal & social (failure to achieve), ↓ testosterone gynecomastia; hyperemesis (rare)		{Urine drug testing (UDT) available; remains +ve: 1-3 days with single use, ~10 days casual use, 2-4 weeks in heavy use, months in chronic heavy use. NOTE: nabilone does not show up on UDS} (See chart <a href="#">pg 139-140</a> )					
Sedatives CNS Depressants	<b>Hallucinogens, Misc</b> {Δs: perceptual, cognitive, ECG}	⇒ altered state of perception & feeling; persisting flashbacks		<b>LSD:</b> most potent; psychedelic effects: onset <1 hour; duration <8 hours; psychotic effects persist 2+ days					
	<b>LSD</b> lysergic acid diethylamide - acid, cubes, microdot, ...	⇒ ↑ body temp, HR, BP; ↓ appetite, ↑ 5HT, ↓ sleep, weakness, tremors (LSD & mescaline); mental disorders long-term (esp LSD)		Treatment: ⇒ provide calm, supportive environment [still used in college; squares on eyes to absorb]					
	<b>Other: Mescaline</b> buttons, cactus, mesc, peyote; <b>Psilocybin</b>			<b>Psilocybin:</b> magic mushroom, purple passion; chewed ⇒ nervousness, paranoia. <b>Mescaline:</b> usually turns out to be something else					
	<b>Codeine</b> +/- acetaminophen - cody, doors & fours, lean, loads, ...	⇒ analgesia, euphoria, drowsiness, nausea, constipation, confusion, ↓ libido/ED, sweating; sleep apnea. On overdose: resp. depression <12/min, coma; ↑ death esp with benzos/gabapentin <sup>23</sup>		<b>Acute toxicity:</b> ⇒ reversed by naloxone <b>MARCAN</b> , an opioid antagonist 0.4 - 2mg IM, may repeat after 2-3 minutes, Max 10mg; or intranasal					
Stimulants	<b>FentaNYL</b> <b>DURAGESIC</b> - China girl, TNT, Tango & Cash	If heroin ⇒ staggering gait; possible cardiac manifestations (due to ↑ QT)		Lasts 45 min-4 hours. May precipitate withdrawal (agitation severe, anxiety, N/V/D, yawn, sneeze, rhinorrhea, cramps). (Deaths often associated with co-use of other CNS depressants. Contaminants: MPTP parkinsonism, quinine, strychnine).					
	<b>Heroin</b> diacetylmorphine - brown sugar, H, junk, skag, smack	⇒ seizures (especially propoxyphene <b>DARVON-N</b> , meperidine <b>DEMEROL</b> , tramadol, combo pentazocine <b>TALWIN</b> + tripeleminamine <b>T's &amp; blues</b> )		<b>Withdrawal:</b> lacrimation, rhinorrhea, yawn, dilated pupils, N/V/D, diaphoresis, chills, ↑ HR & BP, myalgia, cramps; anxiety, dysphoria, craving, restless, insomnia, fatigue. ♦onset <8 hrs from last use; peaking between 36-72 hrs; physical withdrawal resolves in 5-10 days; longer with methadone onset in 24-48 hrs; persists 2-3 wks.					
	<b>HYDROMORPHONE</b> - <b>DILAUDID</b> , dillies, dilly-2 or -4, beads	⇒ long-term tolerance, hyperalgesia;		<b>Symptomatic Tx of Withdrawal:</b> see chart <a href="#">pg 133</a> (Consider local protocols) <sup>24</sup> . Overall goals in opioid use disorder (OUD) are to achieve recovery through ↓ withdrawal symptoms, manage/↓ cravings, prevent relapse, ↓ harm. Core components include: opioid agonist therapy (OAT) with buprenorphine or methadone. [See OUD/OAT chart, <a href="#">pg 136-138</a> ]					
	<b>HYDROcodone</b> combo's - Vike, Watson-387.	Desomorphine <b>KROKODIL</b> : homemade inj; corrosive; necrotize tissue; green scaly lesions		<b>Buprenorphine:</b> partial μ-agonist: e.g. PO buprenorphine + naloxone <b>SUBOXONE</b> ; SC buprenorphine <b>SUBLOCODE</b> ; Implant buprenorphine <b>PROBUPHINE</b>					
Various	<b>Meperidine</b> <b>DEMEROL</b> - demmies.	♦ Be careful to distinguish between appropriate use versus an opioid use disorder; there is some overlap in presentation		<b>Methadone:</b> very LA μ-opioid agonist; daily admin; Many DIs: e.g. ↑ QT. OAT: ↓ cravings: prevent withdrawal without intoxication.					
	<b>Loperamide</b> <b>IMODIUM</b> central opioid @ >70mg/day - poor man's methadone	♦ Always check med profile for hx of opioid, benzo, etc. use!		<b>Clonidine:</b> α-2 adrenergic agonist; non-opioid withdrawal tx option. <b>Harm reduction: e.g. Provide naloxone kit!</b>					
	<b>Morphine</b> <b>MS CONTIN</b> - M, the down, Miss Emma, ...	♦ Address withdrawal: with tapering or opioid agonist therapy		<b>Naltrexone:</b> opioid μ antagonist block analgesia & euphoria; -50mg/d; hepatotoxic if high dose FDA. <b>VIVITROL</b> monthly FDA					
	<b>Opium</b> - big O, black stuff, gum, hop	♦ ↑ Overdose risk if restart same dose after abstinence period!							
Sedatives CNS Depressants	<b>Oxycodone</b> <b>OXY-CONTIN</b> , <b>OxyNEO</b> - Oxy, O.C., killer.	{Contaminants may be an issue; e.g. heroin-anthrax <sup>22</sup> , botulism. If prescribing opioids, counsel to store properly & avoid sharing!!! }		<b>Respiratory Depression &amp; Coma:</b> ⇒ tx intubation & ventilation; Hypoglycemia (e.g. with excessive EtOH in kids); ⇒ tx IV glucose					
	<b>Alcohol</b> <sup>25,26,27</sup> - EtOH, booze, liquor ...	{zero-order kinetics} ⇒ major fetal harm (FASD)		<b>Alcohol:</b> Social Norms Interventions (limit to "moderate drinking" & avoid binge drinking.) Consider cultural factors.					
	<b>GHB</b> Gammahydroxybutyrate - G, grievous bodily harm, liquid ecstasy	GBH, soap, easy lay; "date rape"; clear liquid often mixed (EtOH)		<b>Long-term Skills Interventions</b> (e.g. drinking myths, drink refusal & assertiveness skills): ↓ over-drinking risk					
	<b>Flunitrazepam</b> - R2, Roche, roofies/roofied, rope	⇒ withdrawal esp if >40drinks/wk: tremor; Lab clues: ↑ MCV, ↑ GGT; ↑ ca		<b>Stimulus Control</b> (avoid/limit friends & places visited); Coping Skills; 12 Step Facilitation Therapy <a href="http://www.sagapads.com/12s.htm">http://www.sagapads.com/12s.htm</a>					
Stimulants	<b>ROHYPNOL</b> - "date rape"; forget me pill; roofinol	⇒ HA, loss of reflexes, memory; seizures, coma, death Resp depr		<b>DrugTx: Acute:</b> benzos for tremor (diazepam; lorazepam if hepatic dysfx or elderly; gabapentin <sup>28</sup> ; pregabalin <sup>29</sup> ); thiamine-see pg 221. ↑ clonidine					
	<b>Barbiturates</b> - barbs, reds, phennies, yellows	⇒ visual & GI disturbance; drowsy; urinary retention; memory loss		<b>Long-term Naltrexone</b> <b>ReVIA</b> , <b>DEPADE</b> : <b>Acamprosate</b> <b>CAMPARAL</b> ✓. Topiramate off label <sup>30</sup> See <a href="#">Alcohol Use Disorder (AUD) Chart</a> , pg 221-222					
	<b>Benzodiazepines</b> - candy, downers, sleeping pills	⇒ depression, irritable, dizzy		<b>Disulfiram</b> compounded from powder <b>ANTABUSE</b> ; blocks ALDH enzyme inducing dizziness, flushing, N/V, ↓ BP (aversion treatment);					
	<b>Ativan</b> , <b>Halcion</b> , <b>Librium</b> , <b>Valium</b> , <b>Xanax</b> Alprazolam, Etizolam, [benzos]	⇒ sedation, dizzy; tolerance/dependence		<b>GBH:</b> onset rapid ~10min; duration ≤2-4 hrs. Flunitrazepam: onset rapid 15min; duration ≤6 hrs. Gabapentin 900-1800mg/d ✓					
Stimulants	<b>Methaqualone</b> - ludes, mandrex, quad, quay	⇒ euphoria, depression; coma		<b>Oral benzodiazepine:</b> Acute intox. rarely lethal, except with alcohol or CNS depressants; ⇒ flumazenil <b>ANEXATE</b> inj (benzo antagonist): useful but may cause acute withdrawal/seizures; avoid routine use. Long-term withdrawal: diazepam or clonazepam tapering protocols					
	<b>Amphetamine</b> <b>DEXEDRINE</b> - bennies, speed, uppers, ...	⇒ tremor, ↓ coordination, irritable, restless, aggressive; IV trackmarks		<b>Cocaine:</b> onset ~5 min; peak/duration: snort <30-60 min, oral <90min, IV <5min; t½=1 hr; longer in body packers } most toxicity too brief to tx; anxiety/seizures/↑ temp ⇒ benzodiazepine; ↑ BP ⇒ nitroprusside/NTG; CV toxicity ⇒ BZ					
	<b>Methylphenidate</b> <b>RITALIN</b> ( <b>CONCERTA</b> has ↓ abuse risk!)	⇒ hallucinogen mild; impairment; ↓ Na <sup>+</sup> , ↑ temp; toxicity (cardiac, renal & hepatic)		↓ sympathetic stimulation, ASA ↓ thrombus, NTG (or CCBs: verapamil or diltiazem) ↓ vasoconstriction, O2. (β-blockers: caution!) Sinus bradycardia long-term.					
	<b>MDMA</b> 3,4-methylenedioxymethamphetamine, Ecstasy - E,X,XTC	adulterants common: Adam, lover's speed, hug, clarity, Molly		<b>Amphetamines</b> other: similar toxicity (& tx) as cocaine but ↓ duration. Strokes: hemorrhagic & ischemic. Life-threatening hyperthermia >39°C! Psych sx's may persist. Meth: duration 6-8hr; tooth decay. Ritonavir: DI & ↑ risk fatal overdose. <sup>31</sup>					
Various	<b>Methamphetamine</b> - crystal meth, speed, ice, pint, jib, gak, (made from pseudoephedrine) glass, white, lady, fire, tina, pink, chalk, crank	⇒ aggression, violence, psychotic behaviour; CV & neurological damage		<b>Ecstasy:</b> onset: 20 min; peak: 2-3 hrs; duration: ~4 hrs. Amphetamine like CV effects, rhabdomyolysis, stroke, death <sup>32</sup>					
	<b>Amphet. analogues</b> designer drugs: [MDA love drug, MDEA Eve; PMA Death (similar to MDMA); MDPV bath salts]	⇒ ↑ SHT: ↑ HR, BP, energy, wt loss; hyperkinesia, alertness; ↓ appetite, insomnia, nervousness; violence?; ↑ Parkinson's risk? ⇒ high follow for the crash! lethargy, anhedonia, ↑ sleep, irritable ⇒ HF, MI, CVA; seizure, hyperthermia, abruptio.		Seizures common cause of ER visits ⇒ usual tx; persisting cognitive impairment. Contaminants (amphetamines e.g., PMMA) ⇒ lethal overdose (Hyperthermia: tx with rapid cooling, etc. +/- dantrolene or cyproheptadine). Ritonavir: DI, ↑ risk fatal overdose. <sup>33</sup> Young-healthy: high risk					
	<b>Cocaine</b> <i>Erythroxylum coca leaf</i> - blow, C, candy, coke, snow, adulterants common (e.g. levamisole, snowflake, Charlie, dust)	⇒ ↑ temp, chest/GI pain, resp failure; HA, seizure, panic; MI, vasoconstriction; talc ⇒ pulm fibrosis, HTN; long-term ⇒ excited delirium, rhabdomyolysis; "coke nose" or deviated nasal septum common with long term use (irreversible; requires plastic surgery)		⇒ Long-term: memory/motor impairment; psychosis; MI chest pain, stroke ICH. (↑ DA & ↑ NE release.) Explosive/ fire risk if making! <sup>34,35</sup>					
	<b>clenbuterol</b> , <b>benzocaine</b> , <b>sugar</b> , <b>talc</b> <sup>36,37</sup> ; crack freebase, solid (smokeable), 92% pure			<b>Stimulant Use Disorder Tx:</b> behavioural tx e.g. CBT; insufficient evidence for pharmacotherapy [See <a href="#">chart pg 220</a> ]					
Various	<b>Dissociative Anesthetics</b> (floating, out of body)	⇒ impaired motor fx, memory loss, numbness; ketamine ↑ HR, ↑ BP		<b>Ketamine:</b> duration <1-2 hour, dose dependant. Common: accidental trauma, urinary symptoms, abdo pain.					
	♦ <b>Ketamine</b> Ketalar SV - K, Kat, cat Valiums, Special K	⇒ ketamine: delirium, depression, respiratory depression, ↓ bladder capacity		<b>PCP overdose:</b> may last several days causing psychosis & violence; ⇒ Tx: restraints & BZs					
	♦ <b>PCP</b> Phencyclidine - angel dust, love boat, peace pill	⇒ PCP: ↓ BP, ↓ HR; panic, aggression, violence; ↓ appetite		⇒ supportive tx: BZ for seizures, external cooling for hyperthermia (block NMDA receptors)					
	<b>Steroids, Anabolic</b> - Andriol, testosterone, andro, etc; nandrolone, androsterone, stanozolol {common in unapproved products}	⇒ acne, hostility, aggression; long-term ↑ BP, ↓ clotting, ↑ stroke, hepatic cysts/ca, renal ca; premature growth stagnation, depression		<b>Abused:</b> by athletes/body-builders (along with: stimulants, darbepoetin, DHEA, diuretics, erythropoietin, human growth hormone; creatine, protein)					
Various	<b>Volatile Inhalants</b> - solvents, gases, nitrites whippets N2O {toluene: paint, lacquer, glue}, poppers liquid gold, rush; puffers	⇒ stimulation, ↓ inhibition, HA, N/V, slurred speech, ataxia, ↓ coordination, cramps, ↓ wt, depression; resp depr, coma		♂: prostate ca, ↓ sperm, ↓ testicular size, gynecomastia; ♀: menstrual irregularities, hirsutism, etc.					
	<b>Other:</b> Baclofen; <b>BuPROPION</b> deaths reported with inj & inhalation; <b>Caffeine:</b> e.g. energy drinks <sup>38</sup> ; wt loss <sup>39</sup> , withdrawal esp if >100mg/day (HA 50%, fatigue, drowsy, irritable), over ≤ 9 days. <b>Dextromethorphan (DM):</b> euphoria at 5-10x usual dose → <b>Robotripping</b> (sweat, ↑ HR, ↑ BP, dyskinesias, speech disorders, N/V, mydriasis, photophobia, ↓ resp), ↑ 5HT; blocks NMDA. <b>Dimenhydrinate</b> & <b>Diphenhydramine:</b> <b>Gabapentin</b> <b>NEURONTIN</b> (gabie) snort/inject high dose for euphoria (400mg caps of choice); potentiate or ease withdrawal from alcohol, cocaine. <sup>40</sup> Oxybutynin; Pregabalin <b>LYRICA</b> ~euphoria			⇒ damage to CV & brain/nervous system; ↑ sudden death cv. {Toluene: ↓ K <sup>+</sup> , ↓ phosphate, renal tubular acidosis, abdominal pain, ataxia (may be permanent), resp failure ⇒ supportive tx? <sup>41</sup> Vit B12; avoid arrhythmogenics eg. epinephrine.}					
	4%: <b>Propofol</b> health professionals. <b>QUETiapine</b> <b>SEROQUEL</b> <sup>41</sup> (quell, baby heroin, Susie-Q, Q-ball = Q + cocaine); PO, intranasal, & IV cooked, then injected; use ↓ BZ withdrawal, as sedative/anxiolytic or ↑ heroin effect; dose reported ~200mg-2400mg/d; alternatives antipsychotics, SSRIs, buspirone, VPA, lithium.								
	<b>BP</b> =blood pressure <b>BZ</b> =benzodiazepine <b>ca</b> =cancer <b>CV</b> =cardiovascular <b>DM</b> =diabetes <b>ED</b> =erectile dysfx <b>FAS</b> =fetal alcohol syndrome <b>fx</b> =function <b>HA</b> =headache <b>HCV</b> =hepatitis C <b>Hep</b> =hepatitis <b>HR</b> =heart rate <b>LA</b> =long-acting <b>LFTs</b> =liver fx tests <b>N/V/D</b> =nausea/vomiting/diarrhea <b>sx</b> = symptoms <b>tx</b> =treatment <b>wt</b> =weight								
<b>Other:</b> Gambling, gaming, porn, sexual addictions/behaviours & intimate partner violence may also be present/require tx. <b>Club Drugs</b> <sup>42</sup> : Ecstasy, Rohypnol, ketamine, crystal meth, GHB, poppers. <b>Nicotine</b> [See chart, <sup>42</sup> ]: cigarettes, cigars, snuff, chew, hookah ⇒ ↑ CV/ca									
<b>Impurities/Adulterants:</b> common! Risk of: bacterial (endocarditis, osteomyelitis, sepsis), fungal, viral (HIV/AIDS) infection in IV users (needle sharing) & crack cocaine smoking <sup>43</sup> . Bleach in meth, Talc from tabs crushed for inj. causes pulmonary granulomas. Levamisole rash, neutropenia. Lead.									
<b>Pregnancy:</b> <sup>44</sup> Club drugs (MDMA, Rohypnol, GHB, ketamine), <b>Cocaine</b> , <b>EtOH:</b> avoid (malformations/abortion), <b>Amphetamines:</b> weigh benefit/risk; not teratogenic. <b>Cannabis:</b> avoid (↓ cognitive development/? stillbirth risk). <b>Opioids:</b> Opioid Agonist Therapy (OAT) ↓ risk (See <a href="#">pg 135-136</a> )									



## Management Of Substance Abuse In Emergency {To contact poison centre in your Canadian province: <http://capcc.ca/provcentres/centres.html> }

**Aim:** ↓ morbidity & mortality; ↓ risk of relapse;  
consider plan short & long term

### Assessment & Management issues:

- **Infections:** soft tissue; other (endocarditis, HIV, hepatitis, etc.)
- **Overdose vs Intoxication vs Withdrawal vs Other**  
{Other e.g. subdural hematoma from fight, stroke, infectious component}
- **Consider detailed assessment if:**
  - o Acknowledgment of drug use
  - o Physical signs e.g. track marks, nasal septum atrophy
  - o Urine drug screen +ve {Note: emergency drug screen is unlikely to significantly affect impact upon management in the ER.<sup>45</sup>}

- **Approach for engagement**
  - o Accept patient autonomy
  - o Non-judgemental approach/[Motivational Interviewing](#)
  - o Collaborative approach with patient
  - o Confidentiality
  - o Proactive discussion on meds and behaviours
- **Managing Potentially Violent Patient<sup>46</sup>:**
  - o Have a staff & public safety plan!
  - o Maintain autonomy & dignity of users, intervene early, approach patients with caution, don't startle, avoid provocation, be aware of your own demeanour, use calm

language, don't make promises, provide options and choice, remove dangerous objects from your person, **know exits**, don't turn back on patient, role for distraction, be firm & compassionate, depersonalize issue; avoid confronting, but if necessary maintain distance, **avoid corners/cornering**, explain intension, ask for facts & encourage reasoning, ask for weapons to be put down not handed over, know how to call for help.

Antipsychotics are not 1<sup>st</sup> line for substance abuse withdrawal. If in a controlled setting, temporary use of a benzodiazepine may be preferred.

## Intoxication: Common Presentations – Possible Causes <sup>47,48</sup>

- **Unresponsive:** hypoglycemics, narcotics, alcohol, cyanide, carbon monoxide, tranquilizers, hydrocarbons, barbiturates
- **Seizures:** hypoglycemics, amphetamines, cocaine, hallucinogens, anticonvulsants, TCAs, PCP, mescaline; benzodiazepine withdrawal especially high dose ; alcohol withdrawal tremors/seizures
- **Hyperthermia:** salicylates, Ecstasy, atropine, amphotericin B, phenytoin
- **Hypothermia:** ethanol, narcotics, sedatives/hypnotics, TCAs, barbiturates, carbon monoxide.
- **If mixed presentation consider possibility of mixed ingestion!**

For table outlining Toxic Syndromes or “toxidromes”, see Goldfrank’s Toxicologic Emergencies <sup>56</sup>

## Intoxication Management - [Primary assessment **ABCs**: airway, breathing, circulation]

<b>Opioids</b>	Intoxication {coma, <b>lethargy</b> , <b>stupor</b> ; constipation, N&V; flushing, pruritis; hypotension; <b>miosis</b> ; resp depression} ♦ supportive tx; regular assessment of cardio/respiratory safety ♦ airway protection; ♦ correction of hypoxia ⇒ naloxone option: short term duration; balance reversal of resp depression with opioid withdrawal (naloxone can be considered if opioid toxicity suspected). ♦ consider type of opioid for duration of risk & naloxone effect ♦ consider N-acetyl-para-aminophenol level if overdose cause unknown ( <b>r/o acetaminophen</b> as possible agent). CAUTION: depending on timing, a “non-toxic” level can become toxic; consult poison centre
<b>Stimulant</b>	Supportive tx {agitation, diaphoresis, hypertension, hyperthermia, <b>mydriasis</b> , psychosis, seizures, ↑HR} - oral diazepam or lorazepam for agitation & hypertension e.g cocaine induced - IV lorazepam, diazepam or midazolam <small>short acting</small> if severe agitation/anxiety - Optional (if predominant psychosis): sedating antipsychotic (e.g. olanzapine, risperidone, quetiapine) {Avoid mixing benzodiazepine & antipsychotic if possible due to risk of oversedation & respiratory AE - Monitor: hyperthermia, hypothermia, cardiac, electrolytes - HTN: benzodiazepines; alternatively nitroprusside, NTG - α-blockers. {generally avoid β-blockers as will result in unopposed α constriction} See also <a href="#">Stimulant Use Disorder Chart</a>
<b>Alcohol</b>	Supportive tx {immediate life-threatening complications in kids are respiratory depression & hypoglycaemia} ♦ airway; ♦ IV access (fluid management); correct hypoglycaemia with dextrose soln & electrolytes; ♦ thiamine

\* **Hemodialysis** may be an option in life threatening intoxication. Hemodialysis may be useful to remove barbiturates, sedatives, hypnotics, anticonvulsants, alcohols, analgesics, solvents, etc.

**When to Discharge?** ♦ Consider time from last ingestion. ♦ Can they walk unaided?

## Extras (RxFiles - Substance Abuse)

- o if using cocaine/other stimulants then detox is the only option. Rapid detox is not recommended during **pregnancy**.
- o Patients should only be “nodding” (falling asleep on methadone) if the dose is too high, they are a new start, or if they using BZD’s at the same time – may consider a tox screen to assess if patient is also using any other drugs
- o In Saskatoon methadone doses goes up by 10mg increments and down by 5mg increments for dose adjustments with some physicians.
- o Using both oral LA morphine (Kadian) in addition to methadone when starting patients is sometime done to prevent acute withdrawal & allow for methadone titration ( e.g. a few weeks of dual treatment); controversial.
- o IV drug abusers: considerations see reference <sup>49</sup>
- o Other substances of abuse: volatile inhalants, Listerine mouthwash
- o Be weary of illegitimate on-line pharmacies which supply controlled substances without a prescription.<sup>50</sup>

## Acute Alcohol Intoxication<sup>51,52</sup>

- **Blood Alcohol Levels (BAL):** **<50mg/dl (< 10.9mmol/l)**: impairment in skills, ↑ talkativeness, relax; **>100 mg/dl** = impaired judgement, ↓ coordination & reactions, mood/personality change; **> 200 mg/dl**: amnesia, diplopia, N&V; **>300-500 mg/dl** = ↑ risk of respiratory depression, coma & death
- **DSM-IV:** A) recent EtOH, B) clinically significant behavioural/psychological change e.g. aggression, mood, impairment C) one or more of [1. slurred speech, 2. ↓coordination, 3. unsteady gait, 4. nystagmus, 5. ↓ attention/memory, 6. stupor/coma, other.]
- **Other effects & associations:** Respiratory, GI, alcoholic hepatitis. ↑ risk of injury, ↑ risk of life years lost, ↑ violent crimes.
- **Tx:** 1) Stabilize patient: [airway, resp fx, prevent aspiration, mechanical ventilation prn, IV access & correction of hypoglycaemia, electrolytes (dextrose, Mg, folate, thiamine, multivitamins); 2) Sedate patient (droperidol, haloperidol); 3) evaluate for chronic EtOH abuse; Ref: Ostacher MJ et al. Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: Prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Am J Psychiatry* 2009 Dec 15; [e-pub ahead of print].
- **When to let them leave the emerg?** Consider holding till they can walk out unassisted.

## Management of Cocaine Body Packers<sup>53</sup>:

**Hx:** # & type of packets; other agents; GI symptoms; **Investigations:** ECG, CBC/SCR, etc., chest & abdom x-rays;  
**Management if asymptomatic:** admit, oral gastric lavage till all packets passed; 4 hr observations of vitals after packets passed; light/normal diet, IV access, daily evaluation for intoxication/bowel obstruction.

**Lifespan Spectrum of Complications:** **Pregnancy** - obstetrical complications, fetal distress, stillbirth, low birth weight; **adolescent & young adult** – self inflicted injuries, homicides, premature morbidity; **Later life** - ↑ decline.

{Associate health problems: non-fatal overdose, ↑ infections IV and NIDU (HCV; Hepatitis A, B); liver fibrosis cannabis, periodontitis cannabis; psychiatric (psychosis, anxiety, depression) various, cannabis; long-term ↓ cognitive performance.}<sup>54</sup>

**Substance Abuse in Older Adults<sup>55</sup>:** 2005 USA data on treatment programs: Alcohol only (48%), alcohol + 2<sup>nd</sup> illicit substance (52%); 2<sup>nd</sup> substance cocaine 40%, marijuana 29%, opiates 16%, stimulants 5%, other 10%.

♦ **Signs:** headache, ↓ cognitive/memory ability; **Unique features** in elderly: tendency to drink smaller quantities more often, DI with ↑ metabolism of other drugs, △ in sleep patterns. **Clues:** recent losses, psych hx, family hx of abuse.

**ALDH**=alcohol dehydrogenase **5HT**=serotonin **fx**=function **HCV**= hepatitis C virus **HX**=history **NIDU**= non-injecting drug users **Qt**=qt interval **RR**=respiratory rate

#### Quotes

- ♦ “it takes more than 2½ minutes to assess a patient for a possible opioid prescription” ; a challenge, especially for busy walk-in and minor emergency types of practice
- ♦ “it takes only 30 minutes to argue, but only 30 seconds to write a Rx”; reflecting the realities and frustrations of everyday practice.
- ♦ “Its OK to say ‘No’”
- ♦ “I didn’t realize how big a problem Rx opioids were on the street”

#### UK Study Ranking - most harmful drugs: overall, to individual and to society.

- o Nutt DJ, King LA, Phillips LD: on behalf of the Independent Scientific Committee on Drugs. Lancet. 2010 Oct 29. Drug harms in the UK: a multicriteria decision analysis.
- o BACKGROUND: Proper assessment of the harms caused by the misuse of drugs can inform policy makers in health, policing, and social care. We aimed to apply multicriteria decision analysis (MCDA) modelling to a range of drug harms in the UK. METHODS: Members of the Independent Scientific Committee on Drugs, including two invited specialists, met in a 1-day interactive workshop to score 20 drugs on 16 criteria: nine related to the harms that a drug produces in the individual and seven to the harms to others. Drugs were scored out of 100 points, and the criteria were weighted to indicate their relative importance. FINDINGS: MCDA modelling showed that heroin, crack cocaine, and metamfetamine were the most harmful drugs to individuals (part scores 34, 37, and 32, respectively), whereas alcohol, heroin, and crack cocaine were the most harmful to others (46, 21, and 17, respectively). Overall, alcohol was the most harmful drug (overall harm score 72), with heroin (55) and crack cocaine (54) in second and third places. INTERPRETATION: These findings lend support to previous work assessing drug harms, and show how the improved scoring and weighting approach of MCDA increases the differentiation between the most and least harmful drugs. However, the findings correlate poorly with present UK drug classification, which is not based simply on considerations of harm. FUNDING: Centre for Crime and Justice Studies (UK).

#### Salvia leaves (magic mint, diviner’s sage, sally D, purple sticky)

- o Member of mint family, smoked or chewed. Contains salvinorin A, a selective kappa opioid receptor antagonist; does not bind to 5HT<sub>2A</sub> receptors like other hallucinogens. Halucinogen effects rapid & last <30min. SE: dysphoria, diuresis, chills, headache, insomnia, exhaustion, loss of control, impaired coordination & judgement (= DANGEROUS!). Sensationalized in SK by Saskatoon media DJ who smoked herb on live broadcast in Dec 2010.

#### Angel’s Trumpet: (Angel’s tears, Apple of Peru, Green Dragon, Devil’s trumpet)

- o Alkaloid (atropine, scopolamine) containing flowers & stem. Each flower contains 0.2mg atropine & 0.65mg scopolamine; 3-6 flowers causes hallucinations; 9+ flowers can be life-threatening. Commonly ingested by making a tea. Effects in 1-4hrs; duration 24+hrs. SE: mydriasis, dry mouth, tachycardia, fever, erythema, constipation, ↑↑ thirst, retrograde amnesia & anxiety; arrhythmias & CV collapse / respiratory failure in high doses. (= DANGEROUS!)

#### “Bath Salts” PABS for abuse: are actually designer stimulants (e.g. methylenedioxypropylvalerone-MDPV, NRG-1; mephedrone-M-Cat, Meow, 4-MMC, Bubbles; methylone-methylenedioxyamphetaminone, bk-MDMA,M1, Explosion) being sold in shops & online. Cloud 9, Ivory Wave, Vanilla Sky, Purple Wave, Blizzard, Blue Silk, etc. Common in UK, now USA via New Orleans, India, China.

Similar effects (↑HR, paranoia, psychosis) & tx as stimulants. May/11 CDC: MMWR- Emergency Department Visits After Use of a Drug Sold as “Bath Salts” --- Michigan, November 13, 2010–March 31, 2011 <http://www.cdc.gov/mmwr/pdf/wk/mm60e0518.pdf>

Two common ingredients: MDPV (a dopamine & norepinephrine (NE) reuptake inhibitor → stimulant); mephedrone: MAOI effects that ↑ 5HT, NE, & DA at neuronal synapses (AEs: agitation, aggression, anxiety, bruxism, chest pain, confusion, diaphoresis, headache, hyperreflexia, ↑BP, N&V, palpitations, peripheral vasoconstriction, paresthesia, psychosis, seizure, ↑HR.)

Sep/11: DEA invoked its emergency authority necessary to protect the public & will make Schedule 1 substances in 30 days from now.

Ross EA, Watson M, Goldberger B. Bath Salts Intoxication. NEJM. 2011 Sep 8;365(10):967-8.

Aboujaoude E. Psychology Today, Apr 2012: Accessed 09 May, 2012 <http://www.psychologytoday.com/blog/compulsive-acts/201204/bath-salts>.

National Institute on Drug Abuse (NIDA) <http://www.drugabuse.gov/publications/drugfacts/synthetic-cathinones-bath-salts>

#### Spice – (“legal highs”): a range of synthetic drugs; combustible vegetable material sprayed with a variety of chemicals, each slightly different; often mixed with tobacco & smoked; effect (heightened awareness acoustics; imagination; potential for panic & violence; blackouts).

- The most extreme of effects often subside in 15min. Signs: acrid breath smell; higher voice pitch. Withdrawal: cramping, sweating, twitching. Other cautions: Low moods & self harm common. “Not for human consumption!”

#### Dimethoxybenzeneethanamine (2-CB) – (note 2-CB is a misnomer) a synthetic hallucinogen & club drug; sometimes sold as ecstasy; showed up in Prince Albert, SK, Feb 2017.

#### Poppers – volatile alkyl nitrite compounds inhaled for enhanced sexual experience. AE: foveal maculopathy (vision disturbance).

#### Kratom – herbal product, opioid agonist properties; mostly obtained as a powder and consumed as a beverage; doses >15g may produce opioid like toxicity; severe adverse events, including death, have been reported; naloxone may be given (if drowsy/respiratory depression).

#### Para-fluorofentanyl and metronidazole – two new drugs that are being increasingly associated with overdose deaths in the USA (Jan 2022). [https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a3.htm?cid=mm7104a3\\_w](https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a3.htm?cid=mm7104a3_w)

#### Miscellaneous Other Drug Considerations / Cautions

- Salbutamol: sometimes used to enhance effect of crack cocaine
- Benzodiazepines: calming effect
- Bupropion: sometimes messed with & snorted for high
- Quetiapine: may enhance heroin effects & risk
- Vitamin C sometimes used as an acidifier to help dissolve substances (i.e. crack cocaine, heroin) for injection

#### Harm reduction recommendations for substance abusers at risk of HIV, HCV & other harms (CATIE). Link: <http://www.catie.ca/en/programming/best-practices-harm-reduction>

#### Oxymorphone OPANA ER Abuse

- Thrombotic thrombocytopenic purpura (TTP) strongly associated with injection drug abuse of OPANA ER.

#### Buprenorphine/naloxone (ZUBSOLVE), 1.4mg/0.36mg – new SL tab formulation (available in USA); ↑bioavailability & may taste better than Suboxone. (Achieves plasma concentrations = 2/0.5mg and 8/2mg strengths of other Brand tabs.)

#### Synthetic Cannabinoids – common in herbal incense products

- Full agonists of CB1 & therefore ↑potential for overdose & toxicity
- ↑ association with seeking medical attention. AEs: agitation, altered time perception, anxiety, dysphoria, ↑BP, listlessness, hallucinations/psychosis, nausea, paranoia, seizures, tachycardia.
- Marijuana extraction/concentration ⇒ production of very highly concentrated levels (80-90%) called “Shatter”; easily over consumed resulting in overdose / emergency visits

#### Videos – informational related to teen drug recreational drug use (for teens, by teens) - Canada

- ♦Unwasted - 4 videos by teens regarding gambling, alcohol, marijuana, opioids/oxycontin: <http://unwasted.ca/>; or <http://unwasted.ca/the-pressures> (★★★★★)
- ♦Mixing prescription drugs and alcohol. <http://itdoesntmix.ca/>
- ♦Your when moment (videos from Nova Scotians): <http://changingtheculture.ns.ca/>

#### Videos – other

- ♦Addressing the risk of diversion of Rx drugs; secure storage of medications. Powerful. <http://www.youtube.com/watch?v=sunbJDZe1wh><http://www.youtube.com/watch?v=sunbJDZe1w>

Guidelines of interest:

Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guideline CAMH: [http://www.cpso.on.ca/uploadedFiles/policies/guidelines/office/buprenorphine\\_naloxone\\_gdlns2011.pdf](http://www.cpso.on.ca/uploadedFiles/policies/guidelines/office/buprenorphine_naloxone_gdlns2011.pdf)

Other Links of Interest:

See RxFiles Alcohol Use Disorder Chart: <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-Alcohol-Use-Disorder.pdf> v

Pregnancy Screening: Alcohol, smoking, and other substance use in the perinatal period (BMJ)

Motivational Interviewing – Modules/videos exploring ambivalence in behaviour change: modules/videos of interest: <https://www.youthadtoolbox.org.au/motivational-interviewing>

Get Help for Problematic Substance Use (Patient Links from Health Canada): <https://www.canada.ca/en/health-canada/services/substance-use/get-help/get-help-problematic-substance-use.html>

Low Risk Cannabis Use Guidelines (for youth, by youth): <http://www.camh.ca/en/health-info/guides-and-publications/lrucg-for-youth>

SK Health Links:

[www.saskatchewan.ca/addictions](http://www.saskatchewan.ca/addictions); the target audience is the public.

Direct links re Crystal Meth:

- Infographic: <http://publications.gov.sk.ca/documents/13/106826-Crystal-Meth-Infographic-2018.pdf>
- FaQ : <http://publications.gov.sk.ca/documents/13/106827-CM-FAQ-2018.pdf>
- Fact Sheet : <http://publications.gov.sk.ca/documents/13/99220-CrystalMeth%20Factsheet%20Sept%202016.pdf>

Aberrant Drug Use	218
Abuse	218
Addiction	218
AUDIT	218
CAGE	218
Dependence	218
Drug Abuse	218
Harm Reduction	218
Misuse	218
Substance Use	218
Substance Use Disorder	218
SUD	218
Tolerance	218
Abuse	219
Alcohol	219
Amphetamine	219
Anabolic steroids	219
ATIVAN	219
Barbiturate	219
Benzodiazepine	219
Bupropion	219
Caffeine	219
Cannabinoid	219
Cannabis	219
Cocaine	219
Codeine	219
CONCERTA	219
Crack	219
Crystal Meth	219
DEXEDRINE	219
Dextromethorphan	219
DILAUDID	219
Dimenhydrinate	219
DM	219
Drug Abuse	219
Ecstasy	219
Fentanyl	219
Flunitrazepam	219
Gabapentin	219
GHB	219

Hallucinogen	219
Hashish	219
Heroin	219
HYDROMORPH CONTIN	219
Hydromorphone	219
Inhalant	219
Ketamine	219
KROKODIL	219
Loperamide	219
LSD	219
Marijuana	219
MDMA	219
Mescaline	219
Methamphetamine	219
Methaqualone	219
Methylphenidate	219
Morphine	219
MS-CONTIN	219
NEURONTIN	219
Nicotine	219
Opioid	219
Oxycodone	219
OXYCONTIN	219
PCP	219
Pregabalin	219
Quetiapine	219
RITALIN	219
ROHYPNOL	219
SEROQUEL	219
Solvent	219
Speed	219
Stimulant	219
Substance Use	219
THC	219
Tramadol	219
XANAX	219
Psychostimulant	218

Additional refs for SUBSTANCE ABUSE/ADDICTION: Overview & Treatment Considerations:

A voice from the streets about **Spice**. BMJ. 2016 Jun 7;353:i2708.

AAP Committee on Substance Use and Prevention. **Medication-Assisted Treatment of Adolescents with Opioid Use Disorders**. Pediatrics.2016;138(3):e20161893

AAP: Committee on Substance Use and Prevention. Medication-Assisted Treatment of **Adolescents With Opioid Use Disorders**. Pediatrics. 2016 Sep;138(3).

Abouk R et al. Association between **state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose**. JAMA Intern Med 2019 May 6.

Abraham R, Wilkinson E, Jabbarpour Y, Bazemore A. **Family Physicians Play Key Role** in Bridging the Gap in Access to Opioid Use Disorder Treatment. Am Fam Physician. 2020;102(1):10.

Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of **anabolic-androgenic steroid abuse** on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010 Sep 15;106(6):893-901.

Ackerman AL, O'Connor PG, Doyle DL, et al. Association of an **Opioid Standard of Practice Intervention With Intravenous Opioid Exposure** in Hospitalized Patients. JAMA Intern Med. 2018 May 14.

ACOG: Committee on Obstetric Practice. Committee Opinion No. 711: **Opioid Use and Opioid Use Disorder in Pregnancy**. Obstet Gynecol. 2017 Aug;130(2):e81-e94.

Adams AJ, Banister SD, Irizarry L, et al. **"Zombie" Outbreak** Caused by the **Synthetic Cannabinoid AMB-FUBINACA** in New York. N Engl JMed. 2016 Dec 14.

Adams JM. Increasing **Naloxone Awareness and Use**: The Role of Health Care Practitioners. JAMA. 2018 Apr 5.

Adkins SH, Anderson KN, Goodman AB, et al. Demographics, Substance Use **Behaviors, and Clinical Characteristics** of Adolescents With e-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) in the United States in 2019. JAMA Pediatr. 2020:e200756.

Adler AC, Yamani AN, Sutton CD, et al. **Mail-Back Envelopes for Retrieval of Opioids** After Pediatric Surgery. Pediatrics. 2020 Feb 12. doi: 10.1542/peds.2019-2449.

Admon LK, Bart G, Kozhimannil KB, et al. **Amphetamine- and Opioid-Affected Births**: Incidence, Outcomes, and Costs, United States, 2004-2015. Am J Public Health. 2018 Nov 29:e1-e7.

Agabio R. Non-specialist health workers to treat **excessive alcohol consumption** and depression. Lancet. 2016 Dec 14.

Agarwal S, Bryan JD, Hu HM, et al. Association of State **Opioid Duration Limits With Postoperative Opioid Prescribing**. JAMA Netw Open. 2019 Dec 2;2(12):e1918361.

Afshar M, Poole JA, Cao G, Durazo et al. Exhaled **Nitric Oxide** Levels Among Adults With Excessive **Alcohol Consumption**. Chest. 2016 Jul;150(1):196-209.

Akiyama MJ, Norton BL, Arnsten JH, et al. Intensive Models of **Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy**: A Randomized Controlled Trial. Ann Intern Med. 2019 Apr 9.

Alati R, Betts KS, Williams GM, et al. **Generational Increase in Young Women's Drinking**: A Prospective Analysis of Mother-Daughter Dyads. JAMA Psychiatry. 2014 Jun 25.

Alambyan V, Pace J, Miller B, et al. The Emerging Role of **Inhaled Heroin in the Opioid Epidemic**: A Review. JAMA Neurol. 2018 Jul 9.

Albadareen R, Thornton S, Heshmati A, et al. Unusually Prolonged Presentation of Designer Drug (**methylenedioxybenzylpiperazine**) Encephalopathy Responsive to Steroids. Pediatrics. 2015 Jun 8.

Albaugh MD, Ottino-Gonzalez J, Sidwell A, et al; IMAGEN Consortium. Association of **Cannabis Use During Adolescence With Neurodevelopment**. JAMA Psychiatry. 2021 Jun 16. doi: 10.1001/jamapsychiatry.2021.1258.

**Alcohol Use and Pregnancy** Consensus Clinical Guidelines. SOGC 2010. <http://www.sogc.org/guidelines/documents/gui245cpg1008e.pdf>

Alcover KC, Thompson CL. **Patterns of Mean Age at Drug Use Initiation** Among Adolescents and Emerging Adults, 2004-2017. JAMA Pediatr. 2020 Mar 2. doi:10.1001/jamapediatrics.2019.6235.

Aldy K, Mustaquim D, Campleman S, et al; Fentanyl Study Group. Notes from the Field: **Illicit Benzodiazepines Detected** in Patients Evaluated in Emergency Departments for Suspected Opioid Overdose - Four States, October 6, 2020-March 9, 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1177-1179.

Alford Daniel P.; LaBelle Colleen T.; Kretsch Natalie; et al. Collaborative Care of **Opioid-Addicted Patients in Primary Care Using Buprenorphine**: Five-Year Experience. Arch Intern Med. 2011;171(5):425-431.

Alford DP. **Opioid Prescribing for Chronic Pain**—Achieving the Right Balance through Education. N Engl J Med. 2016 Jan 28;374(4):301-3.

Alford DP, Cohen ML, Reynolds EE. How Would You **Manage Opioid Use** in These Three Patients?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med. 2017 Apr 4;166(7):506-513

Ali WM, Al Habib KF, Al-Motarreh A, et al. Acute coronary syndrome use and **khat herbal amphetamine use (Catha edulis)**. An observational report.Circulation 2011

Allen B, Nolan ML, Kunins HV, Paone D. **Racial differences in opioid overdose deaths** in New York City, 2017 [online Feb 11, 2019]. JAMA Intern Med.

Allsop DJ, Copeland J, Lintzeris N, et al. **Nabiximols** as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial. JAMA Psychiatry. 2014 Jan 15

Almeida OP, Hankey GJ, Yeap BB, et al. **Alcohol consumption** and cognitive impairment in older men: A mendelian randomization study. Neurology. 2014 Mar 25;82(12):1038-44.

Altice FL, Kamarulzaman A, Soriano VV, et al. Treatment of **medical, psychiatric, and substance-use comorbidities in people infected with HIV** who use drugs. Lancet. 2010 Jul 31;376(9738):367-87.

Amato L, Minozzi S, Vecchi S, Davoli M. **Benzodiazepines for alcohol withdrawal**. Cochrane Database Syst Rev. 2010 Mar 17;3:CD005063. Benzodiazepines showed a protective benefit against alcohol withdrawal symptoms, in particular seizures, when compared to placebo and a potentially protective benefit for many outcomes when compared with other drugs. Nevertheless, no definite conclusions about the effectiveness and safety of benzodiazepines was possible, because of the heterogeneity of the trials both in interventions and the assessment of outcomes.

Amato L, Minozzi S, Pani PP, et al. **Dopamine agonists** for the treatment of **cocaine dependence**. Cochrane Database Syst Rev. 2011 Dec 7;12:CD003352. Current evidence from randomised controlled trials does **not support** the use of dopamine agonists for treating cocaine dependence.

Amato L, Davoli M, Minozzi S, et al. **Methodone at tapered doses for the management of opioid withdrawal**. Cochrane Database Syst Rev. 2013 Feb 28;2:CD003409. doi: 10.1002/14651858.CD003409.pub4. Data from literature are hardly comparable; programs vary widely with regard to the assessment of outcome measures, impairing the application of meta-analysis. The studies included in this review confirm that slow tapering with temporary substitution of long-acting opioids, can reduce withdrawal severity. Nevertheless, the majority of patients relapsed to heroin use.



Ambasta A, Malebranche M. **Opioid use disorder in pregnancy.** CMAJ. 2019 Sep 23;191(38):E1057.Pdf Dai H, Richter KP. A National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017. JAMA Netw Open. 2019 Sep 4;2(9):e1911936.

Amer H, Archer JRH, Layne K, et al. **Paracetamol toxicity in mild overdose** in combination with opioids: a retrospective observational study. Br J Clin Pharmacol. 2021 Sep 5. doi: 10.1111/bcp.15070.

**American Psychiatric Association Brochures:** <http://www.healthyminds.org/Functional-Library/brochures.aspx>

Anderson KE, Alexander GC, Niles L, et al. Quality of **Preventive and Chronic Illness Care** for Insured Adults With Opioid Use Disorder. JAMA Netw Open. 2021 Apr 1;4(4):e214925

Anderson DM, Hansen B, Rees DI, Sabia JJ. Association of Marijuana **Laws With Teen Marijuana Use:** New Estimates From the Youth Risk Behavior Surveys. JAMA Pediatr. 2019 Jul 8.

Anderson DM, Rees DI, Sabia JJ, Safford S. Association of Marijuana **Legalization With Marijuana Use** Among US High School Students, 1993-2019. JAMA Netw Open. 2021 Sep 1;4(9):e2124638.

Antoine D, Huhn AS, Strain EC, et al. Method for Successfully Inducting Individuals Who Use Illicit **Fentanyl Onto Buprenorphine/Naloxone.** Am J Addict. 2021 Jan;30(1):83-87

Anton RF, Myrick H, Wright TM, et al. **Gabapentin Combined With Naltrexone** for the Treatment of Alcohol Dependence. Am J Psychiatry. 2011 Mar 31.

Antoniou T, Juurlink DN. **"Bath salts".** CMAJ. 2012 Oct 16;184(15):1713.

Antoniou T, Juurlink DN. **Synthetic cannabinoids.** CMAJ. 2014 Feb 18;186(3):210.

Antoniou T, Juurlink DN. **Dextromethorphan abuse.** CMAJ. 2014 Nov 4;186(16):E631.

Antoniou T, Juurlink DN. **Loperamide abuse.** CMAJ. 2017 Jun 12;189(23):E803.

Appa A, Rodda LN, Cawley C, et al. Drug Overdose **Deaths Before and After Shelter-in-Place Orders** During the COVID-19 Pandemic in San Francisco. JAMA Netw Open. 2021 May 3;4(5):e2110452.

Aquaro GD, Gabutti A, Meini M, Prontera C, Pasanisi E, Passino C, Emdin M, Lombardi M. **Silent myocardial damage in cocaine addicts.** Heart. 2011 Jun 20.

Armenian P, Olson A, Anaya A, Kurtz Aet al. **Fentanyl** and a Novel **Synthetic Opioid U-47700** Masquerading as Street "Norco" in Central California: A Case Report. Ann Emerg Med. 2016 Jul 20.

Arnold C. The new danger of **synthetic drugs.** Lancet. 2013 Jul 6;382(9886):15-6.

Arora NP, Berk WA, Aaron CK, Williams KA. Usefulness of Intravenous **Lipid Emulsion for Cardiac Toxicity from Cocaine** Overdose. Am J Cardiol. 2012 Nov 24.

Artenie AA, Minoyan N, Jacka B, et al. **Opioid agonist treatment dosage** and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs. CMAJ 2019;191:E462-8.

Arterberry BJ, Treloar Padovano H, Foster KT, et al. Higher average potency across the United States is associated with progression to **first cannabis use disorder symptom.** Drug Alcohol Depend. 2018 Dec 6.

Askgaard G, Grønbaek M, Kjaer MS, et al. **Alcohol drinking** pattern and risk of alcoholic liver cirrhosis: A prospective cohort study. J Hepatol. 2015 Jan 20.

Auger N, Low N, Carrier FM, et al. Maternal **pregnancy surgery and risk of neonatal abstinence syndrome** in future newborns: a longitudinal cohort study. CMAJ. 2019 Jul 15;191(28):E779-E786.

Aulet RM, Trieu V, Landrigan GP, Millay DJ. Changes in Opioid **Prescribing Habits for Patients Undergoing Rhinoplasty and Septoplasty.** JAMA Facial Plast Surg. 2019 Oct 10. doi: 10.1001/jamafacial.2019.0937

Axelsson A, et al. "Echocardiographic Findings Suggestive of **Infective Endocarditis** in Asymptomatic Danish Injection Drug Users Attending Urban Injection Facilities." The American Journal of Cardiology (2014).

Aydelotte JD, Brown LH, Luftman KM, et al. **Crash Fatality Rates After Recreational Marijuana Legalization** in Washington and Colorado. Am J Public Health. 2017 Jun 22:e1-e3.

Ayers JW, Nobles AL, Dredze M. **Media Trends** for the Substance Abuse and Mental Health Services Administration 800-662-HELP Addiction Treatment Referral Services **After a Celebrity Overdose.** JAMA Intern Med. 2019 Jan 14.

Azuine RE, Ji Y, Chang HY, et al. **Prenatal Risk Factors and Perinatal and Postnatal Outcomes** Associated With Maternal Opioid Exposure in an Urban, Low-Income, Multiethnic US Population. JAMA Netw Open. 2019 Jun 5;2(6):e196405.

Babu KM, Brent J, Juurlink DN. **Prevention of Opioid Overdose.** N Engl J Med. 2019 Jun 6;380(23):2246-2255.

Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical **cannabis laws and opioid analgesic overdose** mortality in the United States, 1999-2010 [online August 25, 2014]. JAMA Intern Med.

Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing **Benzodiazepine Prescriptions** and Overdose Mortality in the United States, 1996-2013. Am J Public Health. 2016 Feb 18:e1-e3.

Bada HS, Bann CM, Whitaker TM, et al. Protective Factors Can Mitigate Behavior Problems After Prenatal **Cocaine** and Other Drug Exposures. Pediatrics. 2012 Nov 26.

Bada HS, Sithisarn T, Gibson J, et al. **Morphine Versus Clonidine for Neonatal Abstinence Syndrome.** Pediatrics. 2015 Jan 26.

Baggett TP, Hwang SW, O'Connell JJ, et al. **Mortality Among Homeless Adults** in Boston: Shifts in Causes of Death Over a 15-Year Period. JAMA Intern Med. 2013 Jan 14:1-7.

Bagley SM, Forman LS, Ruiz S, et al. Expanding access to **naloxone for family members:** The Massachusetts experience. Drug Alcohol Rev. 2017 Apr 20.

Bagley SM, Gai MJ, Earlywine JJ, et al. Incidence and Characteristics of Nonfatal Opioid **Overdose Among Youths Aged 11 to 24 Years** by Sex. JAMA Netw Open. 2020 Dec 1;3(12):e2030201

Bahji A, Stephenson C, Tyo R, et al. Prevalence of Cannabis **Withdrawal Symptoms** Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Apr 1;3(4):e202370

Bai JW, Bao J, Bhatia A, Chan VWS. **A perioperative approach to the opioid crisis.** CMAJ. 2018 Oct 1;190(39):E1151-E1152.

Bailey AM, Wermeling DP. **Naloxone for opioid overdose prevention:** pharmacists' role in community-based practice settings. Ann Pharmacother. 2014 May;48(5):601-6.

Baillargeon J, Raji MA, Urban RJ, et al. Opioid-Induced **Hypogonadism** in the United States. Mayo Clin Proc Innov Qual Outcomes. 2019 Aug 23;3(3):276-284.

Balaraman S, Schafer JJ, Tseng AM, et al. **Plasma miRNA Profiles** in Pregnant Women Predict Infant Outcomes following **Prenatal Alcohol Exposure.** PLoS One. 2016 Nov 9;11(11):e0165081

Ballantyne JC. Treating **Pain in Patients with Drug-dependence Problems.** BMJ. 2013 Dec 9

Banerjee G, Edelman EJ, Barry DT, et al. **Non-medical use of prescription opioids** is associated with **heroin initiation** among US veterans: a prospective cohort study. Addiction. 2016 Aug 23.

Banerji D, Alvi RM, Afshar M, et al. **Carvedilol** Among Patients With Heart Failure With a Cocaine-Use Disorder. JACC Heart Fail. 2019 Sep;7(9):771-778.

Bao Y et al. **Prescription drug monitoring programs** are associated with sustained reductions in opioid prescribing by physicians. Health Aff (Millwood) 2016 Jun 1; 35:1045.

Barnes MP. The case for **medical cannabis**-an essay by M P Barnes. BMJ. 2018 Jul 25;362:k3230.

Barnett ML, Hicks TR, Jena AB. **Prescription Patterns of Family Members** After Discontinued Opioid or Benzodiazepine Therapy of Users. JAMA Intern Med. 2019 Jul 1.

Barnett ML, Olenski AR, Jena AB. **Opioid-Prescribing Patterns of Emergency Physicians** and Risk of Long-Term Use. N Engl J Med. 2017 Feb 16;376(7):663-673.

Barnett ML, Gray J, Zink A, et al. **Coupling Policymaking with Evaluation - The Case of the Opioid Crisis.** N Engl J Med. 2017 Dec 14;377(24):2306-2309.

Barrowclough Christine, Haddock Gillian, Wykes Til, et al. **Integrated motivational interviewing and cognitive behavioural therapy** for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ 341:doi:10.1136/bmj.c6325 (Published 24 Nov 2010).

Barth RJ Jr, Waljee JF. Classification of Opioid Dependence, Abuse, or Overdose in **Opioid-Naïve Patients as a "Never Event".** JAMA Surg. 2020 Apr 29. doi: 10.1001/jamasurg.2020.0432

Bateman BT, Hernandez-Diaz S, Rathmell JP, et al. Patterns of **Opioid Utilization in Pregnancy** in a Large Cohort of Commercial Insurance Beneficiaries in the United States. Anesthesiology. 2014 Feb 12.

Bateman BT, Choudhry NK. **Limiting the Duration of Opioid Prescriptions:** Balancing Excessive Prescribing and the Effective Treatment of Pain. JAMA Intern Med. 2016 May 1

Baumblatt JA, Wiedeman C, Dunn JR, et al. High-Risk Use by Patients Prescribed **Opioids for Pain and Its Role in Overdose Deaths.** JAMA Intern Med. 2014 Mar 3.

Bechtold J, Hipwell A, Lewis DA, et al. Concurrent and Sustained Cumulative Effects of Adolescent **Marijuana** Use on Subclinical **Psychotic Symptoms.** Am J Psychiatry. 2016 Aug 1;173(8):781-9

Becker WC, Fiellin DA. **Abuse-Deterrent Opioid Formulations** - Putting the Potential Benefits into Perspective. N Engl J Med. 2017 Jun 1;376(22):2103-2105.

Becker WC, Fiellin DA. Limited evidence, faulty reasoning, and potential for a **global opioid crisis.** BMJ. 2017 Jul 5;358:j3115.

Becker WC, Frank JW, Edens EL. Switching From High-Dose, Long-Term **Opioids to Buprenorphine:** A Case Series. Ann Intern Med. 2020 Apr 7. doi: 10.7326/L19-0725

Becker WC, Merlin JS, Manhara A, et al. Management of patients with issues related to opioid safety, efficacy and/or misuse: a case series from an integrated, interdisciplinary clinic. Addict Sci Clin Pract. 2016 Jan 28;11(1):3

Bedene A, Lijfering WM, Niesters M, et al. Opioid **Prescription Patterns and Risk Factors** Associated With Opioid Use in the Netherlands. JAMA Netw Open. 2019 Aug 2;2(8):e1910223.

Bedi P, Rai MP, Bumrah K, et al. Pattern and Burden of **Opioid-Related Hospitalizations** in United States from 2016-2018. Br J Clin Pharmacol. 2021 Apr 15. doi: 10.1111/bcp.14857.

Beetham T, Saloner B, Gaye M, et al. **Therapies Offered** at Residential Addiction Treatment Programs in the United States. JAMA. 2020;324(8):804-806.

Beetham T, Saloner B, Wakeman SE, et al. Access to **office-based buprenorphine treatment** in areas with high rates of opioid-related mortality. An audit study. Ann Intern Med. 2019. [Epub ahead of print]. doi:10.7326/M18-3457

Behnke M, Smith VC; Committee on Substance Abuse, Committee on Fetus and Newborn. **Prenatal Substance Abuse:** Short- and Long-term Effects on the Exposed Fetus. Pediatrics. 2013 Feb 25.

Bell J. Pharmacological Maintenance Treatments of **Opiate Addiction.** Br J Clin Pharmacol. 2012 Dec 4.

Bentzley BS, Han SS, Neuner S, et al. Comparison of **Treatments for Cocaine Use Disorder** Among Adults: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021 May 3;4(5):e218049.

Benzer TI, Nejad SH, Flood JG. Case records of the Massachusetts General Hospital. Case 40-2013. A 36-year-old man with agitation and paranoia. N Engl J Med. 2013 Dec 26;369(26):2536-45. (**Methcathinone-Bath Salt** intoxication)

Berkey, Catherine S., Willett, Walter C., Frazier, A. Lindsay, et al. Prospective Study of Adolescent **Alcohol Consumption and Risk of Benign Breast Disease** in Young Women. Pediatrics 2010 125:e1081-e1087.

Bertin C, Delorme J, Riquelme M, et al. Risk assessment of using **off-label morphine sulfate** in a population-based retrospective cohort of opioid-dependent patients. Br J Clin Pharmacol. 2019 Aug 6.

Bhanushali GK, Jain G, Fatima H, et al. **AKI associated with synthetic cannabinoids:** a case series. Clin J Am Soc Nephrol. 2013 Apr;8(4):523-6.

Binswanger IA. **Opioid Use Disorder and Incarceration** - Hope for Ensuring the Continuity of Treatment. N Engl J Med. 2019 Feb 27.

Birath JB et al. **ludilast** may improve attention during early abstinence from **methamphetamine.** Drug Alcohol Depend 2017 Jun 23; 178:386.

Blanch B, Pearson S, Haber PS. An overview of the patterns of prescription **opioid use, costs and related harms** in Australia. Br J Clin Pharmacol. 2014 Jun 24.

Bianco C, Wall MM, Okuda M, et al. **Pain as a Predictor of Opioid Use** Disorder in a Nationally Representative Sample. Am J Psychiatry. 2016 Jul 22

Blendon RJ, Benson JM. **The Public and the Opioid-Abuse Epidemic.** N Engl J Med. 2018 Jan 3.

Blevins D, Wang XQ, Sharma S, Ait-Daoud N. **Impulsiveness** as a predictor of topiramate response for cocaine use disorder. Am J Addict. 2019 Feb;28(2):71-76.

Blomster JJ, Zoungas S, Chalmers J, et al. The relationship between **alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes.** Diabetes Care. 2014 May;37(5):1353-9.

Blumenberg A, Hughes A, Reckers A, et al. Flualprazolam: Report of an Outbreak of a **New Psychoactive Substance** in Adolescents. Pediatrics. 2020;e20192953.

Bogenschutz MP, Donovan DM, Mandler RN, et al. **Brief intervention** for patients with problematic drug use **presenting in emergency departments:** a randomized clinical trial. JAMA Intern Med. 2014 Nov 1;174(11):1736-45.

Bohnert Amy S. B., Valenstein Marcia, Bair Matthew J., et al. Association Between **Opioid Prescribing Patterns and Opioid Overdose-Related Deaths.** JAMA. 2011;305(13):1315-1321.doi:10.1001/jama.2011.370.

Bohnert ASB, Guy GP Jr, Losby JL. **Opioid Prescribing** in the United States Before and After the Centers for Disease Control and Prevention's **2016 Opioid Guideline.** Ann Intern Med. 2018 Sep 18;169(6):367-375.

Bohnert ASB, Ilgen MA. **Understanding Links among Opioid Use, Overdose, and Suicide.** N Engl J Med. 2019 Jan 3;380(1):71-79.

Bondi SA, Scibilia J; COMMITTEE ON MEDICAL LIABILITY AND RISK MANAGEMENT. Dealing With the **Caretaker Whose Judgment Is Impaired** by Alcohol or Drugs: Legal and Ethical Considerations. Pediatrics. 2019 Nov 25. doi:10.1542/peds.2019-3153.

Bonnie RJ, Kesselheim AS, Clark DJ. Both Urgency and Balance Needed in Addressing Opioid Epidemic: A Report From the National Academies of Sciences, Engineering, and Medicine. JAMA. 2017 Aug 1,318(5):423-424.

Boshuisen K, Arends JE, Rutgers DR, Frijns CJ. A young man with hemiplegia after inhaling the **bath salt "Ivory Wave"**. Neurology. 2012 May 8;78(19):1533-4.

Bostwick JM, Reisfield GM, DuPont RL. Clinical decisions. Medicinal use of marijuana. N Engl J Med. 2013 Feb 28;368(9):866-8.

Bowen S, Witkiewitz K, Clifasefi SL, et al. Relative Efficacy of **Mindfulness-Based** Relapse Prevention, Standard Relapse Prevention, and Treatment as Usual for **Substance Use Disorders**: A Randomized Clinical Trial. JAMA Psychiatry. 2014 Mar 19.

Bradley KA, Rubinsky AD, Sun H, et al. **Alcohol screening** and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med. 2011 Feb;26(2):162-9.

Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential **false-positive urine drug screens**. Am J Health Syst Pharm. 2010 Aug 15;67(16):1344-50.

Brands Bruna, Paglia-Boak Angela, Sproule Beth A., et al. **Nonmedical use of opioid** analgesics among Ontario students. Can Fam Physician 2010 56: 256 -262.

Brat GA, Agniel D, Beam A, et al. **Postsurgical prescriptions for opioid naive patients** and association with overdose and misuse: retrospective cohort study. BMJ. 2018 Jan 17;360:j5790.

Brent DA, Hur K, Gibbons RD. Association Between **Parental Medical Claims for Opioid Prescriptions and Risk of Suicide Attempt by Their Children**. JAMA Psychiatry. 2019 May 22.

Brière FN, Fallu JS, Janosz M, Pagani LS. Prospective associations between **meth/amphetamine (speed) and MDMA (ecstasy) use and depressive symptoms** in secondary school students. J Epidemiol Community Health. 2012 Apr 19.

Brody GH, Chen YF, Kogan SM et al. **Family-centered Program** Deters Substance Use, Conduct Problems, and Depressive Symptoms in Black Adolescents. Pediatrics. 2012 Jan;129(1):108-15.

Brogly SB, Saia KA, Walley AY, et al. **Prenatal Buprenorphine Versus Methadone** Exposure and Neonatal Outcomes: Systematic Review and Meta-Analysis. Am J Epidemiol. 2014 Aug 22.

Brooks MJ. **Mitigating the safety risks** of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer? Mayo Clin Proc. 2014 Dec;89(12):1673-84.

Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with **opioid analgesics and risk for birth defects**. Am J Obstet Gynecol 2011;204:x.ex-x.ex. PII: S0002-9378(10)02524-X doi:10.1016/j.ajog.2010.12.039.

Brown CR, Chen Z, Khurshan F, et al. Development of **Persistent Opioid Use After Cardiac Surgery**. JAMA Cardiol. 2020;10.1001/jamacardio.2020.1445.

Brown JD, Doshi PA, Pauly NJ, et al. Rates of **Neonatal Abstinence Syndrome** Amid Efforts to Combat the Opioid Abuse Epidemic. JAMA Pediatr. 2016 Sep 26.

Brown QL, Sarvet AL, Shmulewitz D, et al. Trends in **Marijuana** Use Among Pregnant and Nonpregnant Reproductive-Aged Women, 2002-2014. JAMA. 2016 Dec 19.

Brubacher JR, Chan H, Erdelyi S, et al. Cannabis Legalization and **Detection of Tetrahydrocannabinol in Injured Drivers**. N Engl J Med. 2022 Jan 13;386(2):148-156.

Brummett CM, Waljee JF, Goessling J, et al. New Persistent **Opioid Use After Minor and Major Surgical Procedures** in US Adults. JAMA Surg. 2017 Apr 12:e170504.

Bruneau J, Ahamad K, Goyer ME, et al; CIHR Canadian Research Initiative in Substance Misuse. **Management of opioid use disorders: a national clinical practice guideline**. CMAJ. 2018 Mar 5;190(9):E247-E257.

Bryant AJ, Newman JH. **Alcohol** intolerance associated with **Hodgkin lymphoma**. CMAJ. 2013 May 14;185(8):E353.

Buchanich JM, Balmert LC, Williams KE, et al. The Effect of **Incomplete Death Certificates on Estimates of Unintentional Opioid-Related Overdose** Deaths in the United States, 1999-2015. Public Health Rep. 2018 Jan 1:33354918774330.

Buckingham-Howes S, Berger SS, Scaletti LA, Black MM. Systematic Review of **Prenatal Cocaine Exposure** and Adolescent Development. Pediatrics. 2013 May 27.

Burbank SR. **Are New Residency Graduates Prepared to Treat Opioid Use Disorder?** Ann Fam Med. 2018 Sep;16(5):iii.

Burns ME, Cook S, Brown LM, et al. Association Between Assistance With **Medicaid Enrollment and Use of Health Care** After Incarceration Among Adults With a History of Substance Use. JAMA Netw Open. 2022 Jan 4;5(1):e2142688.

Bushnell G, Samples H, Gerhard T, et al. **Benzodiazepine and Stimulant Prescriptions** Before Overdose in Youth. Pediatrics. 2022;149(4):e2021055226

Buxton JA, Gauthier T, Kinshella MW, et al. A 52-year-old man with **fantanyl-induced muscle rigidity**. CMAJ. 2018 Apr 30;190(17):E539-E541.

Byford S, Barrett B, Metrebian N, et al. Cost-effectiveness of **injectable opioid treatment v. oral methadone** for chronic heroin addiction. Br J Psychiatry. 2013 Nov;203(5):341-9.

Bykov K, He M, Gagne JJ. Trends in Utilization of **Prescribed Controlled Substances** in US Commercially Insured Adults, 2004-2019. JAMA Intern Med. 2020 Apr 20. doi: 10.1001/jamainternmed.2020.0989

Califf RM, Woodcock J, Ostroff S. A **Proactive Response to Prescription Opioid Abuse**. N Engl J Med. 2016 Feb 4.

Callaghan RC, Cunningham JK, Sajeev G, Kish SJ. Incidence of **Parkinson's disease** among hospital patients with **methamphetamine**-use disorders. Mov Disord. 2010 Aug 24.

CAMH-Hallucinogens:Accessed online 25May2021 at <https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/hallucinogens>

Campbell AN, Nunes EV, Matthews AG, et al. **Internet-delivered treatment for substance abuse**: a multisite randomized controlled trial. Am J Psychiatry. 2014 Jun 1;171(6):683-90.

Cance JD, Doyle E. Changes in Outpatient **Buprenorphine Dispensing During the COVID-19 Pandemic**. JAMA. 2020 Dec 15;324(23):2442-2444

Cannon RD, Beauchamp GA, Roth P, et al. **Sex Differences** in Prevalence of Emergency Department Patient Substance Use. Clin Ther. 2018 Jan 11.

Cao Y, Willet WC, Rimm EB, et al. Light to moderate intake of **alcohol**, drinking patterns, and **risk of cancer**: results from two prospective US cohort studies. BMJ 2015;351:h4238.

Carey CM, Jena AB, Barnett ML. **Patterns of potential opioid misuse** and subsequent adverse outcomes in Medicare, 2008 to 2012. Ann Intern Med. 2018. [Epub ahead of print]. doi:10.7326/M17-3065

Carliner H, Mauro PM, Brown QL, et al. The widening **gender gap in marijuana use** prevalence in the U.S. during a period of economic change, 2002-2014. Drug Alcohol Depend. 2016 Nov 11;170:51-58.

Carroll JJ, Marshall BDL, Rich JD, et al. Exposure to **fantanyl-contaminated heroin and overdose risk among illicit opioid users** in Rhode Island: A mixed methods study. Int J Drug Policy. 2017 Jun 1.

Cartus AR, Li Y, Macmadu A, et al. **Forecasted and Observed Drug Overdose Deaths** in the US During the COVID-19 Pandemic in 2020. JAMA Netw Open. 2022 Mar 1;5(3):e223418.

Casolla B, Dequatre-Ponchelle N, Rossi C, et al. Heavy **alcohol** intake and intracerebral hemorrhage: Characteristics and effect on outcome. Neurology. 2012 Sep 11;79(11):1109-15.

Cassidy EM et al. **Symptom-triggered benzodiazepine therapy for alcohol withdrawal syndrome** in the emergency department: A comparison with the standard fixed dose benzodiazepine regimen. Emerg Med J 2012 Oct; 29:802.

Castellanos-Ryan N, Séguin JR, Vitaro F, Parent S, Tremblay RE. Impact of a 2-year **multimodal intervention for disruptive 6-year-olds** on substance use in adolescence: randomised controlled trial. Br J Psychiatry. 2013 Aug 8.

CDC: Centers for Disease Control and Prevention. **Emergency department visits involving nonmedical use** of selected prescription drugs - United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2010 Jun 18;59(23):705-9. This report describes the results of that review, which showed that the estimated number of ED visits for nonmedical use of opioid analgesics increased 111% during 2004-2008 (from 144,600 to 305,900 visits) and increased 29% during 2007-2008. The highest numbers of ED visits were recorded for oxycodone, hydrocodone, and methadone, all of which showed statistically significant increases during the 5-year period. The estimated number of ED visits involving nonmedical use of benzodiazepines increased 89% during 2004-2008 (from 143,500 to 271,700 visits) and 24% during 2007-2008.

CDC July/11 Drug **Overdose Deaths** --- Florida, 2003—2009 [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6026a1.htm?s\\_cid=mm6026a1\\_x](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6026a1.htm?s_cid=mm6026a1_x)

CDC Feb/12 Severe Methemoglobinemia and Hemolytic Anemia from **Aniline** Purchased as 2C-E (4-ethyl-2,5-dimethoxyphenethylamine), a Recreational Drug, on the Internet — Oregon, 2011. Weekly. February 10, 2012 / 61(05):85-88. [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6105a1.htm?s\\_cid=mm6105a1\\_x](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6105a1.htm?s_cid=mm6105a1_x)

CDC: Centers for Disease Control and Prevention. Severe **methemoglobinemia and hemolytic anemia from aniline purchased as 2C-E(4-ethyl-2,5-dimethoxyphenethylamine)**, a recreational drug, on the Internet - Oregon, 2011. MMWR Morb Mortal Wkly Rep. 2012 Feb 10;61(5):85-8.

CDC: Centers for Disease Control and Prevention (CDC). Vital signs: **Drinking and driving among high school students** aged ≥16 years — United States, 1991–2011. MMWR Morb Mortal Wkly Rep 2012 Oct 5; 61:796.

Centre for Addiction and Mental Health. Opioid Agonist Therapy: A Synthesis of Canadian **Guidelines for Treating Opioid Use Disorder**. Published May 2021. Available at [www.camh.ca](http://www.camh.ca)

Cerdá M, Mauro C, Hamilton A, et al. Association Between Recreational Marijuana Legalization in the United States and **Changes in Marijuana Use and Cannabis Use Disorder** From 2008 to 2016. JAMA Psychiatry. 2019 Nov 13. doi:10.1001/jamapsychiatry.2019.3254.

Cerdá M, Wall M, Feng T, et al. Association of state **recreational marijuana laws** with adolescent marijuana use [online Dec 27, 2016]. JAMA Pediatr. doi:10.1001/jamapediatrics.2016.3624

Chadi N, Schroeder R, Jensen JW, Levy S. Association Between **Electronic Cigarette Use and Marijuana Use** Among Adolescents and Young Adults: A Systematic Review and Meta-analysis. JAMA Pediatr. 2019 Aug 12:e192574.

Chaffee BW, Cheng J, Couch ET, et al. Adolescents' Substance Use and Physical **Activity Before and During the COVID-19 Pandemic**. JAMA Pediatr. 2021 May 3:e210541

Chai D, Rosic T, Panesar B, et al. **Patient-Reported Goals of Youths** in Canada Receiving Medication-Assisted Treatment for Opioid Use Disorder. JAMA Netw Open. 2021 Aug 2;4(8):e2119600.

Chan B, Freeman M, Kondo K, et al. **Pharmacotherapy for Methamphetamine/Amphetamine Use Disorder** – A Systematic Review and Meta-analysis. Addiction. 2019 Jul 22.

Chang HY, Lyapustina T, Rutkow L, et al. Impact of **prescription drug monitoring programs** and pill mill laws on high-risk opioid prescribers: A comparative interrupted time series analysis. Drug Alcohol Depend. 2016 May 26..

Chang HY, Muriini IB, Jones CM, et al. Relationship between **high-risk patients receiving prescription opioids and high-volume opioid prescribers**. Addiction. 2017 Nov 29.

Chang L et al. Sex-specific alterations of **white matter** developmental trajectories in infants with prenatal exposure to **methamphetamine and tobacco**. JAMA Psychiatry 2016 Nov 9.

Chang TR, Kowalski RG, Caserta F, et al. Impact of acute **cocaine use on aneurysmal subarachnoid hemorrhage**. Stroke. 2013 Jul;44(7):1825-9.

Chang Z, Lichtenstein P, Larsson H, et al. Substance use disorders, psychiatric disorders, and mortality after **release from prison**: a nationwide longitudinal cohort study. Lancet Psychiatry. 2015 May;2(5):422-30.

Chapman E, Leipsic J, Satkunam N, Churg A. **Pulmonary alveolar proteinosis** as a reaction to **fantanyl patch smoke**. Chest. 2012 May;141(5):1321-3.

Chasnoff IJ, Wells AM, King L. Misdiagnosis and Missed Diagnoses in Foster and Adopted Children With **Prenatal Alcohol Exposure**. Pediatrics. 2015 Jan 12.

Chaudhary MA, Bhulani N, de Jager EC, et al. Development and Validation of a **Bedside Risk Assessment for Sustained Prescription Opioid Use After Surgery**. JAMA Netw Open. 2019 Jul 3;2(7):e196673

Chaudhary MA, Schoenfeld AJ, Harlow AF, et al. Incidence and predictors of **opioid prescription at discharge after traumatic injury** [published online June 21, 2017]. JAMA Surg. doi:10.1001/jamasurg.2017.1685

Chen A, Blumenthal DM, Jena AB. Characteristics of Physicians Excluded From **US Medicare and State Public Insurance Programs for Fraud, Health Crimes, or Unlawful Prescribing** of Controlled Substances. JAMA Netw Open. 2018;1(8):e185805.

Chen JH, Humphreys K, Shah NH, et al. **Distribution of Opioids by Different Types of Medicare Prescribers**. JAMA Intern Med. 2015 Dec 14:1-3.

Chen LY, Crum RM, Strain EC, et al. Prescriptions, nonmedical use, and emergency department visits involving **prescription stimulants**. J Clin Psychiatry. 2016 Feb 16.

Chen WY, Rosner B, Hankinson SE, et al. Moderate **alcohol** consumption during adult life, drinking patterns, and **breast cancer** risk. JAMA. 2011;306(17): 1884-1890.

Chen Y, Koh HK, Kawachi I, et al. **Religious Service Attendance and Deaths** Related to Drugs, Alcohol, and Suicide Among US Health Care Professionals. JAMA Psychiatry. 2020 May 6. doi: 10.1001/jamapsychiatry.2020.0175.

Chen Y, Shiels MS, Thomas D, et al. **Premature Mortality From Drug Overdoses**: A Comparative Analysis of 13 Organisation for Economic Co-operation and Development Member Countries With High-Quality Death Certificate Data, 2001 to 2015. Ann Intern Med. 2018 Nov 13.

Chidgey BA, McGinigley KL, McNaull PP. When a Vital Sign Leads a Country Astray-**The Opioid Epidemic**. JAMA Surg. 2019 Aug 14

Chihuri S, Li G. Trends in Prescription **Opioids Detected in Fatally Injured Drivers** in 6 US States: 1995-2015. Am J Public Health. 2017 Jul 20:e1-e6

Chihuri S, Li G. Use of **Prescription Opioids and Initiation of Fatal 2-Vehicle Crashes**. JAMA Netw Open. 2019 Feb 1;2(2):e188081.

Chino F, Kamal A, Chino J. Incidence of **Opioid-Associated Deaths in Cancer Survivors** in the United States, 2006-2016: A Population Study of the Opioid Epidemic. JAMA Oncol. 2020 May 7. doi: 10.1001/jamaoncol.2020.0799



Chiu AS, Jean RA, Hoag JR, Freedman-Weiss M, Healy JM, Pei KY. Association of **lowering default pill counts in electronic medical record systems** with postoperative **opioid prescribing** [online July 18, 2018]. JAMA Surg. doi:10.1001/jamasurg.2018.2083

Cho J, Kelley-Quon LI, Barrington-Trimis JL, et al. Behavioral Health Risk Factors for **Nonmedical Prescription Opioid Use** in Adolescence. Pediatrics. 2021 Aug 16:e202105151.

Chou R, Ballantyne J, Lembke A. **Rethinking Opioid Dose Tapering**, Prescription Opioid Dependence, and Indications for Buprenorphine. Ann Intern Med. 2019 Aug 27.

Chou R, Cruciari RA, Fiellin DA, et al. American Pain Society, Heart Rhythm Society. **Methadone safety**: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014 Apr;15(4):321-37.

Chou R, Korthuis PT, McCarty D, Coffin PO, Griffin JC, Davis O'Reilly C, et al. **Management of suspected opioid overdose with naloxone in out-of-hospital settings**. A systematic review. Ann Intern Med. [Epub ahead of print 28 Nov 2017] doi:10.7326/M17-2224

Chu EK, Smith LM, Derauf c, et al. Behavior Problems During Early Childhood in Children With **Prenatal Methamphetamine Exposure**. Pediatrics. 2020; 146(6):e20190270

Chu TH, Rueter M, Palmaro A, Lapeyre-Mestre M. POTENTIAL INAPPROPRIATE USE OF STRONG **OPIOID ANALGESICS IN CANCER OUTPATIENTS** DURING THE LAST YEAR OF LIFE IN FRANCE AND ASSOCIATED FACTORS. Br J Clin Pharmacol. 2021 Jul 29. doi: 10.1111/bcp.15011.

Chua KP, Brummett CM, Conti RM, Bohnert A. Association of Opioid **Prescribing Patterns With Prescription Opioid Overdose** in Adolescents and Young Adults. JAMA Pediatr. 2019 Dec 16. doi: 10.1001/jamapediatrics.2019.4878.

Chua KP, Hu HM, Waljee JF, et al. Persistent Opioid Use Associated With Dental Opioid Prescriptions Among Publicly and Privately Insured US Patients, 2014 to 2018. JAMA Netw Open. 2021 Apr 1;4(4):e216464

Chung T, Smith GT, Donovan JE, et al. **Drinking Frequency as a Brief Screen** for Adolescent Alcohol Problems. Pediatrics. 2012 Jan 4.

Chung CP, Callahan ST, Cooper WO, et al. Outpatient **Opioid Prescriptions for Children and Opioid-Related Adverse Events**. Pediatrics. 2018 Jul 16.

Cicero TJ, Ellis MS, Surratt HL. Effect of **abuse-deterrent formulation of OxyContin**. N Engl J Med. 2012 Jul 12;367(2):187-9.

Cicero TJ, Ellis MS, Surratt HL, et al. The Changing Face of **Heroin Use** in the United States: A Retrospective Analysis of the Past 50 Years. JAMA Psychiatry. 2014 May 28.

Cicero TJ, Ellis MS. **Abuse-Deterrent Formulations** and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin. JAMA Psychiatry. 2015 Mar 11.

Cicero TJ, Ellis MS, Harney J. Shifting Patterns of **Prescription Opioid and Heroin Abuse** in the United States. N Engl J Med. 2015 Oct 29;373(18):1789-90.

Cimolai N. **Zopiclone**: is it a pharmacologic agent for abuse? Can Fam Physician. 2007 Dec;53(12):2124-9.

Claridge H, Williams BD, Copeland CS. A deadly trend in **fantanyl fatalities (England, 1998-2017)**. Br J Clin Pharmacol. 2019 Oct 29. doi: 10.1111/bcp.14135.

Clark B, Kai M, Dix R, et al. Association of a Multimodal **Educational Intervention for Primary Care Physicians** With Prescriptions of Buprenorphine for Opioid Use Disorders. JAMA Netw Open. 2019 Oct 2;2(10):e1913818.

Clark BC, Georgekutty J, Berul CI. Myocardial Ischemia Secondary to **Synthetic Cannabinoid (K2)** Use in Pediatric Patients. J Pediatr. 2015 Jul 1.

Clark DB, Martin CS, Chung T, et al. Screening for **Underage Drinking** and Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Alcohol Use Disorder in Rural Primary Care Practice. J Pediatr. 2016 Mar 28

Clarke H, Soneji N, Ko DT, et al. Rates and risk factors for **prolonged opioid use after major surgery**: population based cohort study. BMJ. 2014 Feb 11;348:g1251.

Clarke H, Soneji N, Ko DT, et al. Rates and risk factors for prolonged **opioid use after major surgery**: population based cohort study. BMJ. 2014 Feb 11;348:g1251.

Claudet I, Mouvrier S, Labadie M, et al. Unintentional **Cannabis** Intoxication in **Toddlers**. Pediatrics. 2017;140(3):e20170017.

Clayton HB, Lowry R, August E, et al. **Nonmedical Use** of Prescription Drugs and **Sexual Risk** Behaviors. Pediatrics. 2015 Dec 14.

Clayton HB, Lowry R, Ashley C et al. Health Risk Behaviors with **Synthetic Cannabinoids Versus Marijuana**. Pediatrics. 2017;139(4):e20162675

Clemency BM, Eggleston W, Shaw EW, et al. Hospital Observation Upon Reversal (**HOUR**) **With Naloxone**: A Prospective Clinical Prediction Rule Validation Study. Acad Emerg Med. 2019 Jan;26(1):7-15.

Coffa D, Snyder H. **Opioid Use Disorder: Medical Treatment Options**. Am Fam Physician. 2019 Oct 1;100(7):416-425.

Coffey KE, Aitelli A, Milligan M, et al. Use of **Involuntary Emergency Treatment** by Physicians and Law Enforcement for Persons With High-Risk Drug Use or Alcohol Dependence. JAMA Netw Open. 2021 Aug 2;4(8):e2120682

Coffin PO, Sullivan SD. Cost-effectiveness of **distributing naloxone to heroin users** for lay overdose reversal. Ann Intern Med. 2013;158:1-9.

Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of **naloxone coprescription** for primary care patients receiving **long-term opioid therapy for pain**. Ann Intern Med. 2016. [Epub ahead of print]. doi:10.7326/M15-2771

Cohen J, Morrison S, Greenberg J et al. Clinical Presentation of **Intoxication Due to Synthetic Cannabinoids**. Pediatrics. 2012 Mar 19.

Cohen JP, Mendoza M, Roland C. Challenges Involved in the **Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics**. Clin Ther. 2018 Feb 2.

Colfax GN, Santos GM, Das M, et al. **Mirtazapine to reduce methamphetamine use**: a randomized controlled trial. Arch Gen Psychiatry. 2011 Nov;68(11):1168-75.

Collin J, Johnson E, Officer H, et al. Government support for **alcohol industry**: promoting exports, jeopardising global health? BMJ. 2014 Jun 6;348:g3648.

Comer SD, Dworkin RH, Strain EC. **Medical Devices to Prevent Opioid Use Disorder**: Innovative Approaches to Addressing the Opioid Crisis. JAMA Psychiatry. 2019 Feb 20.

Committee on Substance Abuse. **Substance use screening, brief intervention, and referral** to treatment for pediatricians. Pediatrics. 2011 Nov;128(5):e1330-40.

Committee Opinion No. 637: **Marijuana Use During Pregnancy** and Lactation. Obstet Gynecol. 2015 Jul;126(1):234-8.

Compton WM, Blanco C, Wargo EM. **Integrating Addiction Services** Into General Medicine. JAMA. 2015 Dec 8;314(22):2401-2.

Compton WM, Han B, Hughes A, et al. Use of **Marijuana for Medical Purposes** Among Adults in the United States. JAMA. 2017 Jan 10;317(2):209-211.

Compton WM, Jones CM. Substance **Use among Men Who Have Sex with Men**. N Engl J Med. 2021 Jul 22;385(4):352-356

Compton WM, Jones CM, Baldwin GT. **Relationship between Nonmedical Prescription-Opioid Use and Heroin Use**. N Engl J Med. 2016 Jan 14;374(2):154-63.

Compton WM, Volkow ND. Improving Outcomes for Persons With **Opioid Use Disorders: Buprenorphine** Implants to Improve Adherence and Access to Care. JAMA. 2016 Jul 19;316(3):277-9.

Conason A, Teixeira J, Hsu CH, et al. **Substance Use Following Bariatric Weight Loss Surgery**. Arch Surg. 2012 Oct 15:1-6. (alcohol)

Connor JP, Haber PS, Hall WD. **Alcohol use disorders**. Lancet. 2015 Sep 3.

Conradt E, Flannery T, Aschner JL, et al. **Prenatal Opioid Exposure**: Neurodevelopmental Consequences and Future Research Priorities. Pediatrics. 2019 Aug 28.

Conrod PJ, O'Leary-Barrett M, Newton N, et al. Effectiveness of a **Selective, Personality-Targeted Prevention Program for Adolescent Alcohol** Use and Misuse: A Cluster Randomized Controlled Trial. JAMA Psychiatry. 2013 Jan 23:1-9.

Conrod PJ, O'Leary-Barrett M, Newton N, et al. Effectiveness of a selective, **personality-targeted prevention program for adolescent alcohol use and misuse**: a cluster randomized controlled trial. JAMA Psychiatry. 2013 Mar 1;70(3):334-42.

Cook JL, Green CR, Lilley CM, et al. **Fetal alcohol spectrum disorder**: a guideline for diagnosis across the lifespan. CMAJ 2015 Dec. 14 [Epub ahead of print].

Coombes R. **Cannabis regulation**: high time for change? BMJ. 2014 May 21;348:g3382.

Copeland WE, Gaydos H, Hill SN, et al. Associations of **Despair With Suicidality and Substance Misuse** Among Young Adults. JAMA Netw Open. 2020;3(6):e208627

Cornish R, Macleod J, Strang J, et al. Risk of death during and after **opiate substitution treatment** in primary care: prospective observational study in UK General Practice Research Database. BMJ. 2010 Oct 26;341:c5475. doi: 10.1136/bmj.c5475.

Cotten SW, Duncan DL, Burch EA, Seashore CJ, Hammitt-Stabler CA. **Unexpected interference of baby wash products (soaps/shampoo)** with a cannabinoid (THC) immunoassay. Clin Biochem. 2012 Jun;45(9):605-9.

Cottler LB, Hu H, Smallwood BA, et al. **Nonmedical Opioid Pain Relievers and All-Cause Mortality**: A 27-Year Follow-Up From the Epidemiologic Catchment Area Study. Am J Public Health. 2016 Mar;106(3):509-16.

Crabtree A, Lostchuck E, Chong M, et al. **Toxicology and prescribed medication histories** among people experiencing fatal illicit drug overdose in British Columbia, Canada. CMAJ 2020 August 24;192 (34):E967-72

Cragg A, Hau JP, Woo SA, et al. **Risk Factors for Misuse of Prescribed Opioids**: A Systematic Review and Meta-Analysis. Ann Emerg Med. 2019 Jun 19.

Cressman AM, Mazereeuw G, Guan Q, et al. **Availability of naloxone** in Canadian pharmacies: a population-based survey. CMAJ Open. 2017 Nov 8;5(4):E779-E784.

Crowley R, Kirschner N, Dunn AS, et al. Health and Public Policy to Facilitate Effective **Prevention and Treatment of Substance Use Disorders Involving Illicit and Prescription Drugs**: An American College of Physicians Position Paper. Ann Intern Med. 2017 Mar 28.

Crum RM, Mojtabai R, Lazareck S, et al. A Prospective Assessment of Reports of **Drinking to Self-medicate Mood Symptoms** With the Incidence and Persistence of Alcohol Dependence. JAMA Psychiatry. 2013 May 1:1-9.

Csete J, Kamarulzaman A, Kazatchkine M, et al. **Public health and international drug policy**. Lancet. 2016 Mar 23.

Cummings JR, Wen H, Ko M, Druss BG. **Race/Ethnicity and Geographic Access to Medicaid Substance Use Disorder Treatment Facilities** in the United States. JAMA Psychiatry. 2013 Dec 25:1-7.

Curfman GD, Beletsky L, Sarpatwari A. Benefits, Limitations, and Value of **Abuse-Deterrent Opioids**. JAMA Intern Med. 2017 Dec 11.

Currie JM, Schnell MK, Schwandt H, Zhang J. Prescribing of **Opioid Analgesics and Buprenorphine** for Opioid Use Disorder During the COVID-19 Pandemic. JAMA Netw Open. 2021 Apr 1;4(4):e216147

Currie JM, Schnell MK, Schwandt H, Zhang J. **Trends in Drug Overdose Mortality** in Ohio During the First 7 Months of the COVID-19 Pandemic. JAMA Netw Open. 2021 Apr 1;4(4):e217112

Czeisler MÉ, Lane RI, Petrosky E, et al. Mental Health, Substance Use, and Suicidal Ideation **During the COVID-19 Pandemic** - United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1049-1057.

Czeisler MÉ, Lane RI, Wiley JF, et al. Follow-up Survey of US Adult Reports of Mental Health, Substance Use, and Suicidal Ideation **During the COVID-19 Pandemic**, September 2020. JAMA Netw Open. 2021 Feb 1;4(2):e2037665

Czynski AJ, Davis JM, Dansereau LM, et al. **Neurodevelopmental Outcomes** of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome. J Pediatr. 2020 Jan 24. doi:10.1016/j.jpeds.2019.12.018.

D'Amico EJ, Parast L, Meredith LS, et al. Screening in Primary Care. What is the **Best Way to Identify At-Risk Youth for Substance Use**? Pediatrics. 2016;138(6):e20161717.

D'Amico EJ, Parast L, Osilla KC, et al. Understanding **Which Teenagers Benefit Most From a Brief Primary Care Substance Use Intervention**. Pediatrics. 2019 Jul 11.

D'Onofrio G, Fiellin DA, Pantalon MV, et al. A brief intervention reduces hazardous and **harmful drinking** in emergency department patients. Ann Emerg Med. 2012 Aug;60(2):181-92.

D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated **buprenorphine/naloxone treatment for opioid dependence**: a randomized clinical trial. JAMA. 2015 Apr 28;313(16):1636-44.

D'Onofrio G, Chawarski MC, O'Connor PG, et al. **Emergency Department-Initiated Buprenorphine for Opioid Dependence** with Continuation in Primary Care: Outcomes During and After Intervention. J Gen Intern Med. 2017 Feb 13.

D'Onofrio G, McCormack RP, Hawk K. **Emergency Departments - A 24/7/365 Option for Combating the Opioid Crisis**. N Engl J Med. 2018 Dec 27;379(26):2487-2490.

Da Silva T, Hafizi S, Watts JJ, et al. **In Vivo Imaging of Translocator Protein in Long-term Cannabis Users**. JAMA Psychiatry. 2019 Sep 18.

Dakwar E, Nunes EV, Hart CL, et al. A **Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification** to Treat Cocaine Dependence: A Randomized Clinical Trial. Am J Psychiatry. 2019 Jun 24;appiaj201918101123.

Dam MK, Hufieldt UA, Tjønneland A, et al. Five year change in **alcohol intake and risk of breast cancer** and coronary heart disease among postmenopausal women: prospective cohort study. BMJ 2016;353:2314.

Darke S, Duflou J, Kaye S, et al. **Psychostimulant Use and Fatal Stroke** in Young Adults. J Forensic Sci. 2019 Apr 2.

Darrell Hulisz. Is **Hookah** Harmful? Medscape: accessed at <http://www.medscape.com/viewarticle/727687>. (Hookah is a waterpipe used for smoking tobacco (often with additional flavours). Hookah smoking, also known as **narghile**, **shisha**, and **goza**. Less studied but similar concerns (CV, cancer, addiction) to tobacco.)

Dart RC, Iwanicki JL, Black J, et al. Measuring Prescription **Opioid Misuse and Its Consequences**. Br J Clin Pharmacol. 2021 Feb 19. doi: 10.1111/bcp.14791

Dart RC, Surratt HL, Cicero TJ, et al. Trends in **Opioid Analgesic Abuse and Mortality in the United States**. N Engl J Med. 2015 Jan 15;372(3):241-248.

Daubresse M, Saloner B, Pollack HA, et al. **Non-buprenorphine opioid utilization** among patients using buprenorphine. *Addiction*. 2017 Jan 20.

Davis CS. The **SUPPORT for Patients and Communities Act** - What Will It Mean for the Opioid-Overdose Crisis? *N Engl J Med*. 2018 Nov 14.

Davis JM, Shenberger J, Terrin N, et al. Comparison of **Safety and Efficacy of Methadone vs Morphine** for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial. *JAMA Pediatr*. 2018 Jun 18.

Davis LL, Pilkinton P, Wisniewski SR, et al. Effect of concurrent substance use disorder on the effectiveness of **single and combination antidepressant medications** for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. *Depress Anxiety*. 2012 Feb;29(2):111-22.

Day E, Copello A, Hull M. Assessment and management of **alcohol use disorders**. *BMJ*. 2015 Feb 19;350:h715.

Dedert EA, McDuffie JR, Stein R, et al. **Electronic Interventions for Alcohol Misuse and Alcohol Use Disorders: A Systematic Review**. *Ann Intern Med*. 2015 Aug 4;163(3):205-14.

Degenhardt L, Bharat C, Glantz MD, et al. Association of Cohort and Individual **Substance Use With Risk of Transitioning** to Drug Use, Drug Use Disorder, and Remission From Disorder: Findings From the World Mental Health Surveys. *JAMA Psychiatry*. 2019 Mar 13.

Degenhardt L, Whiteford HA, Ferrari AJ, et al. **Global burden of disease attributable to illicit drug use and dependence**: findings from the Global Burden of Disease Study 2010. *Lancet* 2013; online Aug 29.

Delgado MK, Huang Y, Meisel Z, et al. National **Variation in Opioid Prescribing and Risk of Prolonged Use for Opioid-Naïve Patients** Treated in the Emergency Department for Ankle Sprains. *Ann Emerg Med*. 2018 Jul 24.

Delgado MK, Shofar FS, Patel MS, et al. Association between **Electronic Medical Record Implementation** of Default Opioid Prescription Quantities and Prescribing Behavior in Two Emergency Departments. *J Gen Intern Med*. 2018 Jan 16.

Deligianni E, Daniel OJ, Corkery JM, et al. Impact of the **UK Psychoactive Substances Act** on awareness, use, experiences and knowledge of potential associated health risks of Novel Psychoactive Substances. *Br J Clin Pharmacol*. 2019 Sep 8.

Department of Veteran Affairs, Department of Defense. **VA/DoD clinical practice guideline for management of substance use disorders (SUD)**. Washington (DC): Department of Veteran Affairs, Department of Defense; 2009 Aug. 158 p. [http://www.healthquality.va.gov/sud/sud\\_full\\_601f.pdf](http://www.healthquality.va.gov/sud/sud_full_601f.pdf)

Derauf C, Lagasse LL, Smith LM. **Prenatal Methamphetamine Exposure and Inhibitory Control** among Young School-Age Children. *J Pediatr*. 2012 Sep;161(3):452-9.

Desveaux L, Saragosa M, Kithulegoda N, et al. Understanding the **behavioural determinants of opioid prescribing** among family physicians: a qualitative study. *BMC Fam Pract*. 2019 May 10;20(1):59.

Devlin LA, Breeze JL, Terrin N, et al M. Association of a Simplified **Finnegan Neonatal Abstinence Scoring Tool** With the Need for Pharmacologic Treatment for Neonatal Abstinence Syndrome. *JAMA Netw Open*. 2020 Apr 1;3(4):e202275

Dewan KC, Dewan KS, Idrees JJ, et al. Trends and Outcomes of **Cardiovascular Surgery in Patients With Opioid Use Disorders**. *JAMA Surg*. 2018 Dec 5.

Deyo RA, Hallivik SE, Hildebran C, et al. Association Between **Initial Opioid Prescribing Patterns and Subsequent Long-Term Use** Among Opioid-Naïve Patients: A Statewide Retrospective Cohort Study. *J Gen Intern Med*. 2016 Aug 2.

Dezfulian C, Orkin AM, Maron BA, et al. **Opioid-Associated Out-of-Hospital Cardiac Arrest**: Distinctive Clinical Features and Implications for Health Care and Public Responses: A Scientific Statement From the American Heart Association. *Circulation*. 2021 Mar 8;CIR00000000000000958

Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with **first-episode psychosis attributable to use of high potency cannabis**: a case-control study. *Lancet Psychiatry* 2015;2:233-8.

Di Iorio CR, Watkins TJ, Dietrich MS, et al. Evidence for Chronically Altered Serotonin Function in the Cerebral Cortex of Female 3,4-**Methylenedioxymethamphetamine** Polydrug Users. *Arch Gen Psychiatry*. 2011 Dec 5.

Diaz SD, Smith LM, Lagasse LL, et al. Effects of **Prenatal Methamphetamine Exposure** on Behavioral and Cognitive Findings at 7.5 Years of Age. *J Pediatr*. 2014 Mar 12.

Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist (**ketamine**) in treatment-resistant bipolar **depression**. *Arch Gen Psychiatry*. 2010 Aug;67(8):793-802.

Dietz P, Ulrich R, Dalaker R, et al. Associations between **Physical and Cognitive Doping - A Cross-Sectional Study** in 2.997 **Triathletes**. *PLoS One*. 2013 Nov 13

Dietze P, Jauncey M, Salmon A, et al. Effect of **Intranasal vs Intramuscular Naloxone** on Opioid Overdose: A Randomized Clinical Trial. *JAMA Netw Open*. 2019 Nov 1;2(11):e1914977.

Dilley JA, Richardson SM, Kilmer B, et al. **Prevalence of Cannabis Use in Youths After Legalization** in Washington State. *JAMA Pediatr*. 2018 Dec 19.

Disher T, Gullickson C, Singh B, et al. **Pharmacological treatments for neonatal abstinence syndrome**: a systematic review and network meta-analysis [online Jan 22, 2019]. *JAMA Pediatr*. doi:10.1001/jamapediatrics.2018.5044

Doctor JN, Nguyen A, Lev R, et al. **Opioid prescribing decreases after learning of a patient's fatal overdose**. *Science*. 2018 Aug 10;361(6402):588-590.

Dong KA, Brouwer J, Johnston C, Hyskha E. **Supervised consumption services** for acute care hospital patients. *CMAJ*. 2020 May 4;192(18):E476-E479.

Donohue JM, Kennedy J, Seymour CW, et al. Patterns of opioid administration among **opioid-naïve inpatients and associations with postdischarge opioid use**. A cohort study. *Ann Intern Med*. 2019. [Epub ahead of print]. doi:10.7326/M18-2864

Donroe JH, Holt SR, Tetrault JM. Caring for patients with **opioid use disorder** in the hospital. *CMAJ*. 2016 Dec 6;188(17-18):1232-1239. Review.

Donroe JH, Tetrault JM. **Narrowing the treatment gap in managing opioid use disorder**. *CMAJ*. 2018 Mar 5;190(9):E236-E237.

Dooley J, Gerber-Finn L, Antone I, et al. **Buprenorphine-naloxone use in pregnancy for treatment of opioid dependence**: Retrospective cohort study of 30 patients. *Canadian Family Physician*. 2016;62(4):e194-e200.

Dormuth CR, Miller TA, Huang A, et al. Effect of a **centralized prescription network** on inappropriate prescriptions for opioid analgesics and benzodiazepines. *CMAJ*. 2012 Sep 4.

dosReis S, Zhang C, Qato DM, et al. Family Adverse Experiences and **Psychotropic Polypharmacy** Among US Youth: 2009-2015. *Pediatrics*. 2020:e20192705.

Doucette ML, Shields WC, Haring RS, et al. Storing and Disposing of Opioid Analgesics: What Does Our Medicine Tell Us? *Ann Intern Med*. 2018 Apr 17.

Dowell D, Haegerich TM, Chou R. **CDC guideline for prescribing opioids for chronic pain—United States, 2016**. *MMWR Recomm Rep*. 2016;65(RR-1): 1-49.

Dowell D, Haegerich TM, Chou R. **CDC guideline for prescribing opioids for chronic pain—United States, 2016**. *JAMA*. doi:10.1001/jama.2016.1464.

Dowell D, Noonan RK, Houry D. **Underlying Factors in Drug Overdose Deaths**. *JAMA*. 2017 Oct 11.

Dreifuss R, Bem P. **Non-violent drug users should face no penalty**- a call from the Global Commission on Drug Policy. *BMJ*. 2016;355:i5921.

Driot D, Jouanjus E, Oustric S, et al. Patterns of **gabapentin and pregabalin use and misuse**: results of a population-based cohort study in France. *Br J Clin Pharmacol*. 2019 Feb 8.

Dubow JS, Singer S, Segal AZ. **Rhombencephalitis due to cocaine-induced** bony erosion of skull base. *Neurology*. 2011 Sep 27;77(13):1313

Ducharme S, Fraser R, Gill K. Update on the clinical use of **buprenorphine-naloxone**: In opioid-related disorders. *Can Fam Physician*. 2012 Jan;58(1):37-41.

Dudovitz RN, Chung PJ, Reber S, et al. Assessment of exposure to **high-performing schools and risk of adolescent substance use**: a natural experiment [online Oct 29,2018]. *JAMA Pediatr*. doi:10.1001/jamapediatrics.2018.3074

Dukes JW, Dewland TA, Vittinghoff E, et al. Access to **alcohol** and heart disease among patients in hospital: observational cohort study using differences in alcohol sales laws. *BMJ*. 2016 Jun14;353:i2714.

Dunlap B, Cifu AS. Clinical Management of **Opioid Use Disorder**. *JAMA*. 2016 Jul 19;316(3):338-9.

Dunn KE, Tompkins DA, Bigelow GE, et al. Efficacy of **Tramadol Extended-Release for Opioid Withdrawal**: A Randomized Clinical Trial. *JAMA Psychiatry*. 2017 Jul 12

Durand Z, Nechuta S, Krishnaswami S, et al. Prevalence and Risk Factors Associated With **Long-term Opioid Use After Injury Among Previously Opioid-Free Workers**. *JAMA Netw Open*. 2019 Jul 3;2(7):e197222.

Duru UB, Pawar G, Barash JA, et al. An Unusual **Amnesic Syndrome Associated With Combined Fentanyl and Cocaine Use**. *Ann Intern Med*. 2018 Jan 30.

Earnshaw VA, Elliot MN, Reisner SL, et al. **Peer Victimization, depressive symptoms, and substance use**: A longitudinal analysis. *Pediatrics*. 2017;139(6):e20163426

Ebrahimi Kalan M, Jebai R, Bursac Z, et al. Trends and Factors Related to **Blunt Use in Middle and High School Students**. 2010-2020. *Pediatrics*. 2021 Jun 14:e2020028159.

Edelman EJ, Fiellin DA. **Alcohol Use**. *Ann Intern Med*. 2016 Jan 5;164(1):ITC1-ITC16.

Edlund MJ, Martin BC, Russo JE, et al. The role of **opioid prescription in incident opioid abuse and dependence** among individuals with chronic noncancer pain: the role of opioid prescription. *Clin J Pain*. 2014 Jul;30(7):557-64.

Eiden C, Ripault MP, Larrey D, et al. Acute hepatitis and renal failure related to intranasal **buprenorphine misuse**: case report and analysis of cases reported to the French network for drug monitoring. *Ann Pharmacother*. 2013 Dec;47(12):1721-6

Eisenberg MD, Saloner B, Krawczyk N, et al. Use of Opioid Overdose Deaths Reported in One State's Criminal Justice, Hospital, and Prescription Databases to **Identify Risk of Opioid Fatalities**. *JAMA Intern Med*. 2019 Apr 15.

Eklström MP, Bornefalk-Hermansson A, et al. Safety of **benzodiazepines and opioids** in very severe respiratory disease: national prospective study. *BMJ*. 2014 Jan 30;348.

El-Bassel N, Norcini Pala A, Mukherjee TI, et al. **Association of Violence Against Female Sex Workers Who Use Drugs With Nonfatal Drug Overdose in Kazakhstan**. *JAMA Netw Open*. 2020 Oct 1;3(10):e2020802

Eldridge WB, Foster C, Wyble L. **Neonatal Abstinence Syndrome Due to Maternal Kratom Use**. *Pediatrics*. 2018 Nov 7.

Elton-Marshall, Tara, Leatherdale, Scott T., Burkhalter, Robin. **Tobacco, alcohol and illicit drug use among Aboriginal youth living off-reserve**: results from the Youth Smoking Survey. *CMAJ* 2011 183: E480-486

England LJ, Bennett C, Denny CH, et al. **Alcohol Use and Co-Use of Other Substances Among Pregnant Females Aged 12-44 Years - United States, 2015-2018**. *MMWR Morb Mortal Wkly Rep*. 2020;69(31):1009-1014.

England R, Dholakia N, Tukmachi E, et al. **Replace clonazepam** with an alternative antiepileptic drug (eg. lamotrigine) to reduce drug misuse. *BMJ*. 2012 Nov 19;345:e7809.

Erwin BL, Slaton RM. **Varenicline** in the Treatment of **Alcohol Use Disorders**. *Ann Pharmacother*. 2014 Nov;48(11):1445-1455.

Esser MB, Guy GP Jr, Zhang K, Brewer RD. **Binge Drinking and Prescription Opioid Misuse** in the U.S., 2012-2014. *Am J Prev Med*. 2019 Jun 7.

Esser MB, Sherk A, Liu Y, et al. Deaths and Years of Potential Life Lost From **Excessive Alcohol Use** - United States, 2011-2015. *MMWR Morb Mortal Wkly Rep*. 2020;69(30):981-987.

Evans EA, Wilson D, Friedmann PD. **Recidivism and mortality after in-jail buprenorphine treatment** for opioid use disorder. *Drug Alcohol Depend*. 2022 Feb 1;231:109254.

Evoy KE, Hill LG, Groff L, et al. **Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas**. *JAMA*. 2018 Nov 3; 320(18):1934-1937.

Ewing BA, Tucker JS, Miles JN, et al. **Early Substance Use and Subsequent DUI in Adolescents**. *Pediatrics*. 2015 Oct 5.

Fagbemi K. Q: What is the best questionnaire to **screen for alcohol use disorder** in an office practice? *Cleve Clin J Med*. 2011 Oct;78(10):649-51.

Faherty LJ, Kranz AM, Russell-Fritch J, et al. Association of **Punitive and Reporting State Policies** Related to Substance Use in Pregnancy With Rates of Neonatal Abstinence Syndrome. *JAMA Netw Open*. 2019 Nov 1;2(11):e1914078

Fahmy V, Hatch SL, Hotopf M, Stewart R. Prevalences of **illicit drug use in people aged 50 years and over** from two surveys. *Age Ageing*. 2012 Apr 5.

Fairbairn N, Ross J, Trew M, et al. **Injectable opioid agonist treatment** for opioid use disorder: a national clinical guideline. *CMAJ*. 2019 Sep 23;191(38):E1049-E1056.

Fairley M, Humphreys K, Joyce VR, et al. **Cost-effectiveness of Treatments for Opioid Use Disorder**. *JAMA Psychiatry*. 2021 Mar 31. doi: 10.1001/jamapsychiatry.2021.0247

Falkstedt D, Wolff V, Allebeck P, et al. **Cannabis, Tobacco, Alcohol Use, and the Risk of Early Stroke**: A Population-Based Cohort Study of 45 000 Swedish Men. *Stroke*. 2017 Feb;48(2):265-270.

Fanari Z, Kennedy KK, Lim MJ, Laddu AA, Stalker JM. Comparison of in-hospital outcomes for **beta-blocker** use versus non-beta blocker use in patients presenting with **cocaine-associated chest pain**. *Am J Cardiol*. 2014 Jun 1;113(11):1802-6.

Farkas A, Lynch MJ, Westover R, et al. **Pulmonary Complications of Opioid Overdose Treated With Naloxone**. *Ann Emerg Med*. 2019 Jun 7.

Farley KX, Anastasio AT, Kumar A, et al. Association Between Quantity of Opioids Prescribed After Surgery or Preoperative **Opioid Use Education With Opioid Consumption**. *JAMA*. 2019 Jun 25;321(24):2465-2467.

Fass JA, Fass AD, Garcia AS. Synthetic **cathinones (bath salts)**: legal status and patterns of abuse. *Ann Pharmacother*. 2012 Mar;46(3):436-41.

Faul M, Dailey MW, et al. Disparity in **Naloxone Administration by Emergency Medical Service Providers** and the Burden of Drug Overdose in US Rural Communities. *Am J Public Health*. 2015 Apr 23:e1-e7.

Faust JS, Du C, Mayes KD, et al. **Mortality From Drug Overdoses, Homicides, Unintentional Injuries, Motor Vehicle Crashes, and Suicides During the Pandemic, March-August 2020**. *JAMA*. 2021 May 21. doi: 10.1001/jama.2021.8012.

FDA Dec/12 **Yxrem (sodium oxybate)**, used to treat narcolepsy and cataplexy, has received an FDA warning cautioning **against its use with alcohol or central nervous system depressants** (e.g., opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, general anesthetics, and muscle relaxants). The agency warns that use of alcohol or these drugs with Yxrem could cause respiratory depression and impaired consciousness.



Feder KA, Letourneau EJ, Brook J. **Children in the Opioid Epidemic:** Addressing the Next Generation's Public Health Crisis. *Pediatrics*. 2018 Dec 4.

Fenton JJ, Agnoli AL, Xing G, et al. Trends and Rapidity of **Dose Tapering Among Patients Prescribed Long-term Opioid Therapy**. 2008-2017. *JAMA Netw Open*. 2019 Nov 1;2(11):e1916271.

Ferri M, Davoli M, Perucci CA. **Heroin maintenance** for chronic heroin-dependent individuals. *Cochrane Database Syst Rev*. 2010 Aug 4;8:CD003410. The available evidence suggests a small added value of heroin prescribed alongside flexible doses of methadone for long-term, treatment-refractory opioid users, considering a decrease in the use of street heroin and other illicit substances, and in the probability of being imprisoned; and an increase in retention in treatment. Due to the higher rate of serious adverse events, heroin prescription should remain a treatment of last resort for people who are currently or have in the past failed maintenance treatment.

Ferrell M, Wodak A, Gowing L. Maintenance drugs to treat opioid dependence. *BMJ* 2012;344:e2823. Accessed online 15 May 2012 at: [http://www.bmi.com/content/344/bmi.e2823?utm\\_source=feedburner&utm\\_medium=feed&utm\\_campaign=Feed%3A+bmi%2Feducation+\(Latest+BMJ+Education\)](http://www.bmi.com/content/344/bmi.e2823?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bmi%2Feducation+(Latest+BMJ+Education))

Field AE, Sonneville KR, Crosby RD, et al. Prospective Associations of Concerns About **Physique and the Development of Obesity**, Binge Drinking, and Drug Use Among Adolescent Boys and Young Adult Men. *JAMA Pediatr*. 2013 Nov 4.

Field C, Walters S, Marti CN, et al. A Multisite Randomized Controlled Trial of **Brief Intervention to Reduce Drinking in the Trauma Care Setting**: How Brief Is Brief?. *Ann Surg*. 2013 Nov 20

Fiellin DA, Schottenfeld RS, Cutter CJ, et al. Primary Care-Based **Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence**: A Randomized Clinical Trial. *JAMA Intern Med*. 2014 Oct 20.

Fill MA, Miller AM, Wilkinson RH, et al. **Educational Disabilities Among Children Born With Neonatal Abstinence Syndrome**. *Pediatrics*. 2018 Sep;142(3). pii: e20180562.

Fine DR, Dickens KA, Adams LD, et al. **Drug Overdose Mortality** Among People Experiencing Homelessness, 2003 to 2018. *JAMA Netw Open*. 2022 Jan 4;5(1):e2142676.

Fine DR, Lewis E, Weinstock K, et al. Office-Based Addiction **Treatment Retention and Mortality** Among People Experiencing Homelessness. *JAMA Netw Open*. 2021 Mar 1;4(3):e210477

Fink DS, Schleimer JP, Sarvet A, et al. Association between **prescription drug monitoring programs** and nonfatal and fatal drug overdoses. A systematic review. *Ann Intern Med*. 2018. [Epub ahead of print].

Finnell JT, Twillman RK, Breslan SA, et al. The Role of **Continuing Medical Education** in Increasing Enrollment in **Prescription Drug Monitoring Programs**. *Clin Ther*. 2017 Aug 30.

Finney FT, Gossett TD, Hu HM, et al. Rate of Opioid **Prescriptions for Patients With Acute Ankle Sprain**. *Ann Intern Med*. 2019 Jul 9.

Fiscella K, Wakeman SE, Beletsky L. Implementing **Opioid Agonist Treatment in Correctional Facilities**. *JAMA Intern Med*. 2018 Jul 30.

Fiscella K, Wakeman SE, Beletsky L. **Buprenorphine Deregulation and Mainstreaming Treatment** for Opioid Use Disorder: X the X Waiver. *JAMA Psychiatry*. 2018 Dec 26.

Fischer B, Rehm J, Tyndall M. Effective Canadian **policy to reduce harms from prescription opioids**: learning from past failures. *CMAJ*. 2016 Dec 6;188(17-18):1240-1244. Review.

Fischer B, Russell C, Sabioni P, et al. **Lower-Risk Cannabis Use Guidelines**: A Comprehensive Update of Evidence and Recommendations. *Am J Public Health*. 2017 Jun 23:e1-e12.

Flegel K, Macdonald N, Hébert PC. Binge drinking: all too prevalent and hazardous. *CMAJ*. 2011 Jan 17. Accessed online at: <http://www.cmaj.ca/cgi/content/full/183/4/411?etoc>

Flegel K. **Big alcohol catches up with adolescent girls**. *CMAJ*. 2013 Jul 9;185(10):859.

Foa EB, Yuskov DA, McLean CP, et al. Concurrent **naltrexone and prolonged exposure therapy** for patients with **comorbid alcohol dependence and PTSD**: a randomized clinical trial. *JAMA*. 2013 Aug 7;310(5):488-95.

Follman S, Arora VM, Lyytke C, et al. **Naloxone Prescriptions Among Commercially Insured Individuals at High Risk of Opioid Overdose**. *JAMA Netw Open*. 2019 May 3;2(5):e193209.

Fontanella CA, Steelesmith DL, Brock G, et al. Association of **Cannabis Use With Self-harm and Mortality Risk** Among Youths With Mood Disorders. *JAMA Pediatr*. 2021 Jan 19. doi: 10.1001/jamapediatrics.2020.5494

Forray A, Sofuoglu M. **Future Pharmacological Treatments** for Substance Use Disorders. *Br J Clin Pharmacol*. 2012 Oct 5.

Foxcroft DR, Tsertsvadze A. **Universal school-based prevention programs for alcohol misuse** in young people. *Cochrane Database of Systematic Reviews* 2011, Issue 5. Art. No.: CD009113. DOI: 10.1002/14651858.CD009113.

Foxcroft DR, Coombes L, Wood S, et al. **Motivational interviewing for alcohol misuse** in young adults. *Cochrane Database of Systematic Reviews* 2014, Issue 8. Art.No.: CD007025. DOI: 10.1002/14651858.CD007025.pub2. The results of this review indicate that there are no substantive, meaningful benefits of MI interventions for the prevention of alcohol misuse. Although some significant effects were found, we interpret the effect sizes as being too small, given the measurement scales used in the studies included in the review, to be of relevance to policy or practice. Moreover, the statistically significant effects are not consistent for all misuse measures, heterogeneity was a problem in some analyses and bias cannot be discounted as a potential cause of these findings.

Frank RG, Pollack HA. **Addressing the Fentanyl Threat to Public Health**. *N Engl J Med*. 2017 Feb 16;376(7):605-607.

Franklin SM, Thihaloipavan S, Fontaine JM. **Sinus Bradycardia in Habitual Cocaine Users**. *Am J Cardiol*. 2017 Mar 1.

Frazier W, Cochran G, Lo-Ciganic WH, et al. Medication-Assisted Treatment and **Opioid Use Before and After Overdose** in Pennsylvania Medicaid. *JAMA*. 2017 Aug 22;318(8):750-752.

Freeman MJ, Rose DZ, Myers MA, Gooch CL, Bozeman AC, Burgin WS. Ischemic stroke after use of the **synthetic marijuana "spice."** *Neurology* 2013;81: 2090–2093.

Freedman Neal D, Murray Liam J, Kamangar Farin, et al. **Alcohol intake and risk of oesophageal adenocarcinoma**: a pooled analysis from the BEACON Consortium. *Gut* gut.2010.233866Published Online First: 14 March 2011 doi:10.1136/gut.2010.233866

French DD, Margo CE, Harman LE. Substance Use Disorder (**cocaine**) and the Risk of Open-angle **Glaucoma**. *J Glaucoma*. 2011 Sep;20(7):452-7.

Friedman J, Beletsky L, Schriger DL. **Overdose-Related Cardiac Arrests** Observed by Emergency Medical Services During the US COVID-19 Epidemic. *JAMA Psychiatry*. 2020 Dec 3. doi: 10.1001/jamapsychiatry.2020.4218

Friedman JH, Chang V. **Crack cocaine use due to dopamine agonist therapy in Parkinson disease**. *Neurology*. 2013 Jun 11;80(24):2269-70.

Friedman JR, Hansen H. Evaluation of **Increases in Drug Overdose Mortality Rates** in the US by Race and Ethnicity Before and During the COVID-19 Pandemic. *JAMA Psychiatry*. 2022 Mar 2:e220004.

Friedmann PD. Clinical practice. **Alcohol use in adults**. *N Engl J Med*. 2013 Jan 24;368(4):365-73.

Friedmann PD, Andrews CM, Humphreys K. How **ACA Repeal Would Worsen the Opioid Epidemic**. *N Engl J Med*. 2017 Mar 9;376(10):e16.

Friedman J, Kim D, Schneberk T, et al. Assessment of **racial/ethnic and income disparities in the prescription of opioids and other controlled medications** in California [online Feb 11, 2019]. *JAMA Intern Med*.

From D, Paltser G. **Types of Opioid Harms in Canadian Hospitals**: Comparing Canada and Australia. *Healthc Q*. 2019 Jul;22(2):10-12.

Frost L, Mostofsky E, Rosenbloom JL, Mukamal KJ, Mittleman MA. **Marijuana use** and long-term mortality among survivors of acute myocardial infarction. *Am Heart J*. 2013 Feb;165(2):170-5.

Furlan AD, Reardon R, Weppler C; **National Opioid Use Guideline Group**. Opioids for chronic noncancer pain: a new Canadian practice guideline. (**NOUGG**) *CMAJ*. 2010 Jun 15;182(9):923-30. Links: <http://nationalpaincentre.mcmaster.ca/opioid/documents.html>

Part A Executive summary & background: [http://nationalpaincentre.mcmaster.ca/documents/opioid\\_guideline\\_part\\_a\\_v4\\_5.pdf](http://nationalpaincentre.mcmaster.ca/documents/opioid_guideline_part_a_v4_5.pdf)

Part B Recommendations for practice: [http://nationalpaincentre.mcmaster.ca/documents/opioid\\_guideline\\_part\\_b\\_v5\\_6.pdf](http://nationalpaincentre.mcmaster.ca/documents/opioid_guideline_part_b_v5_6.pdf)

Gaeta JM, Racine M. New Strategies Are Needed to Stop Overdose Fatalities: The Case for **Supervised Injection Facilities**. *Ann Intern Med*. 2018 Feb 6.

Gaither JR, Leventhal JM, Ryan SA, et al. **National Trends in Hospitalizations for Opioid Poisonings Among Children and Adolescents**, 1997 to 2012. *JAMA Pediatr*. 2016 Oct 31.

Gaither JR, Shabanova V, Leventhal JM. US National **Trends in Pediatric Deaths From Prescription and Illicit Opioids**, 1999-2016. *JAMA Netw Open*. 2018;1(8):e186558.

Galéra C, Pingault JB, Fombonne E, et al. **Attention problems** in childhood and adult substance use. *J Pediatr*. 2013 Dec;163(6):1677-1683.e1.

Galinkin J, Koh JL; Committee on Drugs; Section On Anesthesiology and Pain Medicine; American Academy of Pediatrics. Recognition and management of **iatrogenically induced opioid dependence and withdrawal in children**. *Pediatrics*. 2014 Jan;133(1):152-5.

Ganson KT, Mitchison D, Murray SB, Nagata JM. **Legal Performance-Enhancing Substances** and Substance Use Problems Among Young Adults. *Pediatrics*. 2020:e20200409.

Gao L, Robertson JR, Bird SM. Scotland's 2009-2015 **methadone-prescription cohort**: quintiles for daily-dose of prescribed methadone and risk of methadone-specific death. *Br J Clin Pharmacol*. 2020;10.1111/bcp.14432

Gapstur Susan M; Jacobs Eric J; Deka Anusila; et al. Association of **Alcohol Intake With Pancreatic Cancer Mortality** in Never Smokers. *Arch Intern Med*. 2011;171(5):444-451.

Garbutt JC, Kampov-Polevoy AB, Kalka-Juhl LS, et al. Association of the Sweet-Liking Phenotype and Craving for **Alcohol** With the Response to **Naltrexone** Treatment in Alcohol Dependence: A Randomized Clinical Trial. *JAMA Psychiatry*. 2016 Sep 14.

Gardly JL, Johnston JC, Sui SJ, et al. Whole-genome sequencing and social-network analysis (**crack cocaine**) of a tuberculosis outbreak. *N Engl J Med*. 2011 Feb 24;364(8):730-9.

Garcia-Portilla MP, Bobes-Bascaran MT, Bascaran MT, et al. Long-term outcomes of pharmacological treatments for **opioid dependence**: Does **methadone** still lead the pack? *Br J Clin Pharmacol*. 2012 Nov 12.

Garland EL, Hanley AW, Nakamura Y, et al. Mindfulness-Oriented Recovery Enhancement **vs Supportive Group Therapy** for Co-occurring Opioid Misuse and Chronic Pain in Primary Care: A Randomized Clinical Trial. *JAMA Intern Med*. 2022 Feb 28:e220033

Gehrie EA, Keiser A, Haglock-Adler CJ, et al. **Detecting Pharmaceuticals in the Red Blood Cell Inventory** of a Hospital Blood Bank. *J Pediatr*. 2017 Jun 29.

Gellad WF, Good CB, Shulkin DJ. **Addressing the Opioid Epidemic in the United States**: Lessons From the Department of Veterans Affairs. *JAMA Intern Med*. 2017 Mar 13.

Ghazawi FM, Beecker J. **Necrotic leg ulcers** associated with krokodil injection in a 41-year-old man. *CMAJ*. 2019 Jun 24;191(25):E712.

Gilman JM, Kuster JK, Lee S, et al. **Cannabis** use is quantitatively associated with **nucleus accumbens and amygdala abnormalities** in young adult recreational users. *J Neurosci*. 2014 Apr 16;34(16):5529-38.

Girard HL, Litkowiec S, Sohn M. **Attention-Deficit/Hyperactivity Disorder** and Psychotropic Polypharmacy Prescribing Trends. *Pediatrics*. 2020:e20192832.

Gladstone E, Smolina K, Morgan SG, et al. Sensitivity and specificity of **administrative mortality data** for identifying **prescription opioid-related deaths**. *CMAJ*. 2015 Nov 30.

Glanz JM, Binswanger IA, Shetterly SM, et al. Association Between **Opioid Dose Variability and Opioid Overdose** Among Adults Prescribed Long-term Opioid Therapy. *JAMA Netw Open*. 2019 Apr 5;2(4):e192613.

Glei DA, Preston SH. Estimating the **impact of drug use on US mortality**, 1999-2016. *PLoS One*. 2020 Jan 15;15(1):e0226732.

Glod SA. The Other **Victims of the Opioid Epidemic**. *N Engl J Med*. 2017 Jun 1;376(22):2101-2102.

Goedel WC, Shapiro A, Cerdá M, et al. Association of **Racial/Ethnic Segregation With Treatment Capacity** for Opioid Use Disorder in Counties in the United States. *JAMA Netw Open*. 2020 Apr 1;3(4):e203711

Goldman RD. Drug-induced **gynecomastia** in children and adolescents. *Can Fam Physician*. 2010 Apr;56(4):344-5. Adolescents who use anabolic steroids, or who abuse alcohol, marijuana, heroin, or amphetamines, should be alerted to the fact that gynecomastia might develop.

Gomes T, Campbell TJ, Kitchen SA, et al. Association Between Increased Dispensing of Opioid Agonist Therapy **Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation**. *JAMA*. 2022 Mar 1;327(9):846-855.

Gomes T, Greaves S, Tadrus M, et al. Measuring the Burden of Opioid-related Mortality in Ontario, Canada. *J Addict Med*. 2018 Apr 25.

Gomes T, Greaves S, van den Brink W, et al. **Pregabalin and the Risk for Opioid-Related Death**: A Nested Case-Control Study. *Ann Intern Med*. 2018 Aug 21.

Gomes T, Khuu W, Martins D, et al. Contributions of **prescribed and non-prescribed opioids to opioid related deaths**: population based cohort study in Ontario, Canada. *BMJ*. 2018 Aug 29;362:k3207.

Gomes T, Kitchen SA, Murray R. Measuring the **Burden of Opioid-Related Mortality** in Ontario, Canada, During the COVID-19 Pandemic. *JAMA Netw Open*. 2021 May 3;4(5):e2112865.

Gomes T, Mamdani MM, Dhalla IA, et al. The burden of **premature opioid-related mortality**. *Addiction*. 2014 Jul 7.

Gomes T, Mamdani MM, Paterson JM, et al. Trends in **high-dose opioid prescribing** in Canada. *Can Fam Physician*. 2014 Sep;60(9):826-32.

Gomes T, Tadrus M, Mamdani MM, et al. The **burden of opioid-related mortality** in the United States. *JAMA Netw Open*. 2018;1(2):e180217.

Gonçalves A, Jhund PS, Claggett B, et al. Relationship between **alcohol consumption** and cardiac structure and function in the elderly: the atherosclerosis risk in communities study. *Circ Cardiovasc Imaging*. 2015 Jun;8(6).

Goodwin JS, Kuo Y-F, Brown D, et al. Association of **chronic opioid use with presidential voting patterns in US counties** in 2016. *JAMA Netw Open*. 2016;1(2):e180450.

Gottlieb S, Woodcock J. **Marshaling FDA Benefit-Risk Expertise** to Address the Current Opioid Abuse Epidemic. *JAMA*. 2017 Jul 6.

Gowing L, Farrell MF, Ali R, White JM. **Alpha2-adrenergic agonists** for the management of **opioid withdrawal**. *Cochrane Database of Systematic Reviews* 2014, Issue 3. Art. No.: CD002024. DOI: 10.1002/14651858.CD002024.pub4. Clonidine and lofexidine are more effective than placebo for the management of withdrawal



from heroin or methadone. No significant difference in efficacy was detected for treatment regimens based on clonidine or lofexidine, and those based on reducing doses of methadone over a period of around 10 days but methadone is associated with fewer adverse effects than clonidine, and lofexidine has a better safety profile than clonidine.

Gowing L, Ali R, White JM, et al. **Buprenorphine for managing opioid withdrawal.** Cochrane Database Syst Rev. 2017 Feb 21;2:CD002025. Buprenorphine is more effective than clonidine or lofexidine for managing opioid withdrawal in terms of severity of withdrawal, duration of withdrawal treatment, and the likelihood of treatment completion. Buprenorphine and methadone appear to be equally effective, but data are limited. It remains possible that the pattern of withdrawal experienced may differ and that withdrawal symptoms may resolve more quickly with buprenorphine. It is not possible to draw any conclusions from the available evidence on the relative effectiveness of different rates of tapering the buprenorphine dose. The divergent findings of studies included in this review suggest that there may be multiple factors affecting the response to the rate of dose taper. One such factor could be whether or not the initial treatment plan includes a transition to subsequent relapse prevention treatment with naltrexone. Indeed, the use of buprenorphine to support transition to naltrexone treatment is an aspect worthy of further research. Most participants in the studies included in this review were male. None of the studies reported outcomes on the basis of sex, preventing any exploration of differences related to this variable. Consideration of sex as a factor influencing response to withdrawal treatment would be relevant research for selecting the most appropriate type of intervention for each individual.

Gowing L, Farrell M, Ali R, White JM. **Alpha<sub>2</sub>-adrenergic agonists for the management of opioid withdrawal.** Cochrane Database Syst Rev. 2016 May 3;(5):CD002024. Clonidine and lofexidine are more effective than placebo for the management of withdrawal from heroin or methadone. We detected no significant difference in efficacy between treatment regimens based on clonidine or lofexidine and those based on reducing doses of methadone over a period of around 10 days, but methadone was associated with fewer adverse effects than clonidine, and lofexidine has a better safety profile than clonidine.

Graetz I, Yarbrough CR, Hu X, Howard DH. Association of **Mandatory-Access Prescription Drug Monitoring Programs** With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist. JAMA Oncol. 2020 May 7. doi: 10.1001/jamaoncol.2020.0804

Graf J, Lynch K, Yeh CL et al. Purpura, cutaneous necrosis, and antineutrophil cytoplasmic antibodies associated with **levamisole-adulterated cocaine**. Arthritis Rheum. 2011 Dec;63(12):3998-4001.

Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015 Jun 3.

Grant BF, Saha TD, Ruan WJ, et al. Epidemiology of **DSM-5 Drug Use Disorder**: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry. 2015 Nov 18;1-9.

Green TC, Clarke J, Brinkley-Rubinstein L, et al. **Postincarceration Fatal Overdoses** After Implementing Medications for Addiction Treatment in a Statewide Correctional System. JAMA Psychiatry. 2018 Feb 14.

Gregson M. **Alcohol abuse** and teens. Parenting Today's Teens. Accessed online 04 Aug at: <http://www.heartlightministries.org/blogs/markgregston/2011/06/03/alcohol-abuse-teens/>

Grelotti DJ, Closson EF, Mimiaga MJ. Pretreatment antiretroviral exposure under recreational use. Lancet Infect Dis. 2013 Jan;13(1):10-2. (**efavirenz, ritonavir**)

Grenard JL, Dent CW, Stacy AW. Exposure to **Alcohol Advertisements** and Teenage Alcohol-Related Problems. Pediatrics. 2013 Jan 28.

Gressler LE, Shah S, Shaya FT. Association of **Criminal Statutes for Opioid Use Disorder** With Prevalence and Treatment Among Pregnant Women With Commercial Insurance in the United States. JAMA Netw Open. 2019 Mar 1;2(3):e190338.

Griesler PC, Hu MC, Wall MM, Kandel DB. Assessment of Prescription **Opioid Medical Use and Misuse** Among Parents and Their Adolescent Offspring in the US. JAMA Netw Open. 2021 Jan 4;4(1):e2031073

Griesler PC, Hu MC, Wall MM, Kandel DB. **Nonmedical Prescription Opioid Use** by Parents and Adolescents in the US. Pediatrics. 2019 Mar;143(3).

Groenewald CB, Zhou C, Palermo TM, Van Cleve WC. Associations Between **Opioid Prescribing Patterns and Overdose** Among Privately Insured Adolescents. Pediatrics. 2019 Oct 1. doi: 10.1542/peds.2018-4070.

Grossman MR, Berkwitz AK, Osborn RR, et al. An Initiative to Improve the Quality of Care of **Infants With Neonatal Abstinence Syndrome**. Peds. 2017;139(6):e20163360

Gruener AM, Jeffries MA, El Housseini Z, et al. **Poppers maculopathy**. Lancet. 2014 Jun 19.

Gruza RA, Agrawal A, Krauss MJ, et al. Recent Trends in the Prevalence of **Marijuana Use and Associated Disorders** in the United States. JAMA Psychiatry. 2016 Feb 10.

Gryczynski J, Nordeck CD, Welsh C, et al. **Preventing Hospital Readmission** for Patients With Comorbid Substance Use Disorder : A Randomized Trial. Ann Intern Med. 2021 Apr 6. doi: 10.7326/M20-5475

Guadamuz JS, Alexander GC, Chaudhri T, et al. **Availability and Cost of Naloxone Nasal Spray at Pharmacies** in Philadelphia, Pennsylvania, 2017. JAMA Netw Open. 2019 Jun 5;2(6):e195388.

Gubner NR, Kozar-Konieczna A, Szoltysek-Boldys I, et al. **Cessation of alcohol consumption decreases rate of nicotine metabolism** in male alcohol-dependent smokers. Drug Alcohol Depend. 2016 Apr 14.

Guille C, Simpson AN, Douglas E, et al. Treatment of **Opioid Use Disorder in Pregnant Women** via Telemedicine: A Nonrandomized Controlled Trial. JAMA Netw Open. 2020 Jan 3;3(1):e1920177

Gunderson EW. **Synthetic Cannabinoids**: A New Frontier of Designer Drugs. Ann Intern Med. 2013 Sep 10.

Guo L, Xu Y, Deng J, et al. Association Between **Nonmedical Use of Prescription Drugs and Suicidal Behavior Among Adolescents**. JAMA Pediatr. 2016 Oct 1;170(10):971-978

Gupta N, Washam JB, Mountantonakis SE, et al. Characteristics, Management, and Outcomes of **Cocaine-Positive Patients** With Acute Coronary Syndrome (from the National Cardiovascular Data Registry). Am J Cardiol. 2014 Mar 1;113(5):749-56.

Gupta R, Shah ND, Ross JS. The **Rising Price of Naloxone** - Risks to Efforts to Stem Overdose Deaths. N Engl J Med. 2016 Dec 8;375(23):2213-2215

Gurudevan SV, Nelson MD, Rader F et al. **Cocaine**-induced vasoconstriction in the human coronary microcirculation: new evidence from myocardial contrast echocardiography. Circulation. 2013 Aug 6;128(6):598-604.

Gustafson DH, McTavish FM, Chih MY, et al. A **Smartphone Application** to Support Recovery From **Alcoholism**: A Randomized Clinical Trial. JAMA Psychiatry. 2014 Mar 26.

Guy GP Jr, Zhang K, Schieber LZ, et al. **County-level opioid prescribing** in the United States, 2015 and 2017 [online Feb 11, 2019]. JAMA Intern Med.

Hadland SE, Bagley SM, Gai MJ, et al. **Opioid Use Disorder and Overdose** Among Youth Following an Initial Opioid Prescription. Addiction. 2021 Mar 19. doi: 10.1111/add.15487

Hadland SE, Bagley SM, Rodean J, et al. Receipt of **Timely Addiction Treatment** and Association of Early Medication Treatment With Retention in Care Among Youths With **Opioid Use Disorder**. JAMA Pediatr. 2018 Sep 10.

Hadland SE, Cerdá M, Li Y, et al. Association of Pharmaceutical Industry **Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing**. JAMA Intern Med. 2018 May 14.

Hadland SE, Copelas SH, Harris SK. **Trajectories of Substance Use** Frequency among **Adolescents** Seen in Primary Care: Implications for Screening. J Pediatr. 2017 Feb 10.

Hadland SE, Krieger MS, Marshall BDL. **Industry Payments to Physicians for Opioid Products**, 2013-2015. Am J Public Health. 2017 Sep;107(9):1493-1495

Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerdá M. Association of **pharmaceutical industry marketing** of opioid products with mortality from opioid-related overdoses. JAMA Netw Open. 2019;2(1):e186007. doi:10.1001/jamanetworkopen.2018.6007

Hadland SE, Wharam JF, Schuster MA, et al. **Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults**, 2001-2014 [published online June 19, 2017]. JAMA Pediatr. doi:10.1001/jamapediatrics.2017.0745

Haffajee RL, Frank RG. Making the Opioid Public Health Emergency Effective. JAMA Psychiatry. 2018 Apr 25.

Haffajee RL, Jena AB, Weiner SG. **Mandatory Use of Prescription Drug Monitoring Programs**. JAMA. 2015 Jan 26.

Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of US Counties With High Opioid Overdose Mortality and **Low Capacity to Deliver Medications for Opioid Use Disorder**. JAMA Netw Open. 2019 Jun 5;2(6):e196373.

Haffajee RL, MacCoun RJ, Mello MM. Behind Schedule - **Reconciling Federal and State Marijuana Policy**. N Engl J Med. 2018 Jul 11.

Haffajee RL, Mello MM. **Drug Companies' Liability for the Opioid Epidemic**. N Engl J Med. 2017 Dec 14;377(24):2301-2305.

Hagan JF, Balachova T, Bertrand J, et al. Neurobehavioral disorder associated with **prenatal alcohol** exposure. Pediatrics. 2016;138(4):e20151553

Hall ES, Wexelblatt SL, Crowley M, et al; CHNAS Consortium. Implementation of a **Neonatal Abstinence Syndrome Weaning Protocol**: A Multicenter Cohort Study. Pediatrics. 2015 Sep 14.

Hall W, Stjepanović D, Caulkins J, et al. Public health implications of **legalising the production and sale of cannabis** for medicinal and recreational use. Lancet. 2019 Oct 26;394(10208):1580-1590.

Haller DM, Meynard A, Lefebvre D, et al. Effectiveness of **training family physicians to deliver a brief intervention** to address excessive substance use among young patients: a cluster randomized controlled trial. CMAJ. 2014 Mar 10.

Han B, Compton WM, Jones CM, et al. **Methamphetamine Use**, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. JAMA Psychiatry. 2021 Sep 22. doi: 10.1001/jamapsychiatry.2021.2588

Han B, Compton WM, Jones CM, et al. **Nonmedical Prescription Opioid Use and Use Disorders** Among Adults Aged 18 Through 64 Years in the United States, 2003-2013. JAMA. 2015 Oct 13;314(14):1468-78.

Han B, Compton WM, Blanco C, et al. Prescription Opioid Use, **Misuse**, and Use **Disorders** in U.S. Adults: 2015 National Survey on Drug Use and Health. Ann Intern Med. 2017 Aug 1.

Han B, Jones CM, Einstein EB, Compton WM. Trends in and Characteristics of **Buprenorphine Misuse** Among Adults in the US. JAMA Netw Open. 2021 Oct 1;4(10):e2129409.

Han BH, Leddy JF, Lopez FA, Palamar JJ. Prevalence of Psychoactive **Substance Use Among Middle-aged and Older Adults With Visual Impairment** in the US. JAMA Ophthalmol. 2021 Nov 11. doi: 10.1001/jamaophthalmol.2021.4667.

Han BH, Palamar JJ. **Marijuana use by middle-aged and older adults in the United States**, 2015-2016. Drug Alcohol Depend. 2018 Oct 1;191:374-381.

Han BH, Sherman S, Mauro PM, et al. **Demographic trends among older cannabis users** in the United States, 2006-13. Addiction. 2016 Oct 21.

Han C, Sreenivasan G, Dutz JP. Reversible **retiform purpura**: a sign of **cocaine** use. CMAJ. 2011 Jun 14;183(9):E597-600. (contamination with levamisole)

Handford C. **Buprenorphine/naloxone for opioid dependence**: clinical practice guideline. Toronto: Centre for Addiction and Mental Health; 2011. [http://knowledge.camh.net/primary\\_care/guidelines\\_materials/Documents/buprenorphine\\_naloxone\\_gdlns2011.pdf](http://knowledge.camh.net/primary_care/guidelines_materials/Documents/buprenorphine_naloxone_gdlns2011.pdf) (accessed November 14, 2011).

Hanewinkel R, Sargent JD, Hunt K, et al. Portrayal of **Alcohol Consumption in Movies and Drinking Initiation in Low-Risk Adolescents**. Pediatrics. 2014 May 5.

Harbaugh CM, Lee JS, Chua K-P, et al. Association between **long-term opioid use in family members and persistent opioid use after surgery** among adolescents and young adults [online Feb 27, 2019]. JAMA Surg.

Harbaugh CM, Lee JS, Hu HM, et al. **Persistent opioid use among pediatric patients after surgery**. Pediatrics. 2018;141(1):e20172439Harris SK, Csémy L, Sherritt L, et al. **Computer-Facilitated Substance Use Screening and Brief Advice** for Teens in Primary Care: An International Trial. Pediatrics. 2012 May 7.

Harbaugh CM, Nalliah RP, Hu HM, et al. Persistent **Opioid Use After Wisdom Tooth Extraction**. JAMA. 2018 Aug 7;320(5):504-506.

Harbaugh CM, Vargas G, Streur CS, et al. Eliminating Unnecessary Opioid **Exposure After Common Children's Surgeries**. JAMA Surg. 2019 Sep 4.

Hartz SM, Pato CN, Medeiros H, et al. for the Genomic Psychiatry Cohort Consortium, **Comorbidity of Severe Psychotic Disorders** With Measures of Substance Use. JAMA Psychiatry. 2014 Jan 1.

Hasin DS, Wall M, Keyes KM, et al. **Medical marijuana laws and adolescent marijuana use** in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys. Lancet Psychiatry. 2015 Jul;2(7):601-8.

Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of **Marijuana Use Disorders** in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015 Oct 21;1-9.

Hauk L. **Management of Chronic Pain and Opioid Misuse**: A Position Paper from the AAFP. Am Fam Physician. 2017 Apr 1;95(7):458-459

Hawk KF, D'Onofrio G, Chawarski MC, et al. Barriers and Facilitators to Clinician Readiness to Provide **Emergency Department-Initiated Buprenorphine**. JAMA Netw Open. 2020 May 1;3(5):e204561

Hawkes N. UK drug service is ill equipped to deal with new **"legal highs"** taken by clubbers, conference is told. BMJ. 2012 Oct 24;345:e7162.

Haymond S, Nagpal G, Heiman H. **Urine Drug Screens** to Monitor **Opioid Use** for Managing Chronic Pain. JAMA. 2017 Sep 19;318(11):1061-1062.

Health Canada Mar/11 **Salvia divinorum** (S. divinorum) is a species of sage belonging to the mint family. Some street names for S. divinorum include: Sally D, Lady Sally, Maria pastora, ska Maria pastora, ska pastora, diviner's sage, magic mint, puff, incense special, and salvia. Canadians are cautioned against the use of products containing S. divinorum and/or salvinorin A because these products are known to cause hallucinations and little is known about the long-term effects of these substances on the brain and body.

Health Canada May/13 has been made aware of three products ("Rochefort", "Rush" and "Amsterdam Special"), commonly known as **"poppers"**, labelled to contain alkyl nitrites. These products, labelled as leather cleaners and/or liquid incense, are known to be used by consumers to get "high" and may pose serious risks to health if they are inhaled or swallowed.

Health Canada Jun/13 Eight products labelled as leather cleaners or liquid incense contain, or allege to contain, **alkyl nitrites** were being sold by Saints N Sinners Ltd, 1715 Centre Street N.W., Calgary, Alberta. These products, commonly known as "poppers" are used by consumers to get "high" and may pose serious risks to health if they are inhaled or swallowed

Health Canada Dec/14 is following up with Rapha Biotech Inc. **Rapha Diet** (630 mg, 270 Capsules) -- undeclared ingredients: amphetamine, methamphetamine.

Health Canada Jun/17 is advising health care professionals and Canadians that the **Canadian authorized version of NARCAN** will transition onto the market by July 5, 2017. NARCAN is a nasal spray form of naloxone, the life-saving drug that temporarily reverses the effects of an opioid overdose.

Health Canada June/18: Health Canada reminds Canadians of the **limitations of fentanyl test strips being used to check street drugs** before consumption.

Health Canada Sep/19 is advising Canadians about the increased risk of **opioid overdose and serious side effects when taking gabapentin (e.g., Neurontin) or pregabalin (e.g., Lyrica)** with an opioid.

Heard K, Monte AA, Hoyte CO. Brief Commentary: Consequences of Marijuana: **Observations From the Emergency Department**. Ann Intern Med. 2019 Jan 8.

Heil SH, Melbostad HS, Matusiewicz AK, et al. Efficacy and Cost-Benefit of Onsite **Contraceptive Services With and Without Incentives** Among Women With Opioid Use Disorder at High Risk for Unintended Pregnancy: A Randomized Clinical Trial. JAMA Psychiatry. 2021 Jul 14:e211715

Hellinger WC, Bacalis LP, Kay RS, et al. Health care-associated **hepatitis C virus infections attributed to narcotic diversion**. Ann Intern Med. 2012 Apr 3;156(7):477-82.

Henke RM, Tehrani AB, Ali MM, et al. **Opioid Prescribing to Adolescents** in the United States From 2005 to 2016. Psychiatr Serv. 2018 Jul 9:apps201700562.

Herder M, Juurlink D. High-strength opioid formulations: the **case for a ministerial recall**. CMAJ. 2018 Dec 3;190(48):E1404-E1405.

Herzig SJ, et al. **Improving the Safety of Opioid Use for Acute Noncancer Pain in Hospitalized Adults**: A Consensus Statement From the Society of Hospital Medicine.

J Hosp Med. 2018 Apr;13(4):263-271.

Herzig SJ. Web Exclusive. Annals for Hospitalists Inpatient Notes – **Managing Acute Pain in the Hospital in the Face of the Opioid Crisis**. Ann Intern Med. 2018 Sep 18;169(6):HO2-HO3.

Heyward J, Olson L, Sharfstein JM, et al. Evaluation of the Extended-Release/Long-Acting Opioid **Prescribing Risk Evaluation and Mitigation Strategy Program** by the US Food and Drug Administration: A Review. JAMA Intern Med. 2019 Dec 30. doi: 10.1001/jamainternmed.2019.5459.

Hines L, Glick J, Bilka K, et al. **Medical Marijuana for Minors May Be Considered Child Abuse**. Pediatrics. 2018 Sep 13.

Hines LA, Freeman TP, Gage SH, et al. Association of **High-Potency Cannabis Use** With Mental Health and Substance Use in Adolescence. JAMA Psychiatry. 2020:e201035.

Hirai AH, Ko JY, Owens PL, et al. **Neonatal Abstinence Syndrome** and Maternal Opioid-Related Diagnoses in the US, 2010-2017. JAMA. 2021 Jan 12;325(2):146-155

Hjorthøj C, Albert N, Nordentoft M. Association of **Substance Use Disorders** With Conversion From **Schizotypal Disorder to Schizophrenia**. JAMA Psychiatry. 2018 Apr 25.

Hjorthøj C, Posselt CM, Nordentoft M. Development Over Time of the Population-Attributable **Risk Fraction for Cannabis Use Disorder in Schizophrenia** in Denmark. JAMA Psychiatry. 2021 Jul 21. doi: 10.1001/jamapsychiatry.2021.1471

Hockenhuill J, Amioka E, Black JC, et al. Non-medical use of **benzodiazepines and GABA analogues** in Europe. Br J Clin Pharmacol. 2020 Sep 4. doi: 10.1111/bcp.14537

Hockenhuill J, Black JC, Haynes CM, et al. Non-medical use of **benzodiazepines and Z-drugs** in the United Kingdom. Br J Clin Pharmacol. 2020;10.1111/bcp.14397

Hockenhuill J, Wood D, Dargan P. An evaluation of **online discussion relating to non-medical use** of prescription opioids within the United Kingdom. BJCP 2020 Oct 14. doi: 10.1111/bcp.14603

Hohl BC, Wiley S, Wiebe DJ, et al. Association of **drug and alcohol use** with adolescent firearm homicide at individual, family, and neighborhood levels [online Jan 3, 2017]. JAMA Intern Med. 2019 Dec 30. doi: 10.1001/jamainternmed.2016.8180

Holmes AV, Atwood EC, Whalen B, et al. **Rooming-In to Treat Neonatal Abstinence Syndrome**: Improved Family-Centered Care at Lower Cost. Pediatrics. 2016 May 18.

Holmes MV, Dale CE, Zuccolo L, et al. Association between **alcohol and cardiovascular disease**: Mendelian randomization analysis based on individual participant data. BMJ 2014;

Honein MA, Boyle C, Redfield RR. Public Health Surveillance of **Prenatal Opioid Exposure** in Mothers and Infants. Pediatrics. 2019 Jan 17.

Hooten WM, St Sauver JL, McGree ME, et al. Incidence and Risk Factors for Progression From **Short-term to Episodic or Long-term Opioid Prescribing**: A Population-Based Study. Mayo Clin Proc. 2015 Jul;90(7):850-6.

Horvat P, Richards M, Kubinova R, et al. **Alcohol consumption**, drinking patterns, and cognitive function in older Eastern European adults. Neurology. 2015 Jan 20;84(3):287-95.

Howard R, Hallway A, et al. Optimizing **Postoperative Opioid Prescribing** Through Quality-Based Reimbursement. JAMA Netw Open. 2019 Sep 4;2(9):e1911619.

Howard R, Waljee J, Brummett C, et al. **Reduction in Opioid Prescribing Through Evidence-Based Prescribing Guidelines**. JAMA Surg. 2017 Dec 6.

Hoyme HE, Kalberg WO, Elliott AJ, et al. Updated Clinical Guidelines for Diagnosing **Fetal Alcohol Spectrum Disorders**. Pediatrics. 2016 Aug;138(2).

Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of **synthetic cannabinoid exposures** (spice) reported to the national poison data system in 2010. Ann Emerg Med. 2012 Oct;60(4):435-8.

Hser YI, Huang D, Saxon AJ, et al. **Distinctive Trajectories of Opioid Use** Over an Extended Follow-up of Patients in a Multisite Trial on **Buprenorphine + Naloxone and Methadone**. J Addict Med. 2017 Jan/Feb;11(1):63-69.

Hu T, Nijmeh L, Pyle A. **Buprenorphine-naloxone**. CMAJ. 2018 Nov 26;190(47):E1389.

Huang X, Keyes KM, Li G. Increasing **Prescription Opioid and Heroin Overdose Mortality** in the United States, 1999-2014: An Age-Period-Cohort Analysis. Am J Public Health. 2017 Nov 21:e1-e6

Hudak ML, Tan RC et al. **Neonatal Drug Withdrawal**. Pediatrics. 2012 Jan 30.

Hudgins JD, Porter JJ, Monuteaux MC, Bourgeois FT. Trends in **opioid prescribing for adolescents and young adults in ambulatory care settings**. Pediatrics. 2019;143(6):e20181578

Hudson TJ, Painter JT, Martin BC, et al. Pharmacoepidemiologic analyses of **opioid use** among OEF/OIF/OND veterans. Pain. 2017 Mar 25.

Hughto JMW, Quinn EK, Dunbar MS, et al. Prevalence and **Co-occurrence of Alcohol, Nicotine, and Other Substance Use Disorder** Diagnoses Among US Transgender and Cisgender Adults. JAMA Netw Open. 2021 Feb 1;4(2):e2036512

Hulme J, Sheikh H, Xie E, et al. Mortality among patients with **frequent emergency department use for alcohol-related reasons** in Ontario: a population-based cohort study. CMAJ. 2020 Nov 23;192(47):E1522-E1531

Humphreys K. Avoiding globalisation of the prescription opioid epidemic. Lancet. 2017 Jul 29;390(10093):437-439

Humphreys KL, Eng T, Lee SS. **Stimulant Medication** and Substance Use Outcomes: A Meta-analysis. JAMA Psychiatry. 2013 Jul 1;70(7):740-9.

Humphriss R, Hall A, May M, et al. **Prenatal alcohol exposure** and childhood balance ability: findings from a UK birth cohort study. BMJ Open. 2013 Jun 20;3(6).

Hurley R. Consider **legalising drugs despite UN treaties**, says influential commission. BMJ. 2016 Apr 29;353:i2474

Huskamp HA, Busch AB, Uscher-Pines L, et al. **Treatment of Opioid Use Disorder** Among Commercially Insured Patients in the Context of the COVID-19 Pandemic. JAMA. 2020 Dec 15;324(23):2440-2442

Huskamp HA, Iglehart JK. Mental Health and **Substance-Use Reforms**—Milestones Reached, Challenges Ahead. N Engl J Med. 2016 Aug 18;375(7):688-95

Hwang CS, Turner LW, Kruszewski SP, et al. **Prescription Drug Abuse**: A National Survey of Primary Care Physicians. JAMA Intern Med. 2014 Dec 8.

Hwang CS, Turner LW, Kruszewski SP, Kolodny A, Alexander GC. **Primary Care Physicians' Knowledge And Attitudes Regarding Prescription Opioid Abuse and Diversion**. Clin J Pain. 2015 Jun 22.

Hwang CS, Kang EM, Ding Y, et al. Patterns of **immediate-release and extended-release opioid analgesic** use in the management of chronic pain, 2003-2014.JAMA Netw Open. 2018;1(2):e180216.

Ilgen MA, Coughlin LN, Bohnert ASB, et al. Efficacy of a **Psychosocial Pain Management** Intervention for Men and Women With Substance Use Disorders and Chronic Pain: A Randomized Clinical Trial. JAMA Psychiatry. 2020;10.1001/jamapsychiatry.2020.2369.

Iparraguirre J. Socioeconomic determinants of risk of harmful **alcohol drinking** among people aged 50 or over in England. BMJ Open. 2015 Jul 23;5(7):e007684.

Ipsen JC, Wilson D, Akindepe TO, et al. Pharmacotherapy for **anxiety and comorbid alcohol use disorders**. Cochrane Database Syst Rev. 2015 Jan 20;1:CD007505. The evidence-base for the effectiveness of medication in treating anxiety disorders and comorbid alcohol use disorders is currently inconclusive. There was a small amount of evidence for the efficacy of medication, but this was limited and of very low quality. The majority of the data for the efficacy and tolerability of medication were for SSRIs; there were insufficient data to establish differences in treatment efficacy between medication classes or patient subgroups. There was a small amount of very low quality evidence that medication was well tolerated. There was no evidence that alcohol use was responsive to medication. Large, rigorously conducted RCTs would help supplement the small evidence-base for the efficacy and tolerability of pharmacotherapy for anxiety and comorbid alcohol use disorders. Further research on patient subgroups who may benefit from pharmacological treatment, as well as novel pharmacological interventions, is warranted.

Irvine MA, Buxton JA, Otterstatter M, et al. Distribution of **take-home opioid antagonist kits** during a synthetic opioid epidemic in British Columbia, Canada: a modelling study. Lancet Public Health. 2018 Apr 17.

Isoardi KZ, Polkinghorne G, Harris K, Isbister GK. **PREGABALIN POISONING AND RISING RECREATIONAL USE: A RETROSPECTIVE OBSERVATIONAL SERIES**. Br J Clin Pharmacol. 2020 May 6. doi: 10.1111/bcp.14348

Issa MA, Narang S, Jamison RN, et al. The subjective **psychoactive effects of oral dronabinol** studied in a randomized, controlled crossover clinical trial for pain. Clin J Pain. 2014 Jun;30(6):472-8.

Jansson LM, Jordan CJ, Velez ML. **Perinatal Marijuana Use and the Developing Child**. JAMA. 2018 Jul 16.

Jarvis M, Williams J, Hurford M, et al. Appropriate Use of **Drug Testing** in Clinical Addiction Medicine. J Addict Med. 2017 May/Jun;11(3):163-173.

Jeffers AM, Glantz S, Byers A, Keyhani S. Sociodemographic Characteristics Associated With and Prevalence and Frequency of **Cannabis Use Among Adults in the US**. JAMA Netw Open. 2021 Nov 1;4(11):e2136571.

Jeffery MM, Hooten WM, Henk HJ, et al. Trends in **opioid use in commercially insured and Medicare Advantage populations** in 2007-16: retrospective cohort study. BMJ. 2018 Aug 1;362:k2833.

Jeffery MM, Hooten WM, Hess EP, et al. **Opioid Prescribing for Opioid-Naïve Patients in Emergency Departments and Other Settings**: Characteristics of prescriptions and Association With Long-Term Use. Ann Emerg Med. 2017 Sep 21.

Jensen TK, Gottschau M, Madsen JO, et al. Habitual **alcohol** consumption associated with reduced **semen** quality and changes in reproductive hormones; a cross sectional study among 1221 young Danish men. BMJ Open. 2014 Oct 2;4(9):e005462.

Jerry J, Collins G, Stream D. Synthetic legal intoxicating drugs: The emerging **'incense' and 'bath salt'** phenomenon. Cleve Clin J Med. 2012 Apr;79(4):258-64.

Jiang R, Lee I, Lee TA, et al. The **societal cost of heroin use** disorder in the United States. PLoS One. 2017 May 30;12(5):e0177323.

Johnson BA, Ait-Daoud N, Wang XQ, Penberthy et al. **Topiramate for the Treatment of Cocaine** Addiction: A Randomized Clinical Trial. JAMA Psychiatry. 2013 Oct 16.

Johnson BA. Medication treatment of different types of **alcoholism**. Am J Psychiatry. 2010 Jun;167(6):630-9.

Johnson LM, Kaye EC, Sawyer K, et al. **Opioid Management in the Dying Child With Addiction**. Pediatrics. 2021 Jan 14:e2020046219

Jonas DE, Garbutt JC, Amick HR, et al. **Behavioral Counseling After Screening for Alcohol Misuse** in Primary Care: A Systematic Review and Meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2012 Sep 25.

Jonas DE, Amick HR, Feltnr C, et al. **Pharmacotherapy for adults with alcohol use disorders** in outpatient settings. JAMA. doi:10.1001/jama.2014.3628.

Jonas DE, Amick HR, Feltnr C, et al. **Pharmacotherapy for Adults With Alcohol-Use Disorders** in Outpatient Settings. Comparative Effectiveness Review No. 134. AHRQ Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 May. Report No.: 14-EHC029-EF.

Jonas DE, Garbutt JC, Amick HR, et al. **Behavioral Counseling After Screening for Alcohol Misuse** in Primary Care: A Systematic Review and Meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2012 Sep 25.

Jones AA, Jang K, Panenka WJ, et al. Rapid Change in **Fentanyl Prevalence** in a Community-Based, High-Risk Sample. JAMA Psychiatry. 2018 Jan 31.

Jones CM. Frequency of **Prescription Pain Reliever Nonmedical Use**: 2002-2003 and 2009-2010. Arch Intern Med. 2012 Jun 25;1-2.

Jones CM, Clayton HB, Deputy NP, et al. Prescription **Opioid Misuse and Use of Alcohol and Other Substances** Among High School Students - Youth Risk Behavior Survey, United States, 2019. MMWR Suppl. 2020;69(1):38-46.

Jones CM, Compton WM, Mustaquim D. **Patterns and Characteristics of Methamphetamine Use** Among Adults - United States, 2015-2018. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):317-323

Jones CM, Lurie P, Woodcock J. Addressing **prescription opioid overdose**: data support a comprehensive policy approach. JAMA. 2014 Nov 5;312(17):1733-4.

Jones CM, Lurie PG, Throckmorton DC. Effect of US Drug Enforcement Administration's **Rescheduling of Hydrocodone Combination Analgesic Products** on Opioid Analgesic Prescribing. JAMA Intern Med. 2016 Jan 25.

Jones CM, Mack KA, Paulozzi LJ. **Pharmaceutical overdose deaths**, United States, 2010. JAMA. 2013 Feb 20;309(7):657-9.

Jones CM, Paulozzi LJ, Mack KA. **Sources of Prescription Opioid Pain Relievers** by Frequency of Past-Year Nonmedical Use: United States, 2008-2011. JAMA Intern Med. 2014 Mar 3.

Jones HE, Kallenbach K, Heil SH, et al. Neonatal abstinence syndrome after **methadone or buprenorphine exposure**. N Engl J Med. 2010 Dec 9;363(24):2320-31.

Jones CM, Einstein EB, Compton WM. Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016. JAMA. 2018 May 1;319(17):1819-1821.

Jongbloed K, Pearce ME, Pooyak S, et al. The Cedar Project: mortality among young **Indigenous people who use drugs** in British Columbia. CMAJ. 2017 Nov 6;189(44):E1352-E1359.

Jouanjus E, Gibaja V, Fabre F, Lapeyre-Mestre M. Medical prescription forms of **opioid cough suppressants falsified by the patients** before and after they switched from OTC to prescription-only in France. Br J Clin Pharmacol. 2021 Aug 24. doi: 10.1111/bcp.15052

Jumah NA, Graves L, Kahan M. The management of **opioid dependence during pregnancy** in rural and remote settings. CMAJ. 2015 Jan 6;187(1):E41-E46.

Jumah NA, Edwards C, Balfour-Boehm J, et al. Observational study of the safety of **buprenorphine+naloxone in pregnancy** in a rural and remote population. BMJ Open. 2016 Oct 31;6(10):e011774.

Kadlecová P, Andel R, Mikulík R, et al. **Alcohol Consumption** at Midlife and Risk of Stroke During 43 Years of Follow-Up: Cohort and Twin Analyses. Stroke. 2015 Jan 29.

Kahan, Meldon, Srivastava, Anita, Ordean, Alice, Cione, Sharon. **Buprenorphine**: New treatment of opioid addiction in primary care. Can Fam Physician 2011 57: 281-289.

Kaiser S, Asteria-Penalaza R, Vittinghoff E, et al. **National patterns of codeine prescriptions** for children in the emergency department. Pediatrics. 2014;133(5).

Kalakoti P, Volkmar AJ, Bedard NA, et al. Preoperative **Chronic Opioid Therapy Negatively Impacts Long-term Outcomes** Following Cervical Fusion Surgery. Spine (Phila Pa 1976). 2019 Sep;44(18):1279-1286.

Kale N. **Urine Drug Tests**: Ordering and Interpretation. Am Fam Physician. 2019;99(1):33-39.

Kalk N, Lingford-Hughes A. The Clinical Pharmacology of **Acamprosate**. Br J Clin Pharmacol. 2012 Dec 25.

Kalk NJ, Boyd A, Strang J, et al. **Spice** and all things nasty: the challenge of **synthetic cannabinoids**. BMJ. 2016 Oct 24;355:i5639.

Kalkman GA, Kramers C, van Dongen RT, et al. Trends in use and misuse of **opioids in the Netherlands**: a retrospective, multi-source database study. Lancet Public Health. 2019 Oct;4(10):e498-e505.

Kamangar F, Shakeri R, Malekzadeh R, et al. **Opium use**: an emerging risk factor for **cancer**? Lancet Oncol. 2014 Feb;15(2):e69-77

Kane JM, Colvin JD, Bartlett AH, et al. **Opioid-Related Critical Care Resource Use in US Children's Hospitals**. Pediatrics. 2018 Mar 5.

Kaner E, Bland M, Cassidy P, Coulton S, Dale V, Deluca P, et al. Effectiveness of **screening and brief alcohol intervention in primary care**: pragmatic cluster randomised controlled trial (the SIPS trial). BMJ 2012;345:e8501.

Kapil V, Green J, Le Lait C, et al. **Misuse** of the GABA-Analogues **Baclofen, Gabapentin and Pregabalin** in the United Kingdom. British Journal of Clinical Pharmacology. 2013.

Kaplan LM, Nayak MB, Greenfield TK, et al. **Alcohol's Harm to Children**: Findings from the 2015 United States National Alcohol's Harm to Others Survey. J Pediatr. 2017 Feb 10.

Karamchandani K, Pyati S, Bryan W, et al. New Persistent **Opioid Use After Postoperative Intensive Care** in US Veterans. JAMA Surg. 2019 Jun 5

Karasick AS, Thomas RJ, Cannon DL, et al. Notes from the Field: **Amphetamine Use Among Workers** with Severe Hypertension - Eight States, 2010-2019. MMWR Morb Mortal Wkly Rep. 2020;69(30):1004-1005

Kariisa M, Patel P, Smith H, Bittling J. Notes from the Field: **Xylazine Detection** and Involvement in Drug Overdose Deaths — United States, 2019. MMWR Morb Mortal Wkly Rep 2021;70:1300–1302. DOI: <http://dx.doi.org/10.15585/mmwr.mm7037a4>

Kariisa M, Scholl L, Wilson N, et al. Drug Overdose **Deaths Involving Cocaine and Psychostimulants** with Abuse Potential - United States, 2003-2017. MMWR Morb Mortal Wkly Rep. 2019 May 3;68(17):388-395.

Kasper AM, Ridpath AD, Arnold JK, et al. Severe illness associated with reported use of **synthetic cannabinoids** - Mississippi, April 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1121-1122.

Katzman JG, Takeda MY, Greenberg N, et al. Association of **Take-Home Naloxone and Opioid Overdose Reversals** Performed by Patients in an Opioid Treatment Program. JAMA Netw Open. 2020 Feb 5;3(2):e200117.

Kelkar AH, Smith NA, Martial A, et al. An **Outbreak of Synthetic Cannabinoid-Associated Coagulopathy** in Illinois. N Engl J Med. 2018 Sep 27;379(13):1216-1223.

Kelley-Quon LI, Cho J, Strong DR, et al. Association of Nonmedical **Prescription Opioid Use With Subsequent Heroin Use** Initiation in Adolescents. JAMA Pediatr. 2019 Jul 8:e191750.

Kelly JF, Kaminer Y, Kahler CW, et al. A pilot randomized clinical trial testing integrated **12-Step facilitation (ITSF)** treatment for adolescent substance use disorder. Addiction. 2017 Jul 25.

Kelly L, Guilfoyle J, Dooley J, et al. Incidence of **narcotic abuse during pregnancy** in northwestern Ontario: Three-year prospective cohort study. Can Fam Physician. 2014 Oct 60(10):e493-8.

Kelly SM, Gryczynski J, Mitchell SG, et al. Validity of Brief **Screening Instrument for Adolescent Tobacco, Alcohol, and Drug Use**. Pediatrics. 2014 Apr 21.

Kelsall D. **Cannabis legislation fails to protect Canada's youth**. CMAJ. 2017 May 29;189(21):E737-E738.

Kelsall D. **Watching Canada's experiment with legal cannabis**. CMAJ. 2018 Oct 15;190(41):E1218.

Kendler KS, Ohlsson H, Sundquist J, Sundquist K. **Alcohol Use Disorder** and Mortality Across the Lifespan: A Longitudinal Cohort and Co-relative Analysis. JAMA Psychiatry. 2016 Apr 20.

Kendler KS et al. Effect of **marriage on risk for onset of alcohol use disorder**: A longitudinal and co-relative analysis in a Swedish national sample. Am J Psychiatry 2016 May 16.

Kennedy-Hendricks A, Levin J, Stone E, et al. News Media Reporting On **Medication Treatment For Opioid Use Disorder** Amid The Opioid Epidemic. Health Aff (Millwood). 2019 Apr;38(4):643-651.

Kennedy-Hendricks A, Richey M, McGinty EE, Stuart EA, et al. Opioid Overdose Deaths and **Florida's Crackdown on Pill Mills**. Am J Public Health. 2015 Dec 21:e1-e8.

Kennedy-Hendricks A, Gielen A, McDonald E, et al. **Medication Sharing, Storage, and Disposal Practices for Opioid Medications** Among US Adults. JAMA Intern Med. 2016 Jun 13.

Keyhani S, Steigerwald S, Ishida J, et al. **Risks and Benefits of Marijuana Use**: A National Survey of U.S. Adults. Ann Intern Med. 2018 Jul 24.

Khademi H, Malekzadeh R, Pourshams A, Jafari E, Salahi R, et al. **Opium use and mortality** in Golestan Cohort Study: prospective cohort study of 50 000 adults in Iran. BMJ 2012;344:e2502.

Khan NF, Bateman BT, Landon JE, Gagne JJ. Association of Opioid Overdose With **Opioid Prescriptions to Family Members**. JAMA Intern Med. 2019 Jun 24.

Khatni UG, Pizzicato LN, Viner K, et al. **Racial/Ethnic Disparities** in Unintentional Fatal and Nonfatal Emergency Medical Services-Attended Opioid Overdoses During the COVID-19 Pandemic in Philadelphia. JAMA Netw Open. 2021 Jan 4;4(1):e2034878

Khatni UG, Viner K, Perrone J. **Lethal Fentanyl and Cocaine Intoxication**. N Engl J Med. 2018 Nov 1;379(18):1782.

Kiang MV, Basu S, Chen J, Alexander MJ. Assessment of Changes in the Geographical **Distribution of Opioid-Related Mortality** Across the United States by Opioid Type, 1999-2016. JAMA Netw Open. 2019 Feb 1;2(2):e190040.

Kilaru AS, Xiong A, Lowenstein M, et al. Incidence of Treatment for Opioid Use Disorder Following **Nonfatal Overdose in Commercially Insured Patients**. JAMA Netw Open. 2020;3(5):e205852

Kiluk BD et al. Randomized clinical trial of computerized and **clinician-delivered CBT** in comparison with **standard outpatient treatment for substance use disorders**: Primary within-treatment and follow-up outcomes. Am J Psychiatry 2018 May 24; [e-pub].

Kiluk BD, Nich C, Buck MB, et al. Randomized Clinical Trial of Computerized and Clinician-Delivered **CBT in Comparison With Standard Outpatient Treatment for Substance Use Disorders**: Primary Within-Treatment and Follow-Up Outcomes. Am J Psychiatry. 2018 May 24;appiajp201817090978.

Kim HK, Smiddy M, Hoffman RS, Nelson LS. **Buprenorphine** may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics. 2012 Dec;130(6):e1700-3.

Kim HS, Hall KE, Genco EK, et al. **Marijuana Tourism** and Emergency Department Visits in Colorado. N Engl J Med. 2016 Feb 25;374(8):797-8.

Kim HS, Anderson JD, Saghaei O, et al. **Cyclic vomiting** presentations following **marijuana** liberalization in Colorado. Acad Emerg Med. 2015 Jun;22(6):694-9.

Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of **opiate substitution treatment**. BMJ. 2010 Jul 1;341:c3172. doi: 10.1136/bmj.c3172.

Kimmel SD, Walley AY, Li Y, et al. Association of Treatment With Medications for **Opioid Use Disorder** With Mortality After Hospitalization for Injection Drug Use-Associated Infective Endocarditis. JAMA Netw Open. 2020 Oct 1;3(10):e2016228

King WC, Chen JY, Mitchell JE, et al. Prevalence of **Alcohol Use Disorders Before and After Bariatric Surgery**. JAMA. 2012 Jun18:1-10.

Kinnard EN, Bluthenthal RN, Kral AH, et al. The **naloxone delivery cascade**: Identifying disparities in access to naloxone among people who inject drugs in Los Angeles and San Francisco, CA. Drug Alcohol Depend. 2021 May 21;225:108759.

Kirschner N, Ginsburg J, Sulmasy LS. **Prescription Drug Abuse: A Policy** Position Paper From the American College of Physicians. Ann Intern Med. 2013 Dec 10

Kirschner N, Ginsburg J, Snyder Sulmasy L. **Prescription drug abuse: executive summary of a policy position paper from the American College of Physicians**. Ann Intern Med. 2014;160:198-200.

Klega AE, Keehbauch JT. **Stimulant and Designer Drug Use**: Primary Care Management. Am Fam Physician. 2018 Jul 15;98(2):85-92.

Kleinman RA. **Comparison of Driving Times** to Opioid Treatment Programs and Pharmacies in the US. JAMA Psychiatry. 2020;e201624.

Klimas J, Gorfinkel L, Fairbairn N, et al. **Strategies to Identify Patient Risks** of Prescription Opioid Addiction When Initiating Opioids for Pain: A Systematic Review. JAMA Netw Open. 2019 May 3;2(5):e193365.

Knight JR, Sherritt L, Gibson EB, et al. Effect of **Computer-Based Substance Use Screening and Brief Behavioral Counseling vs Usual Care** for Youths in Pediatric Primary Care: A Pilot Randomized Clinical Trial. JAMA Netw Open. 2019 Jun 5;2(6):e196258.

Knott CS, Coombs N, Stamatakis E, Biddulph JP. **All cause mortality** and the case for age specific **alcohol consumption** guidelines: pooled analyses of up to 10 population based cohorts. BMJ 2015;350:h384.

Ko JY, Patrick SW, Tong VT, et al. Incidence of **Neonatal Abstinence Syndrome** - 28 States, 1999-2013. MMWR Morb Mortal Wkly Rep. 2016 Aug 12;65(31):799-802.

Kocherlakota P. **Neonatal Abstinence Syndrome**. Pediatrics. 2014 Aug;134(2):e547-e561. Review.

Koh JJ, Klaiman M, Miles I, et al. CAEP Position Statement: Emergency department **management of people with opioid use disorder**. CJEM. 2020 Oct 8:1-4. doi: 10.1017/cem.2020.459

Kolodny A, Frieden TR. **Ten Steps the Federal Government Should Take Now to Reverse the Opioid Addiction Epidemic**. JAMA. 2017 Oct 12.

Konova AB, Lopez-Guzman S, Urmache A, et al. **Computational Markers of Risky Decision-making** for Identification of Temporal Windows of Vulnerability to Opioid Use in a Real-world Clinical Setting. JAMA Psychiatry. 2019 Dec 8. doi: 10.1001/jamapsychiatry.2019.4013.

Kontopantelis E, Buchan I, Webb RT, et al. **Disparities in mortality among 25-44-year-olds in England**: a longitudinal, population-based study. Lancet Public Health. 2018 Dec;3(12):e567-e575.

Koons AL, Rayl Greenberg M, Cannon RD, et al. **Women and the Experience of Pain and Opioid Use Disorder**: A Literature-based Commentary. Clin Ther. 2018 Jan 9.

Korantzopoulos P, Liu T, Papaioannides D, et al. **Atrial fibrillation and marijuana** smoking. Int J Clin Pract. 2008 Feb;62(2):308-13.

Koren G. Water by the spoonful: **Children of addiction**. Can Fam Physician. 2013 Mar;59(3):e141-2.

Korownyk C, Perry D, Ton J, et al. **Managing opioid use disorder in primary care**. PEER simplified guideline. Can Fam Physician 2019;65:321-30. <http://www.cfp.ca/content/cfp/65/5/321.full.pdf>

Korthuis PT, McCarty D, Weimer M, et al. **Primary care**-based models for the **treatment of opioid use disorder**. A scoping review. Ann Intern Med. 2016. [Epub ahead of print]. doi: 10.7326/M16-2149

Kosten T, Domingo C, Orson F, Kinsey B. **Vaccines against stimulants: Cocaine and Methamphetamine**. Br J Clin Pharmacol. 2013 Mar 19.

Kosten TR, Graham DP, Nielsen DA. Opioid Use Disorder After Self-medicating Pain From **Traumatic Brain Injury**. JAMA Psychiatry. 2018 Apr 25.

Kosten TR, Graham DP, Nielsen DA. Neurobiology of Opioid Use Disorder and Comorbid **Traumatic Brain Injury**. JAMA Psychiatry. 2018 Apr 25.

Kowalczyk WJ, Phillips KA, Jobes ML, et al. **Clonidine Maintenance Prolongs Opioid Abstinence** and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment. Am J Psychiatry. 2015 Aug 1;172(8):760-7. Clonidine is a promising drug when used as adjuvant treatment to buprenorphine for maintaining abstinence from opioids. These authors documented longer duration of abstinence with clonidine as compared with placebo. They also credibly documented that patients in the clonidine-treated group experienced less craving when confronted with life stresses. (LOE = 1b)

Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. **Buprenorphine** for the Treatment of the **Neonatal Abstinence Syndrome**. N Engl J Med. 2017 May 4.

Kral AH, Davidson PJ. Addressing the Nation's Opioid Epidemic: Lessons from an Unsanctioned **Supervised Injection Site** in the U.S. Am J Preventive Med. 2017.

Krane EJ, Weisman SJ, Walco GA. The **National Opioid Epidemic and the Risk of Outpatient Opioids in Children**. Pediatrics. 2018 Jul 16.



Kranzler HR, Covault J, Feinn R, et al. **Topiramate Treatment for Heavy Drinkers:** Moderation by a GRIK1 Polymorphism. *Am J Psychiatry*. 2014 Feb 14.

Krebs E, Enns B, Evans E, Urada D, Anglin MD, Rawson RA, et al. **Cost-effectiveness of publicly funded treatment of opioid use disorder in California.** *Ann Intern Med*. 2017. [Epub ahead of print]. doi: 10.7326/M17-0611

**Krokodil** (desomorphine): roughly same effect as heroin but is at least three times cheaper & extremely easy to make. The active component is codeine, & addicts mix it with ingredients including gasoline, paint thinner, hydrochloric acid, iodine and red phosphorous, which they scrape from the striking pads on matchboxes.

Krupitsky E, Nunes EV, Ling W, Illeperuma A, et al. **Injectable extended-release naltrexone for opioid dependence:** a double-blind, placebo-controlled, multicentre randomised trial. *Lancet* 2011; published online April 28. DOI:10.1016/S0140-6736(11)60358-9.

Kubo JT et al. **Alcohol** consumption and risk of melanoma and non-melanoma **skin cancer** in the Women's Health Initiative. *Cancer Causes Control* 2013 Oct 31

Kuehn BM. Colorado Tackles **Medical Implications of Marijuana.** *JAMA*. 2014 May 14.

Kuepper R, van Os J, Lieb R, Wittchen H, Höfler M, Henquet C. Continued **cannabis** use and risk of incidence and persistence of **psychotic** symptoms: 10 year follow-up cohort study *BMJ* 342;doi:10.1136/bmj.d738 (Published 1 March 2011)Accessed online at: <http://www.bmj.com/content/342/bmj.d738.full>

Kulak JA, Griswold KS. **Adolescent Substance Use and Misuse:** Recognition and Management *Am Fam Physician* 2019;99(11): 689-696.

Kumar D, Batal I, Jim B, et al. Unusual case of **levamisole-induced dual-positive ANCA vasculitis and crescentic glomerulonephritis.** *BMJ Case Rep*. 2018 Sep 19;2018. pii: bcr-2018-225913.

Kunøe N, Lobmaier P, Ngo H, Hulse GK. Injectable and implantable sustained release **naltrexone** in the treatment of opioid addiction. *Br J Clin Pharmacol*. 2012 Oct 22.

Kuo YF, Raji MA, Goodwin JS. Association of **Disability With Mortality From Opioid Overdose** Among US Medicare Adults. *JAMA Netw Open*. 2019 Nov 1;2(11):e1915638.

Kurdyak P, Jacob B, Zahere J, et al. Patterns of **methadone maintenance treatment provision in Ontario:** Policy success or pendulum excess? *Can Fam Physician*. 2018 Feb;64(2):e95-e103.

Kypri K, Vater T, Bowe SJ, et al. **Web-based alcohol screening** and brief intervention for university students: a randomized trial. *JAMA*. 2014 Mar 26;311(12):1218-24

La Gerche A, Brosnan MJ. Cardiovascular Effects of **Performance-Enhancing Drugs.** *Circulation*. 2017 Jan 3;135(1):89-99.

LaBotz M, Griesemer BA; Council on Sports Medicine and Fitness. Use of **Performance-Enhancing Substances.** *Pediatrics*. 2016 Jun 27.

Lacson JC, Carroll JD, Tuazon E, et al. Population-based case-control study of recreational drug use and **testis cancer** risk confirms an association between **marijuana** use and nonseminoma risk. *Cancer*. 2012 Sep 10.

Ladapo JA, Larochele MR, Chen A, et al. Physician Prescribing of Opioids to Patients at Increased Risk of Overdose From Benzodiazepine Use in the United States. *JAMA Psychiatry*. 2018 Apr 12.

Ladha KS, Gagne JJ, Patomoe E, et al. **Opioid Overdose After Surgical Discharge.** *JAMA*. 2018 Aug 7;320(5):502-504.

Ladha KS, Neuman MD, Broms G, et al. Opioid **Prescribing After Surgery** in the United States, Canada, and Sweden. *JAMA Netw Open*. 2019 Sep 4;2(9):e1910734.

Lagasse LL, Derauf C, Smith LM et al. **Prenatal Methamphetamine** Exposure and Childhood Behavior Problems at 3 and 5 Years of Age. *Pediatrics*. 2012 Mar 19.

Lagisetty PA, Ross R, Bohnert A, et al. **Buprenorphine Treatment Divide by Race/Ethnicity** and Payment. *JAMA Psychiatry*. 2019 May 8.

Lalic S, Gisev N, Simon Bell J, et al. **Predictors of persistent prescription opioid analgesic use** among people without cancer in Australia. *Br J Clin Pharmacol*. 2018 Feb 16.

Lambdin BH, Bluthenthal RN, Wenger LD, et al. Overdose **Education and Naloxone Distribution** Within Syringe Service Programs - United States, 2019. *MMWR Morb Mortal Wkly Rep*. 2020;69(33):1117-1121

Lancaster E, Inglis-Arkell C, Hirose K, et al. **Variability in Opioid-Prescribing Patterns** in Endocrine Surgery and Discordance With Patient Use. *JAMA Surg*. 2019 Aug 14.

Lange S, Shield K, Rehm J, Popova S. Prevalence of **Fetal Alcohol Spectrum Disorders** in Child Care Settings: A Meta-analysis. *Pediatrics*. 2013 Sep 9.

Lanza HI, Barrington-Trimis JL, McConnell R, et al. Trajectories of **Nicotine and Cannabis Vaping and Polyuse** From Adolescence to Young Adulthood. *JAMA Netw Open*. 2020 Oct 1;3(10):e2019181

Lanza ST, Vasilenko SA, Dziak JJ, Butera NM. Trends Among U.S. High School Seniors in Recent **Marijuana Use** and Associations **With Other Substances:** 1976-2013. *J Adolesc Health*. 2015 Aug;57(2):198-204.

Laporte C, Vaillant-Roussel H, Pereira B, et al. **Cannabis and Young Users**-A Brief Intervention to Reduce Their Consumption (CANABIC): A Cluster Randomized Controlled Trial in Primary Care. *Ann Fam Med*. 2017 Mar;15(2):131-139.

Lappin JM, Darke S, Farrell M. **Stroke and methamphetamine** use in young adults: a review. *J Neurol Neurosurg Psychiatry*. 2017 Aug 23.

Larach DB, Sahara MJ, As-Sanie S, et al. **Patient Factors Associated with Opioid Consumption** in the Month Following Major Surgery. *Ann Surg*. 2019 Aug 5.

Larance B, Dobbins T, Peacock A, et al. The effects of a potentially **tamper resistant oxycodone formulation** on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. *Lancet Psychiatry* 2018; online Jan 11.

Larney S, Tran LT, Leung J, et al. All-Cause and Cause-Specific **Mortality Among People Using Extramedical Opioids:** A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2019 Dec 26. doi: 10.1001/jamapsychiatry.2019.4170.

Larochele MR, Bemson D, Land T, et al. **Medication for opioid use disorder** after nonfatal opioid overdose and association with mortality. A cohort study. *Ann Intern Med*. 2018. [Epub ahead of print]. doi:10.7326/M17-3107

Larochele MR, Zhang F, Ross-Degnan D, et al. Rates of **Opioid Dispensing and Overdose After Introduction of Abuse-Deterrent Extended-Release Oxycodone** and Withdrawal of **Propoxyphene.** *JAMA Intern Med*. 2015 Apr 20.

Larson JJ, Graham DL, Singer LT, et al. **Cognitive and Behavioral Impact on Children Exposed** to Opioids During Pregnancy. *Pediatrics*. 2019 Aug;144(2).

Larsson SC, Drca N, Wolk A. **Alcohol consumption and risk of atrial fibrillation:** prospective study and dose-dependent meta-analysis. *J Am Coll Cardiol* 2014;

LaRue L, Twillman RK, Dawson E, et al. Rate of **Fentanyl Positivity Among Urine Drug Test Results** Positive for Cocaine or Methamphetamine. *JAMA Netw Open*. 2019 Apr 5;2(4):e192851.

Lasser KE. Prescription Opioid Use Among U.S. Adults: Our Brave New World. *Ann Intern Med*. 2017 Aug 1.

Laszkowska M, Rodriguez S, Kim J, Hur C. Heavy **Alcohol Use Is Associated With Gastric Cancer:** Analysis of the National Health and Nutrition Examination Survey From 1999 to 2010. *Am J Gastroenterol*. 2021 Feb 9. doi: 10.14309/ajg.0000000000001166

Latif ZE, Šaltyte Benth J, Solli KK, et al. **Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence** Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study. *JAMA Psychiatry*. 2018 Dec 19.

Latino-Martel P, Arwidson P, Ancellin R, et al. **Alcohol consumption and cancer risk:** revisiting guidelines for sensible drinking. *CMAJ*. 2011 Nov 8;183(16):1861-5.

Lavalley J, Kastor S, Valleriani J, et al. **Reconciliation and Canada's overdose crisis:** responding to the needs of Indigenous Peoples. *CMAJ*. 2018 Dec 17;190(50):E1466-E1467.

Law R, Schier J, Martin C, Chang A, Wolk A; Centers for Disease Control (CDC). Notes from the field: increase in reported adverse health effects related to **synthetic cannabinoid** use - United States, January-May 2015. *MMWR Morb Mortal Wkly Rep*. 2015;64:618-619.

Layne KA, Dargan PI, Dines AM, et al. **Acute Toxicity Related to Misuse** (Non-Medical Use) of **Tramadol:** Experience of the European Drug Emergencies Network Plus (Euro-DEN Plus) Project. *Br J Clin Pharmacol*. 2020;10.1111/bcp.14408.

Le Foll B, Loheswaran G. **Alcohol inhalation.** *CMAJ*. 2014 Jul 8;186(10):E399.

Lee C-H, Ko AM-S, Yang FM, et al. Association of DSM-5 **betel-quid use disorder** with oral potentially malignant disorder in 6 betel-quid endemic Asian populations [online Feb 7, 2018]. *JAMA Psychiatry*. doi:10.1001/jamapsychiatry.2017.4307

Lee JD et al. Extended-release **naltrexone** to prevent **opioid relapse** in ex-prisoners (criminal justice offenders). *N Engl J Med* 2016 Mar 31; 374:1232.

Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of **extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT):** a multicentre, open-label, randomized controlled trial. *Lancet* 2017; online Nov 14.

Lee JZ, Pasha AK, Glasgow AE, et al. Postoperative opioid **prescription patterns and new opioid refills** following cardiac implantable electronic device procedures. *Heart Rhythm*. 2019 Oct 9. doi: 10.1016/j.hrthm.2019.08.011.

Leece P, Orkin AM, Kahan M. **Tamper-resistant drugs** cannot solve the opioid crisis. *CMAJ*. 2015 Jul 14;187(10):717-8.

Lehmann SW, Fingerhoo M. **Substance-Use Disorders in Later Life.** *N Engl J Med*. 2018 Dec 13;379(24):2351-2360.

Lei Y, Shah V, Biely C, et al. **Discrimination and Subsequent Mental Health, Substance Use,** and Well-being in Young Adults. *Pediatrics*. 2021;148(6):e2021051378

Lennox R, Mangin D. **Gabapentin misuse.** *CMAJ*. 2019 Jan 14;191(2):E47.

Lerner AM, Fauci AS. **Opioid Injection in Rural Areas** of the United States: A Potential Obstacle to Ending the HIV Epidemic. *JAMA*. 2019 Aug 1.

Leshner AI, Dzau VJ. **Medication-Based Treatment** to Address Opioid Use Disorder. *JAMA*. 2019 May 2.

Letourneau LM, Ritzo J, Shonk R, et al. **Supporting Physicians and Practice Teams** in Efforts to Address the Opioid Epidemic. *Ann Fam Med*. 2019 Aug 12;17(Suppl 1):S77-S81.

Leung JG, Hall-Flavin D, Nelson S, et al. The Role of **Gabapentin** in the Management of **Alcohol Withdrawal and Dependence.** *Ann Pharmacother*. 2015 May 12.

Levensgood TW, Yoon GH, Davoust MJ, et al. **Supervised Injection Facilities** as Harm Reduction: A Systematic Review. *Am J Prev Med*. 2021 Jul 1:S0749-3797(21)00275-0

Lev-Ran S et al. **Cannabis use** and cannabis use disorders among individuals with mental illness. *Compr Psychiatry* 2013 Jan 30.

Levy S. **Brief interventions for substance use in adolescents:** still promising, still unproven. *CMAJ*. 2014 May 13;186(8):565-6.

Levy S. **Youth and the Opioid Epidemic.** *Pediatrics*. 2019 Jan 2.

Levy S, Campbell MD, Shea CL, et al. Trends in **Abstaining From Substance Use in Adolescents:** 1975-2014. *Pediatrics*. 2018 Jul 19.

Levy S, Campbell MD, Shea CL, et al. **Trends in Substance Nonuse** by High School Seniors: 1975-2018. *Pediatrics*. 202; 146 (6):e202007 187

Levy S, Schizer M; Committee on Substance Abuse. **Adolescent Drug Testing Policies in Schools.** *Pediatrics*. 2015 Mar 30. pii: peds.2015-0054.

Levy S, Siqueira LM; and Committee on Substance Abuse. **Testing for Drugs of Abuse in Children and Adolescents.** *Pediatrics*. 2014 May 26.

Levy S, Weiss R, Sherritt L, et al. An **Electronic Screen** for Triaging Adolescent Substance Use by Risk Levels. *JAMA Pediatr*. 2014 Jul 28.

Levy S, Weitzman ER. Building a Learning **Marijuana Surveillance System.** *JAMA Pediatr*. 2016 Jan 19;1-2.

Levy S, Weitzman ER. Acute **Mental Health Symptoms in Adolescent Marijuana Users.** *JAMA Pediatr*. 2018 Dec 17.

Leung PTM, Macdonald EM, Stanbrook MB, et al. A **1980 Letter on the Risk of Opioid Addiction.** *N Engl J Med*. 2017 Jun 1;376(22):2194-2195.

Lewis M. **Brain Change in Addiction as Learning,** Not Disease. *N Engl J Med*. 2018 Oct 18;379(16):1551-1560.

Lewis SJ, Zuccolo L, Davey Smith G, et al. Fetal **Alcohol** Exposure and IQ at Age 8: Evidence from a Population-Based Birth-Cohort Study. *PLoS One*.2012;7(11):e49407.

Leyenaar JK, Schaefer AP, Wasserman JR, et al, Goodman DC. **Infant Mortality** Associated With Prenatal Opioid Exposure. *JAMA Pediatr*. 2021 Apr 12. doi: 10.1001/jamapediatrics.2020.6364.

Li K, Simons-Morton BG, Vaca FE, et al. Association Between Riding With an **Impaired Driver and Driving While Impaired.** *Pediatrics*. 2014 Mar 17.

Liang Y, Mente A, Yusuf S, et al. **Alcohol consumption and the risk of incident atrial fibrillation** among people with cardiovascular disease. *CMAJ*. 2012 Oct 1.

Liang Y, Wang L, Yuan TF. Targeting **Withdrawal Symptoms in Men Addicted to Methamphetamine** With Transcranial Magnetic Stimulation: A Randomized Clinical Trial. *JAMA Psychiatry*. 2018 Sep 12.

Liebschutz JM, Crooks D, Herman D, et al. **Buprenorphine** treatment for hospitalized, **opioid-dependent** patients: a randomized clinical trial [published online June 30, 2014]. *JAMA Intern Med*. doi:10.1001/jamainternmed.2014.2556.

Liebschutz JM, Xuan Z, Shanahan CW, et al. **Improving Adherence to Long-term Opioid Therapy Guidelines** to Reduce Opioid Misuse in Primary Care: A Cluster-Randomized Clinical Trial. *JAMA Intern Med*. 2017 Jul 17.

Linas BP, Savinkina A, Madushani RWMA, et al. Projected Estimates of **Opioid Mortality After Community-Level Interventions.** *JAMA Netw Open*. 2021 Feb 1;4(2):e2037259

Lindqvist AS, Moberg T, Eriksson BO, et al. A retrospective 30-year follow-up study of former Swedish-elite male athletes in power sports with a past **anabolic androgenic steroids** use: a focus on mental health. *Br J Sports Med*. 2013 Apr 23.

Ling Walter; Casadonte Paul; Bigelow George; et al. **Buprenorphine Implants** for Treatment of Opioid Dependence: A Randomized Controlled Trial. *JAMA*. 2010;304(14):1576-1583.

Lintzeris N, Bhardwaj A, Mills L, et al; (ARCD) study group. **Nabiximols** for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. *JAMA Intern Med*. 2019 Jul 15.

Lintzeris N, Dunlop AJ, Haber PS, et al. Patient-Reported **Outcomes of Treatment of Opioid Dependence** With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. *JAMA Netw Open*. 2021 May 3;4(5):e219041.

Lipton RB, Buse DC, Friedman BW, et al. Characterizing **opioid use in a US population with migraine**: Results from the CaMEO study. *Neurology*. 2020;95(5):e457-e468

Lisonkova S, Richter LL, Ting J, et al. **Neonatal Abstinence Syndrome** and Associated Neonatal and Maternal Mortality and Morbidity. *Pediatrics*. 2019 Jul 12.

Liu S, Scholl L, Hoots B, Seth P. **Nonfatal Drug and Polydrug Overdoses** Treated in Emergency Departments - 29 States, 2018-2019. *MMWR Morb Mortal Wkly Rep*. 2020;69(34):1149-1155.

Lo-Ciganic WH, Huang JL, Zhang HH, et al. Evaluation of **Machine-Learning Algorithms for Predicting Opioid Overdose Risk** Among Medicare Beneficiaries With Opioid Prescriptions. *JAMA Netw Open*. 2019 Mar 1;2(3):e190968.

Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial. *JAMA Intern Med*. 2018 May 14.

Louis CE, Kelly JL, Barth RJ Jr. Association of Decreased Postsurgical Opioid **Prescribing With Patients' Satisfaction With Surgeons**. *JAMA Surg*. 2019 Oct 16. doi: 10.1001/jamasurg.2019.2875.

Lovecchio F, Derman P, Stepan J, et al. **Support for Safer Opioid Prescribing Practices**: A Catalog of Published Use After Orthopaedic Surgery. *J Bone Joint Surg Am*. 2017 Nov 15;99(22):1945-1955

Lowery EM, Kuhlmann EA, Mahoney EL, et al. **Heavy alcohol** use in lung donors increases the risk for primary **graft dysfunction**. *Alcohol Clin Exp Res*. 2014 Nov;38(11):2853-61.

Lu W, Muñoz-Laboy M, Sohler N, Goodwin RD. Trends and Disparities in Treatment for **Co-occurring Major Depression and Substance Use Disorders** Among US Adolescents From 2011 to 2019. *JAMA Netw Open*. 2021 Oct 1;4(10):e2130280.

Lucas BR, Latimer J, Pinto RZ, et al. **Gross Motor Deficits in Children Prenatally Exposed to Alcohol**: A Meta-analysis. *Pediatrics*. 2014 Jul;134(1):e192-e209.

Lucyk S, Nelson L. Consequences of **unsafe prescribing of transdermal fentanyl**. *CMAJ*. 2016 Jun 14;188(9):638-9.

Luze K, Idrisov B, Golichenko M, et al. **Mandatory addiction treatment for people who use drugs**: global health and human rights analysis. *BMJ*. 2016 Jun 9;353:i2943.

Lyndon A, Audrey S, Wells C, et al. **Risk to heroin users of polydrug use of pregabalin or gabapentin**. *Addiction*. 2017 May 10.

Lyon JE, Khan RA, Gessert CE, et al. Treating **alcohol withdrawal with oral baclofen**: a randomized, double-blind, placebo-controlled trial. *J Hosp Med*. 2011 Oct;6(8):469-74.

Macfarlane GJ, Beasley M. Moderate **alcohol** consumption is associated with lower risk (and severity) of chronic **widespread pain**: Results from a UK population-based study. *Arthritis Care Res (Hoboken)*. 2015 Jul 20.

Macmadu A, Bathala S, Correia Gabel AM, et al. Comparison of **Characteristics of Deaths From Drug Overdose** Before vs During the COVID-19 Pandemic in Rhode Island. *JAMA Netw Open*. 2021 Sep 1;4(9):e2125538

MacMillan KDL, Rendon CP, Verma K, et al. Association of **Rooming-in With Outcomes for Neonatal Abstinence Syndrome**: A Systematic Review and Meta-analysis. *JAMA Pediatr*. 2018 Feb 5.

MacNiven KH, Jensen ELS, Borg N, et al. Association of **neural responses to drug cues with subsequent relapse to stimulant use**. *JAMA Netw Open*. 2018;1(8):e186466. doi:10.1001/jamanetworkopen.2018.6466

Maeda A, Bateman BT, Clancy CR, Creanga AA, Leffert LR. **Opioid Abuse and Dependence during Pregnancy**: Temporal Trends and Obstetrical Outcomes. *Anesthesiology*. 2014 Dec;121(6):1158-65.

Mahtta D, Ramsey D, Krittana Wong C, et al. **Recreational substance use** among patients with premature atherosclerotic cardiovascular disease. *Heart*. 2021 Apr;107(8):650-656

Mannes PZ, Wang TL, Ma W, et al. **Student Substance Use Policies** in US Allopathic Medical Schools: A National Study. *JAMA Psychiatry*. 2021 Sep 29. doi: 10.1001/jamapsychiatry.2021.2666.

March 11, 2010 (Savannah, Georgia) — **Barbiturates** are still the drugs of first choice among adults 60 years and older who commit suicide by overdose, despite a significant decrease in their use since 1990. In a study presented here at the American Association for Geriatric Psychiatry 2010 Annual Meeting, Robert C. Abrams, MD, Weill Cornell Medical College, New York City, found that 27.2% of adults 60 years and older living in New York City who overdosed fatally between 1990 and 2006 used barbiturates.

Mark TL, Parish W, Zarkin GA. Association Between Medicare and FDA Policies and **Prior Authorization Requirements for Buprenorphine Products** in Medicare Part D Plans. *JAMA*. 2019 Jul 9;322(2):166-167.

Marshall BD, Milloy MJ, Wood E, et al. Reduction in overdose mortality after the opening of North America's first medically supervised **safer injecting facility**: a retrospective population-based study. *Lancet*. 2011 Apr 15.

Marsolek, Melinda R., White, Nicole K., Litovitz, Toby L. **Inhalant Abuse**: Monitoring Trends by Using Poison Control Data, 1993-2008. *Pediatrics* 2010 0: peds.2009-2080.

Martin J, Cunliffe J, Décarry-Hélu D, et al. Effect of **restricting the legal supply of prescription opioids** on buying through online illicit marketplaces: interrupted time series analysis. *BMJ*. 2018 Jun 13;361:k2270.

Martin SA, Chido LM, Bosse JD, Wilson A. The next stage of **buprenorphine care for opioid use disorder**. *Ann Intern Med*. 2018; 169:628-35.

Martins SS, Sarvet A, Santaella-Tenorio J, et al. Changes in **US Lifetime Heroin Use** and Heroin Use Disorder: Prevalence From the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions. *JAMA Psychiatry*. 2017 Mar 29.

Mason BJ et al. A proof-of-concept randomized controlled study of **gabapentin**: Effects on **cannabis** use, withdrawal and executive function deficits in cannabis-dependent adults. *Neuropsychopharmacology* 2012 Jun; 37:1689.

Mason BJ, Quello S, Goodell V, et al. **Gabapentin Treatment for Alcohol Dependence**: A Randomized Clinical Trial. *JAMA Intern Med*. 2013 Nov 4.

Mason M, Arukumar P, Feinglass J. The Pandemic **Stay-at-Home Order and Opioid-Involved Overdose** Fatalities. *JAMA*. 2021 Apr 23. doi: 10.1001/jama.2021.6700.

Mason M, Soliman R, Kim HS, Post LA. Disparities by Sex and Race and Ethnicity in **Death Rates Due to Opioid Overdose** Among Adults 55 Years or Older, 1999 to 2019. *JAMA Netw Open*. 2022 Jan 4;5(1):e2142982.

Masonbrink AR, Hunt JA, Bhandal A, et al. **Self-reported and Documented Substance Use** Among Adolescents in the Pediatric Hospital. *Pediatrics*. 2021 May 3:e2020031468.

Mattick RP, Breen C, Kimber J, Davoli M. **Buprenorphine maintenance versus placebo or methadone** maintenance for opioid dependence. *Cochrane Database of Systematic Reviews* 2014, Issue 2. Art.No.: CD002207. DOI: 10.1002/14651858.CD002207.pub4.

Matison CL, Tanz LJ, Quinn K, et al. **Trends and Geographic Patterns** in Drug and Synthetic Opioid Overdose Deaths - United States, 2013-2019. *MMWR Morb Mortal Wkly Rep*. 2021 Feb 12;70(6):202-207

Maughan BC, Hersh EV, Shofer FS, et al. **Unused opioid analgesics and drug disposal** following outpatient **dental surgery**: A randomized controlled trial. *Drug Alcohol Depend*. 2016 Sep 16.

Mazer-Amirshahi M, Mullins PM, Rasooly I, et al. **Rising Opioid Prescribing in Adult U.S. Emergency Department Visits**: 2001-2010. *Acad Emerg Med*. 2014 Mar;21(3):236-243.

Mbuvah F, Venur VA, Kistangari G. The Clinical Picture: An intravenous drug user with persistent dyspnea and **lung infiltrates (talcosis)**. *Cleve Clin J Med*. 2014 Apr;81(4):223-4.

McBain RK, Dick A, Sorbero M, Stein BD. Growth and Distribution of **Buprenorphine-Waivered Providers** in the United States, 2007-2017. *Ann Intern Med*. 2020 Jan 7. doi: 10.7326/M19-2403.

McCabe SE, Arterberry BJ, Dickinson K, et al. Assessment of Changes in **Alcohol and Marijuana Abstinence, Co-Use, and Use Disorders** Among US Young Adults From 2002 to 2018. *JAMA Pediatr*. 2020 Oct 12. doi: 10.1001/jamapediatrics.2020.3352

McCabe SE, Schulenberg J, McCabe VV, Veliz PT. Medical Use and Misuse of **Prescription Opioids** in US 12th-Grade Youth: School-Level Correlates. *Pediatrics*. 2020 Sep 10:e20200387.

McCabe SE, Schulenberg JE, Schepis TS, et al. Trajectories of **Prescription Drug Misuse** Among US Adults From Ages 18 to 50 Years. *JAMA Netw Open*. 2022 Jan 4;5(1):e2141995.

McCabe SE, Veliz PT, Dickinson K, et al. Trajectories of prescription **drug misuse during the transition from late adolescence into adulthood** in the USA: a national longitudinal multicohort study. *Lancet Psychiatry*. 2019 Oct;6(10):840-850.

McCambridge J, Saitz R. **Rethinking brief interventions for alcohol** in general practice. *BMJ*. 2017 Jan 20;356:j116.

McCann UD, Sgambati FP, Schwartz AR, Ricaurte GA. **Sleep apnea** in young abstinent recreational **MDMA ("ecstasy")** consumers. *Neurology*. 2009 Dec 8;73(23):2011-7.

McCarthy, Fergus, O'Keeffe et al. Association Between **Maternal Alcohol Consumption in Early Pregnancy** and Pregnancy Outcomes. *Obstetrics&Gynecology*. September 2013.

McCarthy M. How **inappropriate prescribing prompted the opioid addiction** ravaging small town America. *BMJ*. 2017 Oct 19;359:j4730.

McClure AC, Tanski SE, Li Z, et al. **Internet Alcohol Marketing** and Underage Alcohol Use. *Pediatrics*. 2016 Jan 6.

McCord J, Jneid H, et al. Management of **Cocaine**-Associated Chest Pain and Myocardial Infarction. A Scientific Statement From the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. *Circulation* online Mar 17,2008.

McCormack RP, Williams AR, Goldfrank LR, et al. Commitment to assessment and treatment: **comprehensive care** for patients gravely disabled by **alcohol** use disorders. *Lancet*. 2013 Sep 14;382(9896):995-7.

McCoy MS, Kanter GP. **Campaign Contributions From Political Action Committees** to Members of Congressional Committees Responding to the **Opioid Crisis**. *JAMA*. 2018 Sep 6.

McDonnell MG, Graves MC, West II, et al. Utility of **point-of-care urine drug tests** in the treatment of primary care patients with drug use disorders. *J Addict Med [Internet]*. 2016 May [cited 2017 Jun 27];10(3):196-201.

McGinty EE, Stone EM, Kennedy-Hendricks A, et al. **Medication for Opioid Use Disorder**: A National Survey of Primary Care Physicians. *Ann Intern Med*. 2020 Apr 21. doi: 10.7326/M19-3975

McKetin R, Lubman DI, Baker AL, et al. Dose-Related Psychotic Symptoms in Chronic **Methamphetamine** Users: Evidence From a Prospective Longitudinal Study. *JAMA Psychiatry*. 2013 Jan 9;1-6.

McLarnon ME, Monaghan TL, Stewart SH, Barrett SP. Drug misuse and diversion in adults prescribed **anxiolytics and sedatives**. *Pharmacotherapy*. 2011;31: 262-272.

McLellan AT. New Department of **Veterans Affairs and Department of Defense Guidelines on Pain Management With Opioids**: Comment and Concern. *Ann Intern Med*. 2017 May 30

McNeely J, Wu LT, Subramaniam G, et al. Performance of the **Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool** for Substance Use Screening in Primary Care Patients. *Ann Intern Med*. 2016 Sep 6.

McPherson S, Lucey MR, Moriarty KJ. **Decompensated alcohol related liver disease**: acute management. *BMJ*. 2016 Jan 26;352:i124.

McQueen K, Murphy-Oikonen J. **Neonatal Abstinence Syndrome**. *N Engl J Med*. 2016 Dec 22;375(25):2468-2479.

McQuire C, Paranjothy S, Hurt L, et al. Objective Measures of **Prenatal Alcohol Exposure**: A Systematic Review. *Pediatrics*. 2016 Sep;138(3).

Meara E, Horwitz JR, Powell W, McClelland et al **State Legal Restrictions and Prescription-Opioid Use** among Disabled Adults. *N Engl J Med*. 2016 Jun 22.

Medicaid Outcomes Distributed Research Network (MODRN), Donohue JM, Jarlenski MP, et al. Use of **Medications for Treatment** of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018. *JAMA*. 2021 Jul 13;326(2):154-164

Meemken L, Hanhoff N, Tseng A, et al. **Drug-Drug Interactions With Antiviral Agents** in People Who Inject Drugs Requiring **Substitution Therapy**. *Ann Pharmacother*. 2015 Jul;49(7):796-807.

Mehra MR, Jarcho JA, Cherikh W, et al. The **Drug-Intoxication Epidemic and Solid-Organ Transplantation**. *N Engl J Med*. 2018 May 17;378(20):1943-1945.

Meisel ZF, Lupulescu-Mann N, Charlesworth CJ, et al. Conversion to Persistent or High-Risk **Opioid Use After a New Prescription From the Emergency Department**: Evidence From Washington Medicaid Beneficiaries. *Ann Emerg Med*. 2019 Jun 20.

Melotti, Roberto, Heron, Jon, Hickman, Matthew, et al. **Adolescent Alcohol and Tobacco Use and Early Socioeconomic Position**: The ALSPAC Birth Cohort. *Pediatrics* 2011 127: e948-e955

Merhar SL, Ounpraseuth S, Devlin LA, et al. **Phenobarbital and Clonidine** as Secondary Medications for **Neonatal Opioid Withdrawal** Syndrome. *Pediatrics*. 2021;147(3):e2020017830

Merlo LJ, Singhakant S, Cummings SM, et al. **Reasons for misuse of prescription medication among physicians** undergoing monitoring by a physician health program. *J Addict Med*. 2013 Sep-Oct;7(5):349-53

Mersfelder TL, Nichols WH. **Gabapentin: Abuse, Dependence, and Withdrawal**. *Ann Pharmacother*. 2015 Dec 31.

Miech R, Johnston L, O'Malley PM, et al. **Prescription Opioids** in Adolescence and Future Opioid Misuse. *Pediatrics*. 2015 Oct 26.

Miech RA, Patrick ME, O'Malley PM, Johnston LD. The Influence of **College Attendance on Risk for Marijuana Initiation** in the United States: 1977 to 2015. *Am J Public Health*. 2017 Jun;107(6):996-1002.

Meisenberg BR, Grover J, Campbell C, et al. Assessment of **Opioid Prescribing Practices Before and After Implementation of a Health System Intervention to Reduce Opioid Overprescribing**. *JAMA Netw Open*.2018;1(5):e182908.

Mikkelsen EM, Riis AH, Wise LA, et al. **Alcohol consumption and fecundability**: prospective Danish cohort study. *BMJ* 2016;354:i4262.

Miller CL, Pearce ME, Moniruzzaman A, et al; for the Cedar Project Partnership. The Cedar Project: risk factors for transition to **injection drug use among young, urban Aboriginal** people. *CMAJ*. 2011 Jul 12;183(10):1147-1154.

Milloy MJ, Wood E. Withdrawal from **methadone in US prisons**: cruel and unusual? Lancet. 2015 May 28.

Minozzi S, Amato L, Vecchi S, Davoli M. **Anticonvulsants for alcohol withdrawal**. Cochrane Database Syst Rev. 2010 Mar 17;3:CD005064.

Mir TA, Papudesu C, Fang W, Hinkle DM. Incidence of **Drug Use-Related Endogenous Endophthalmitis** Hospitalizations in the United States, 2003 to 2016. JAMA Ophthalmol. 2020 Nov 5. doi: 10.1001/jamaophthalmol.2020.4741.

Mitchell C, Dolan N, Dürsteler KM. Management of **dependent use of illicit opioids**. BMJ. 2020 Mar 9;368:m710.

MMWR: **Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs** — United States, 2004–2008. MMWR Morbidity and Mortality Weekly Report June2010. <http://www.cdc.gov/mmwr/pdf/wk/mm5923.pdf>

Moe-Byrne T, Brown JVE, McGuire W. **Naloxone for opioid-exposed newborn infants**. Cochrane Database Syst Rev. 2018 Oct 12;10:CD003483. The existing evidence from randomised controlled trials is insufficient to determine whether naloxone confers any important benefits to newborn infants with cardiorespiratory or neurological depression that may be due to intrauterine exposure to opioid. Given concerns about the safety of naloxone in this context, it may be appropriate to limit its use to randomised controlled trials that aim to resolve these uncertainties.

Moeller SJ, Konova AB, Parvaz MA, et al. Functional, Structural, and Emotional Correlates of Impaired Insight in **Cocaine Addiction**. JAMA Psychiatry. 2013 Nov 20.

Moeller SJ et al. **Behavioral preference for viewing drug v. pleasant images predicts current and future opioid misuse among chronic pain patients**. Psychol Med 2019 Apr 15.

Molero Y, Zetterqvist J, Binswanger IA, et al. **Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior**, Acidental Overdoses, and Crime. Am J Psychiatry. 2018 Aug 2;appiaip201817101112.

Mongeau-Pérusse V, Brissette S, Bruneau J, et al. **Cannabidiol as a treatment for craving and relapse** in individuals with cocaine use disorder: a randomized placebo-controlled trial. Addiction. 2021 Sep;116(9):2431-2442.

Montandon G, Slutsky AS. Solving the Opioid Crisis: **Respiratory Depression by Opioids as Critical Endpoint**. Chest. 2019 Jun 10.

Montastruc F, Montastruc G, Vigreux P et al. Valvular Heart Disease in a patient taking 3,4-Methylenedioxymethamphetamine (**MDMA, "Ecstasy"**). Br J Clin Pharmacol. 2012 Feb 24.

Monte AA, Bronstein AC, Cao DJ, et al. An outbreak of exposure to a **novel synthetic cannabinoid**. N Engl J Med. 2014 Jan 23;370(4):389-90 (Black mamba : ADB-PINACA)

Montoy JCC, Coralic Z, Herring AA, et al. Association of Default Electronic Medical Record Settings With Health Care Professional **Patterns of Opioid Prescribing in Emergency Departments**: A Randomized Quality Improvement Study. JAMA Intern Med. 2020 Jan 21. doi: 10.1001/jamainternmed.2019.6544.

Moore K, Magee M, Sevinisky H, et al. **Methadone and buprenorphine pharmacokinetics and pharmacodynamics** when coadministered with **fostemsavir** to opioid-dependent, HIV-seronegative participants. Br J Clin Pharmacol. 2019 Apr 13.

Morales KB, Park JN, Glick JL, et al. **Preference for drugs containing fentanyl** from a cross-sectional survey of people who use illicit opioids in three United States cities. Drug Alcohol Depend. 2019 Aug 23;204:107547.

Montecal L, Reynolds C, Donaldson LJ, et al. **Patterns of regional variation of opioid prescribing in primary care in England**: a retrospective observational study. Br J Gen Pract. 2018 Feb 12.

Moreno MA, Gower AD, Jenkins MC, et al. **Social Media Posts by Recreational Marijuana Companies and Administrative Code Regulations** in Washington State. JAMA Netw Open. 2018;1(7):e182242.

Morgan JR, Barocas JA, Murphy SM, et al. Comparison of **Rates of Overdose and Hospitalization** After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. JAMA Netw Open. 2020 Dec 1;3(12):e2029676

Morrow RL, Bassett K, Wright JM, et al. **Influence of opioid prescribing standards on drug use** among patients with long-term opioid use: a longitudinal cohort study. CMAJ Open. 2019 Jul 25;7(3):E484-E491.

Mostofsky E, Chahal HS, Mukamal KJ, et al. **Alcohol and Immediate Risk of Cardiovascular Events**: A Systematic Review and Dose-Response Meta-Analysis. Circulation. 2016 Mar 2.

Moyer A, Finney JW. **Brief interventions for alcohol misuse**. CMAJ. 2015 Apr 21;187(7):502-506.

Moyer VA. **Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse**: U.S. Preventive Services Task Force Recommendation Statement (**USPSTF**). Ann Intern Med. 2013 May 14. The USPSTF recommends that clinicians screen adults aged 18 years or older for alcohol misuse and provide persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce alcohol misuse. (Grade B recommendation)The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening and behavioral counseling interventions in primary care settings to reduce alcohol misuse in adolescents. (I statement).

Moyer VA: U.S. Preventive Services Task Force. **Primary care behavioral interventions to reduce illicit drug and nonmedical pharmaceutical use** in children and adolescents: u.s. Preventive services task force recommendation statement. (**USPSTF**) Ann Intern Med. 2014 May 6;160(9):634-9.

Moyo P, Zhao X, Thorpe CT, et al. **Dual receipt of prescription opioids** from the Department of Veterans Affairs and Medicare Part D and prescription opioid overdoses among veterans. A nested case–control study. Ann Intern Med. 2019. [Epub ahead of print]. doi:10.7326/M18-2574

Muncie Jr HL, Yasinian YY, Oge L. Outpatient Management of **Alcohol Withdrawal Syndrome**. Am Fam Physician. 2013;88(9):589-595.

Murphy SM, McColister KE, Leff JA, et al. **Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse**. Ann Intern Med. 2018. [Epub ahead of print]. doi:10.7326/M18-0227

Murthy VH. Ending the **Opioid Epidemic** - A Call to Action. N Engl J Med. 2016 Nov 9.

Muvvala SB, Edens EL, Petrakis IL. **What Role Should Psychiatrists Have** in Responding to the Opioid Epidemic? JAMA Psychiatry. 2018 Nov 28.

Muzyk AJ, Fowler JA, Norwood DK, Chilipko A. Role of **[alpha]2-Agonists (clonidine, dexmedetomidine) in the Treatment of Acute Alcohol Withdrawal**. Ann Pharmacother. 2011 May;45(5):649-57.

Myran DT, Cantor N, Rhodes E, et al. Physician Health Care Visits for Mental Health and **Substance Use During the COVID-19 Pandemic** in Ontario, Canada. JAMA Netw Open. 2022 Jan 4;5(1):e2143160.

Nadkarni A, Weobong B, Weiss HA, et al. Counselling for **Alcohol Problems (CAP)**, a lay counsellor-delivered brief psychological treatment for harmful drinking in men, in primary care in India: a randomised controlled trial. Lancet. 2016 Dec 14.

Nagata JM, Ganson KT, Gorrell S, et al. Association Between Legal Performance-Enhancing Substances and **Use of Anabolic-Androgenic Steroids** in Young Adults. JAMA Pediatr. 2020;e200883.

Naimi TS, Mosher JF. **Powdered Alcohol Products**: New Challenge in an Era of Needed Regulation. JAMA. 2015 Jul 14;314(2):119-120.

Nakagawa K, Vento MA, Ing MM, et al. Racial disparities in **methamphetamine-associated intracerebral hemorrhage**. Neurology. 2015 Feb 6.

National Treatment Agency for Substance Misuse. **Club drugs**: emerging trends and risks. Nov 2012. <http://www.nta.nhs.uk/uploads/clubdrugsreport201201.pdf>

Nejad SH, Schaefer PW, Bajwa EK, Smith FA. Case records of the Massachusetts General Hospital. Case 39-2012. A 55-year-old man with **alcoholism**, recurrent seizures, and agitation. N Engl J Med. 2012 Dec 20;367(25):2428-34.

Nelson DE, Jarman DW, Rehm J, et al. **Alcohol-Attributable Cancer Deaths** and Years of Potential Life Lost in the United States. Am J Public Health. 2013 Feb 14.

Nemiroff L, Cormier S, Leblanc C, Murphy N. Don't you forget about me: Considering acute **rabdomyolysis in ED patients with cocaine** ingestion. Can Fam Physician. 2012 Jul;58(7):750-4.

Nesoff ED, Branas CC, Martins SS. Association of **Neighborhood Characteristics and Travel Patterns** With Fatal Drug Overdoses. JAMA Intern Med. 2020 Nov 23:e203823

Newton AS, Soleimani A, Kirkland SW, et al. A Systematic Review of **Instruments to Identify Mental Health and Substance Use Problems Among Children** in the Emergency Department. Acad Emerg Med. 2017 Feb 1.

Newton NC, Andrews G, Champion KE, et al. **Universal Internet-based prevention for alcohol and cannabis use** reduces truancy, psychological distress and moral disengagement: A cluster randomised controlled trial. Prev Med. 2014 May 10;65C:109-115.

Ngueta G, Ndjaboue R. Lifetime **marijuana use in relation to insulin resistance** in lean, overweight, and obese US adults. J Diabetes. 2019 Jun 1.

Nguyen JL, Gilbert LR, Beasley L, et al. **Availability of Naloxone** at Rural Georgia Pharmacies, 2019. JAMA Netw Open. 2020 Feb 5;3(2):e1921227.

Nguyen T, Andraka-Christou B, Simon K, Bradford WD. Comparison of Rural vs Urban Direct-to-Physician **Commercial Promotion of Medications for Treating Opioid Use Disorder**. JAMA Netw Open. 2019 Dec 2;2(12):e1916520.

Nguyen TD, Gupta S, Ziedan E, et al. **Assessment of Filled Buprenorphine Prescriptions** for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic. JAMA Intern Med. 2020 Dec 21. doi: 10.1001/jamainternmed.2020.7497

**NICE:Methadone and buprenorphine** for the management of opioid dependence. NICE technology appraisal guidance 114 (2007). [www.nice.org.uk/guidance/TA114](http://www.nice.org.uk/guidance/TA114)

**NICE:Naltrexone** for the management of opioid dependence. NICE technology appraisal guidance 115 (2007). [www.nice.org.uk/guidance/TA115](http://www.nice.org.uk/guidance/TA115)

**NICE: Drug misuse: opioid detoxification**. NICE clinical guideline 52 (2007). [www.nice.org.uk/guidance/CG52](http://www.nice.org.uk/guidance/CG52)

**NICE**: Guidance for **methadone & buprenorphine** in addiction management. Evidence link: [http://guidance.nice.org.uk/TA114/Guidance/Evidence\\_1](http://guidance.nice.org.uk/TA114/Guidance/Evidence_1)

**NICE**: Clinical Guideline 120. Mar 2011. **Psychosis with coexisting substance misuse**. <http://www.nice.org.uk/nicemedia/live/13414/53691/53691.pdf> Quick Guide <http://www.nice.org.uk/nicemedia/live/13414/53731/53731.pdf>

**NICE: Alcohol-use disorders**: diagnosis, assessment and management of harmful drinking and alcohol dependence. NICE clinical guideline 115 (2011). [www.nice.org.uk/guidance/CG115](http://www.nice.org.uk/guidance/CG115)

Nicholas B. King, Veronique Fraser, Constantina Boikos, Robin Richardson, Sam Harper. Determinants of Increased **Opioid-Related Mortality** in the United States and Canada, 1990–2013: A Systematic Review. American Journal of Public Health, 2014; e1-11

Nielsen SF, Hjorthøj CR, Erlangsen A, Nordentoft M. Psychiatric disorders and mortality among people in **homeless shelters** in Denmark: a nationwide register-based cohort study. Lancet 2011; published online June 14. DOI:10.1016/S0140-6736(11)60747-2.

Nielsen S, Laranche B, Degenhardt L, et al. **Opioid agonist treatment for pharmaceutical opioid dependent people**. Cochrane Database Syst Rev. 2016 May 9;5:CD011117. There was low to moderate quality evidence supporting the use of maintenance agonist pharmacotherapy for pharmaceutical opioid dependence. Methadone or buprenorphine appeared equally effective. Maintenance treatment with buprenorphine appeared more effective than detoxification or psychological treatments. Due to the overall low to moderate quality of the evidence and small sample sizes, there is the possibility that the further research may change these findings.

Nielsen S, Laranche B, Lintzeris N. **Opioid Agonist Treatment** for Patients With **Dependence on Prescription Opioids**. JAMA. 2017 Mar 7;317(9):967-968

Niles JK, Gudín J, Vivolo-Kantor AM, et al. Notes from the Field: **Testing for Nonprescribed Fentanyl** and Percentage of Positive Test Results Among Patients with Opioid Use Disorder - United States, 2019-2020. MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1649-1651

Nisavic M, Flores EJ, Heng M, et al. Case 26-2019: A 27-Year-Old Woman with **Opioid Use Disorder and Suicidal Ideation**. N Engl J Med. 2019 Aug 22;381(8):763-771.

Ninmemann AL, Jeong Choi H, Stuart GL, et al. Longitudinal Predictors of **Synthetic Cannabinoid Use in Adolescents**. Pediatrics. 2017;139(4):e20163009

Noormohammadi A, Forinash A, Yancey A, et al. **Buprenorphine Versus Methadone** for Opioid Dependence in **Pregnancy**. Ann Pharmacother. 2016 Aug;50(8):666-72.

Nosrati E, Kang-Brown J, Ash M, et al. **Economic decline, incarceration, and mortality** from drug use disorders in the USA between 1983 and 2014: an observational analysis. Lancet Public Health. 2019 Jul;4(7):e326-e333.

Nosyk B, Guh DP, Bansback NJ, et al. Cost-effectiveness of **diacetylmorphine versus methadone** for chronic opioid dependence refractory to treatment. (**NAOMI**) CMAJ. 2012 Mar 12.

Nuijten M, Blanken P, van de Wetering B, et al. Sustained-release **dexamfetamine** in the treatment of chronic **cocaine**-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 22.

Nutt DJ, King LA, Phillips LD; on behalf of the Independent Scientific Committee on Drugs. **Drug harms** in the UK: a multicriteria decision analysis. Lancet. 2010 Oct 29. Overall, **alcohol was the most harmful drug (overall harm score 72), with heroin (55) and crack cocaine (54) in second and third places**.

Oct/13 The workout supplement marketed as **"Craze"** contains a potentially dangerous designer drug — a methamphetamine analog — according to an article in Drug Testing and Analysis. The analog, N, alpha-diethyl-phenylethylamine (N, alpha-DEPEA), was found in three different samples of the product obtained from separate sources and analyzed by two labs. The product's label claims it contains phenylethylamines derived from dendrobium, but the authors say the component identified as N, alpha-DEPEA has never been identified in dendrobium. They say the amounts of N, alpha-DEPEA found "strongly suggest" that it's not a minor contaminant, adding that if their findings are confirmed, the FDA should "remove all N, alpha-DEPEA-containing supplements from the marketplace." The Boston Globe reports that another supplement, **"Detonate,"** also contained N, alpha-DEPEA upon analysis.

Okie, Susan. A Flood of Opioids, a **Rising Tide of Deaths**. N Engl J Med 2010; 363:1981-1985

O'Brien CP. **Managing patients with a history of substance abuse**. Can Fam Physician. 2014 Mar;60(3):248-50.

O'Brien KS, Carr S, Ferris J, et al. **Alcohol Advertising** in Sport and Non-Sport TV in Australia, during Children's Viewing Times. PLoS One. 2015 Aug 11;10(8):e0134889.

Ochalek TA, Cumpston KL, Wills BK, et al. **Nonfatal Opioid Overdoses** at an Urban Emergency Department During the COVID-19 Pandemic. JAMA. 2020 Sep 18. doi: 10.1001/jama.2020.17477

O'Donnell J, Tanz LJ, Gladden RM, et al. Trends in and Characteristics of **Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls** - United States, 2019-2020. MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1740-1746.

O'Donoghue AL, Biswas N, Dechen T, et al. Trends in Filled **Naloxone Prescriptions Before and During the COVID-19 Pandemic** in the United States. JAMA Health Forum. 2021;2(5):e210393.

Oei JL, Melhuish E, Uebel H, et al. **Neonatal Abstinence Syndrome** and High School Performance. Pediatrics. 2017 Jan 16.



O'Hara NN, Pollak AN, Welsh CJ, et al. Factors Associated With **Persistent Opioid Use Among Injured Workers' Compensation Claimants**. JAMA Netw Open. 2018;1(6):e184050.

Olds C, Spataro E, Li K, et al. Assessment of **Persistent and Prolonged Postoperative Opioid Use** Among Patients Undergoing Plastic and Reconstructive Surgery. JAMA Facial Plast Surg. 2019 Mar 7.

O'Leary CM, Jacoby PJ, Bartu A, et al. **Maternal Alcohol Use and Sudden Infant Death Syndrome** and Infant Mortality Excluding SIDS. Pediatrics. 2013 Feb 25.

O'Leary CM, Taylor C, Zubrick SR, Kurinczuk JJ, Bower C. **Prenatal alcohol exposure** and educational achievement in children aged 8-9 years. Pediatrics. 2013 Aug;132(2):e468-75.

Olsson M, Crystal S, Wall M, et al. Causes of **Death After Nonfatal Opioid Overdose**. JAMA Psychiatry. 2018 Jun 20.

Olsson M, Rossen LM, Wall MM, et al. **Trends in Intentional and Unintentional Opioid Overdose Deaths** in the United States, 2000-2017. JAMA. 2019 Dec 17;322(23):2340-2342.

Olsson M, Schoenbaum M, Goldman-Mellor S. **Risks of Mortality** Following Nonfatal Intentional and Unintentional Opioid Overdoses. JAMA Psychiatry. 2020;10.1001/jamapsychiatry.2020.1045.

Olsson M, Wall MM, Liu SM, Blanco C. **Cannabis Use and Risk of Prescription Opioid Use Disorder** in the United States. Am J Psychiatry. 2017 Sep 26;appiajp201717040413.

Olsson M, Wall M, Wang S, et al. **Service Use Preceding Opioid-Related Fatality**. Am J Psychiatry. 2017 Nov 28;appiajp201717070808.

Oliva EM, Bowe T, Manhapra A, et al. Associations between **stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths** in US veterans: observational evaluation. BMJ. 2020 Mar 4;368:m283.

O'Mara K, Gal P, Davanzo C. Treatment of neonatal withdrawal with **clonidine after** long-term, high-dose maternal use of **tramadol**. Ann Pharmacother. 2010 Jul-Aug;44(7-8):1342-4.

Onders B, Casavant MJ, Spiller HA, et al. **Marijuana** Exposure Among Children Younger Than Six Years in the United States. Clin Pediatr (Phila). 2015 Jun 7.

Oppedal K, Moller AM, Pedersen B, et al. **Preoperative alcohol cessation** prior to elective surgery. Cochrane Database Syst Rev. 2012 Jul 11;7:CD008343. Based on the finding of two studies, it appears that intensive preoperative alcohol cessation interventions, including pharmacological strategies for relapse prophylaxis and withdrawal symptoms, may significantly reduce postoperative complication rates. No effect was found on mortality rates and length of stay.

Oral R et al. Illicit drug exposure in patients evaluated for **alleged child abuse and neglect**. Pediatr Emerg Care 2011 Jun; 27:490.

Ordean Alice, Kahan Meldon. Comprehensive treatment program for **pregnant substance users** in a family medicine clinic. Can Fam Physician November 2011 57: e430-e435.

O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. **Alcoholic liver disease**. Hepatology. 2010 Jan;51(1):307-28.

Oslin DW, Leong SH, Lynch KG, et al. **Naltrexone** vs Placebo for the Treatment of **Alcohol Dependence**: A Randomized Clinical Trial. JAMA Psychiatry. 2015 Mar 11.

Ostergaard ML, Nordenroft M, et al. Associations between **substance use disorders & suicide** or suicide attempts in people with mental illness: Danish nationwide, prospective, register-based study of patients diagnosed with schizophrenia, bipolar disorder, unipolar depression or personality disorder. Addiction. 2017 Feb 13.

Oviedo-Joekes E, Guh D, Brissette S, et al. **Hydromorphone compared with diacetylmorphine** for long-term **opioid dependence**: a randomized clinical trial [online April 6, 2016]. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2016.0109.

Pace CA, Samet JH. In the Clinic: **Substance Use Disorders**. Ann Intern Med. 2016 Apr 5

Palpacuer C, Laviolle B, Boussageon R, et al. Risks and Benefits of **Nalmefene in the Treatment of Adult Alcohol Dependence**: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials. PLoS Med. 2015 Dec 22;12(12):e1001924.

Palamar JJ. **"Bath salt"** use among a nationally representative sample of high school seniors in the United States. Am J Addict. 2015 Jul 14.

Palamar JJ, Le A. Discordant reporting of **nonmedical amphetamine use among Adderall-using high school seniors** in the US. Drug Alcohol Depend. 2017 Oct 20;181:208-212

Palumbo SA, Adamson KM, Krishnamurthy S, et al. Assessment of **Probable Opioid Use Disorder** Using Electronic Health Record Documentation. JAMA Netw Open. 2020 Sep 13;3(9):e2015909

Pani PP, Trogu E, Pacini M, et al. **Anticonvulsants for alcohol dependence**. Cochrane Database Syst Rev. 2014 Feb 13;2:CD008544.

Pardo B. Insights Into **Mixing Fentanyl and Benzodiazepines** From Canadian Drug Seizures. JAMA Psychiatry. 2021 Nov 17. doi: 10.1001/jamapsychiatry.2021.3292

Parker CM, Hirsch JS, Hansen HB, et al. Facing **Opioids in the Shadow of the HIV Epidemic**. N Engl J Med. 2019 Jan 3;380(1):1-3.

Parthasarathy S, Kline-Simon AH, Jones A, et al. **Three-Year Outcomes** After Brief Treatment of Substance Use and Mood Symptoms. Pediatrics. 2021 Jan;147(1):e2020009191

Patel RA, Gallagher JC. **Drug Fever**. Pharmacotherapy. 2010 Jan;30(1):57-69.

Patnode CD, O'Connor E, Rowland M, et al. **Primary Care Behavioral Interventions to Prevent or Reduce Illicit Drug Use** and Nonmedical Pharmaceutical Use in Children and Adolescents: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014 Mar 11.

Patnode CD, O'Connor E, Rowland M, et al. **Primary Care Behavioral Interventions to Prevent or Reduce Illicit Drug and Nonmedical Pharmaceutical Use** in Children and Adolescents: A Systematic Evidence Review for the U.S. Preventive Services Task Force (**USPSTF**) [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Mar.

Patterson DA, Morris GW, Houghton A. **Uncommon Adverse Effects of Commonly Abused Illicit Drugs**. Am Fam Physician. 2013;88(1):15-16.

Patra J, Bakker R, Irving H, et al. Dose-response relationship between **alcohol consumption before and during pregnancy** and the risks of low birthweight, preterm birth and small for gestational age (SGA)-a systematic review and meta-analyses. BJOG. 2011 Nov;118(12):1411-1421.

Patrick ME, Schulenberg JE, Martz ME, et al. Extreme **Binge Drinking** Among 12th-Grade Students in the United States: Prevalence and Predictors. JAMA Pediatr. 2013 Sep 16.

Patrick SW, Barfield WD, Poindexter BB; Committee on Fetus and Newborn, Committee on Substance Use and Prevention. **Neonatal Opioid Withdrawal** Syndrome. Pediatrics. 2020 Nov;146(5):e2020029074.

Patrick SW, Faherty LJ, Dick AW, Scott TA, Dudley J, Stein BD. Association among county-level economic factors, clinician supply, metropolitan or rural location, and **neonatal abstinence syndrome**. JAMA. doi:10.1001/jama.2018.20851

Patrick SW, Richards MR, Dupont WD, et al. Association of **Pregnancy and Insurance Status With Treatment Access** for Opioid Use Disorder. JAMA Netw Open. 2020;3(8):e2013456.

Patrick SW, Schumacher RE, Benneyworth BD, et al. **Neonatal abstinence syndrome** and associated health care expenditures: United States, 2000-2009 [published online April 30, 2012]. JAMA.

Paulus MP, Stewart JL. Neurobiology, Clinical Presentation, and Treatment of **Methamphetamine Use Disorder**: A Review. JAMA Psychiatry. 2020 Apr 8. doi: 10.1001/jamapsychiatry.2020.0246

Pavisian B, MacIntosh BJ, Szilagyi G, et al. Effects of **cannabis on cognition** in patients with **MS**: A psychometric and MRI study. Neurology. 2014 May 27;82(21):1879-87.

Peacock A, Bruno R, Gisev N, et al. **New psychoactive substances**: challenges for drug surveillance, control, and public health responses. Lancet. 2019 Oct 21. doi: 10.1016/S0140-6736(19)32231-7.

Peltz J, Südhof TC. **The Neurobiology of Opioid Addiction** and the Potential for **Prevention Strategies**. JAMA. 2018 Apr 26.

Penner EA, Buettner H, Mittleman MA. The Impact of **Marijuana Use on Glucose, Insulin, and Insulin Resistance** among US Adults. Am J Med. 2013 May 9.

Perry AE, Martyn-St James M, Burns L, et al. **Interventions for drug-using offenders** with co-occurring mental health problems. Cochrane Database Syst Rev. 2019 Oct 7;10:CD010901.

Peters EN, Bae D, Barrington-Trimis JL, et al. **Prevalence and Sociodemographic Correlates of Adolescent Use and Polyuse of Combustible, Vaporized, and Edible Cannabis Products**. JAMA Netw Open. 2018;1(5):e182765.

Peterson BS, Rosen T, Dingman S, et al. Associations of **Maternal Prenatal Drug Abuse** With Measures of Newborn Brain Structure, Tissue Organization, and Metabolite Concentrations. JAMA Pediatr. 2020;e201622

Petrone AB, Gaziano JM, Djoussé L. **Alcohol Consumption** and Risk of Death in Male Physicians With **Heart Failure**. Am J Cardiol. 2014 Jul 18.

Pettinati HM et al. A double-blind, placebo-controlled trial combining **sertraline** and **naltrexone** for treating co-occurring **depression and alcohol dependence**. Am J Psychiatry 2010 Mar 15

Pham D, Addison D, Kayani W, et al. Outcomes of **beta blocker use in cocaine-associated chest pain**: a meta-analysis. Emerg Med J. 2018 Jun 19.

Pharmacist's Letter. Clonidine abuse. Mar,2010.

Pharmacist's Letter. **OTC and Rx Drugs of Abuse**. Nov,2010.

Philip C, Roy S, Eiden C, et al. **Opioid misuse** in community pharmacy patients with chronic non-cancer pain. Br J Clin Pharmacol. 2021 Dec 3. doi: 10.1111/bcp.15164.

Phillips RH, Salzman M, Haroz R, et al. **Elective Naloxone-Induced Opioid Withdrawal** for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder. Ann Emerg Med. 2019 Feb 14.

Piske M, Homayra F, Min JE, et al. **Opioid Use Disorder and Perinatal Outcomes**. Pediatrics. 2021;148(4):e2021050279

Pletcher MJ, Vittinghoff E, Kahan R, et al. Association between **marijuana exposure and pulmonary function over 20 years**. JAMA. 2012 Jan 11;307(2):173-81.

Podolsky SH, Herzberg D, Greene JA. **Preying on Prescribers (and Their Patients)** - Pharmaceutical Marketing, Iatrogenic Epidemics, and the Sackler Legacy. N Engl J Med. 2019 May 9;380(19):1785-1787.

Ponté C, Pi C, Palmaro A, et al. Early Signal of **Diverted Use of Tropicamide Eye Drops** in France. Br J Clin Pharmacol. 2017 Feb 27.

Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. **Adverse health consequences of performance-enhancing drugs**: an Endocrine Society scientific statement. Endocr Rev. 2014 Jun;35(3):341-75.

Pope HG Jr, Khalsa JH, Bhasin S. Body Image Disorders and Abuse of **Anabolic-Androgenic Steroids Among Men**. JAMA. 2016 Dec 8.

Popova S, Lange S, Shield K, et al. Comorbidity of **fetal alcohol spectrum disorder**: a systematic review and meta-analysis. Lancet 2015; online Jan 5.

Post S, Spiller HA, Casavant MJ, et al. **Buprenorphine Exposures Among Children and Adolescents** Reported to US Poison Control Centers. Pediatrics. 2018 Jun 25.

Powell D, Alpert A, Pacula RL. A Transitioning Epidemic: How The **Opioid Crisis Is Driving The Rise In Hepatitis C**. Health Aff (Millwood). 2019 Feb;38(2):287-294.

Probst C, Rehm J. **Alcohol use, opioid overdose and socioeconomic status in Canada**: A threat to life expectancy? CMAJ. 2018 Nov 5;190(44):E1294-E1295.

Provenzano AM. Caring for Ms. L. - **Overcoming My Fear of Treating Opioid Use Disorder**. N Engl J Med. 2018 Feb 15;378(7):600-601.

Pryor JR, Maalouf FI, Krans EE, et al. The **opioid epidemic and neonatal abstinence syndrome** in the USA: a review of the continuum of care. Arch Dis Child Fetal Neonatal Ed. 2017 Mar;102(2):F183-F187.

Psaty BM, Merrill JO. **Addressing the Opioid Epidemic - Opportunities in the Postmarketing Setting**. N Engl J Med. 2017 Apr 20;376(16):1502-1504.

Purshouse RC, Meier PS, Brennan A, Taylor KB, Rafia R. Estimated effect of **alcohol pricing policies** on health and health economic outcomes in England: an epidemiological model. Lancet. 2010 Apr 17;375(9723):1355-64.

Puzantian T, Gasper JJ. Provision of **Naloxone Without a Prescription by California Pharmacists 2 Years After Legislation Implementation**. JAMA. 2018 Nov 13;320(18):1933-1934.

Qato DM, Alexander GC, Guadamuz JS, Lindau ST. **Prescription Medication Use Among Children and Adolescents in the United States**. Pediatrics. 2018 Sep;142(3). pii: e20181042.

Quinlan K, Shults RA, Rudd RA. **Child Passenger Deaths Involving Alcohol-Impaired Drivers**. Pediatrics. 2014 May 5.

Quinn PD, Chang Z, Hur K, et al. **ADHD Medication and Substance-Related Problems**. Am J Psychiatry. 2017 Jun 29;appiajp201716060686.

Quinn PD, Fine KL, Rickert ME, et al. Association of **Opioid Prescription Initiation** During Adolescence and Young Adulthood With Subsequent Substance-Related Morbidity. JAMA Pediatr. 2020;e202539

Raghunathan K, Ray N, Bryan W, et al. Trends in Chronic **Opioid Use Around Inpatient Surgery** Within the Veterans Health Administration. JAMA Surg. 2019 Sep 18.

Raheemullah A, Lembke A. **Initiating Opioid Agonist Treatment** for Opioid Use Disorder in the Inpatient Setting: A Teachable Moment. JAMA Intern Med. 2019 Jan 14.

Rahmati A, Shakeri R, Khademi H, et al. **Mortality from respiratory diseases associated with opium use**: a population-based cohort study. Thorax. 2016 Nov 24.

Raja AS, Miller ES, Flores EJ, et al. Case 37-2017. A 36-Year-Old Man with **Unintentional Opioid Overdose**. N Engl J Med. 2017 Nov 30;377(22):2181-2188.

Raith W, Schmölder GM, Resch B, et al. **Laser Acupuncture for Neonatal Abstinence Syndrome**: A Randomized Controlled Trial. Pediatrics. 2015 Oct 26.

Raleigh MF. **Buprenorphine Maintenance vs. Placebo for Opioid Dependence.** Am Fam Physician. 2017 Mar 1;95(5):Online.

Rangel Carlos; Shu Richard G.; Lazar Lawrence D. et al. **[beta]-Blockers** for Chest Pain Associated With Recent **Cocaine** Use Arch Intern Med. 2010;170(10):874-879.

Rangmar J, Hjern A, Vinnerljung B, et al. Psychosocial outcomes of **fetal alcohol syndrome** in adulthood. Pediatrics. 2015 Jan;135(1):e52-8.

Rasmussen JJ, Selmer C, Østergren PB, Pedersen KB, Schou M, Gustafsson F, Faber J, Juul A, Kistorp C. **Former Abusers of Anabolic Androgenic Steroids** Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. PLoS One. 2016 Aug 17;11(8):e0161208.

Ray LA, Meredith LR, Kiluk BD, et al. Combined **Pharmacotherapy and Cognitive Behavioral Therapy** for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(6):e208279.

Ray WA, Chung CP, Murray KT, et al. **Prescription of Long-Acting Opioids and Mortality** in Patients With Chronic Noncancer Pain. JAMA. 2016 Jun 14;315(22):2415-23.

Reddy RG, Aung T, Karavitaki N, Wass JA. Opioid induced **hypogonadism**. BMJ. 2010 Aug 31;341:c4462. doi: 10.1136/bmj.c4462.

Reddy S, Orenstein LAV, Strunk A, Garg A. Incidence of Long-term Opioid Use Among Opioid-Naïve Patients With **Hidradenitis Suppurativa** in the United States. JAMA Dermatol. 2019 Sep 11.

Reihan N, Schwartz SG, Flynn HW Jr. **Endogenous Fungal Endophthalmitis**: An Increasing Problem Among **Intravenous** Drug Users. JAMA. 2017 Aug 22;318(8):741-742.

Rewbury R, Hughes E, Purbrick R, et al. **Poppers**: legal highs with questionable contents? A case series of poppers maculopathy. Br J Ophthalmol. 2017 Apr 10.

Reynolds K, Kaufman R, Korenoski A, et al. **Trends in gabapentin and baclofen exposures** reported to U.S. poison centers. Clin Toxicol (Phila). 2019 Dec 1;1-10. doi: 10.1080/15563650.2019.1687902.

Rich JD, Adashi EY. Ideological Anachronism Involving Needle and **Syringe Exchange Programs**: Lessons From the Indiana HIV Outbreak. JAMA. 2015 Jul 7;314(1):23-4.

Richman I, Krumholz HM. **Lessons From the Opioid Epidemic to Reinvalidate Tobacco Control Initiatives.** JAMA. 2018 Jan 23;319(4):339-340.

Richter KP, Levy S. **Big Marijuana** - Lessons from Big Tobacco. N Engl J Med. 2014 Jun 11.

Riva JJ, Noor ST, Wang L, et al. **Predictors of Prolonged Opioid Use** After Initial Prescription for Acute Musculoskeletal Injuries in Adults: A Systematic Review and Meta-analysis of Observational Studies. Ann Intern Med. 2020;10.7326/M19-3600.

Rodger L, Glockler-Lauf SD, Shojaei E, et al. Clinical Characteristics and Factors Associated With **Mortality in First-Episode Infective Endocarditis Among Persons Who Inject Drugs.** JAMA Netw Open. 2018;1(7):e185220.

Rose DZ, Guerrero WR, Mokin MV, et al. **Hemorrhagic stroke** following use of the **synthetic marijuana "spice"**. Neurology. 2015 Sep 29;85(13):1177-9.

Rosenquist J, Niels, Murabito Joanne, Fowler James H., et al. The Spread of **Alcohol** Consumption Behavior in a Large **Social Network.** Ann Intern Med April 6, 2010 152:426-433; doi:10.1059/0003-4819-152-7-201004060-00007.

Rösner S, Hackl-Herrwerth A, Leucht S, Lebert P, Vecchi S, Soyka M. **Acamprosate for alcohol dependence.** Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD004332. DOI: 10.1002/14651858.CD004332.pub2. {In pts with EtOH dependence: ↓ return to drinking & ↑ abstinence vs Pl NNNY=10; 6wk-12mo; ↑diarrhea;NS vs naltrexone.}

Ross EA, Watson M, Goldberger B. **Bath Salts Intoxication.** NEJM. 2011 Sep 8;365(10):967-8.

Raffa RB, Pergolizzi JV Jr. **Opioid formulations designed to resist/deter abuse.** Drugs. 2010 Sep 10;70(13):1657-75. doi: 10.2165/11537940-000000000-00000.

Reuben DB, H Alvanzo AA, Ashikaga T, et al. National Institutes of Health Pathways to Prevention Workshop: The Role of **Opioids in the Treatment of Chronic Pain.** Ann Intern Med. 2015 Jan 13.

Rezkalla S, Kloner RA. **Recreational marijuana use: is it safe for your patient?** J Am Heart Assoc. 2014 Apr 23;3(2):e000904.

Rich JD, McKenzie M, Larney S, et al. **Methadone** continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet 2015; published online May 29

Richards JR, Smith NE, Moulin AK. **Unintentional Cannabis Ingestion in Children:** A Systematic Review. J Pediatr. 2017 Sep 6.

Rivera OJS, Havens JR, Parker MA, et al. Risk of **Heroin Dependence in Newly Incident Heroin Users.** JAMA Psychiatry. 2018 May 30.

Robinson M, Shipton D, Walsh D, Whyte B, McCartney G. **Regional alcohol consumption and alcohol-related mortality in Great Britain:** novel insights using retail sales data. BMC Public Health. 2015 Jan 7; 15(1):1.

Roehler DR, Olsen EO, Mustaquim D, Vivolo-Kantor AM. **Suspected Nonfatal Drug-Related Overdoses** Among Youth in the US: 2016-2019. Pediatrics. 2020 Dec 7:e2020003491

Rogal S, Youk A, Agbalajobi O, et al. **Medication Treatment** of Active Opioid Use Disorder in Veterans With Cirrhosis. Am J Gastroenterol. 2021 Mar 30. doi: 10.14309/ajg.0000000000001228

Romanelli F, Smith KM. Clinical effects and **management of methamphetamine abuse.** Pharmacotherapy. 2006 Aug;26(8):1148-56

Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011; DOI:10.1136/bmj.d671.

Rose AJ, McBain R, Schuler MS, et al. **Effect of Age on Opioid Prescribing,** Overdose, and Mortality in Massachusetts, 2011 to 2015. J Am Geriatr Soc. 2019 Jan;67(1):128-132.

Rosenthal RN, Lofwall MR, Kim S, et al. Effect of **Buprenorphine Implants** on Illicit Opioid Use Among AbstinentAdults With Opioid Dependence Treated With Sublingual Buprenorphine: A RandomizedClinical Trial. JAMA. 2016 Jul 19;316(3):282-90

Rosic T, Najli L, Bawor M, et al. The impact of **comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder:** a prospective cohort study. Neuropsychiatr Dis Treat 2017;13:1399-408.

Roy-Byrne P, Bumgardner K, Krupski A, et al. **Brief intervention for problem drug use** in safety-net primary care settings: a randomized clinical trial. JAMA. 2014 Aug 6;312(5):492-501.

Roydhouse JK, Suzman DL, Menapace LA, et al. Global Variation in Opioid Use in **Prostate Cancer Trials.** JAMA Oncol. 2019 Sep 12:e192971.

Rudd RA, Seth P, David F, et al. Increases in **Drug and Opioid-Involved Overdose Deaths** - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(5051):1445-1452.

Ruhm CJ. Geographic Variation in **Opioid and Heroin** Involved Drug Poisoning Mortality Rates. Am J Preventive Med. 2017.

Russolillo A, Moniruzzaman A, Somers JM. Association of **Methadone Treatment With Substance-Related Hospital Admissions** Among a Population in Canada With a History of Criminal Convictions. JAMA Netw Open. 2019 Mar 1;2(3):e190595.

Rutkow L, Chang HY, Daubresse M, et al. Effect of **Florida's Prescription Drug Monitoring Program** and Pill Mill Laws on Opioid Prescribing and Use. JAMA Intern Med. 2015 Aug 17.

Rutkow L, Vernick JS. **Emergency Legal Authority and the Opioid Crisis.** N Engl J Med. 2017 Dec 28;377(26):2512-2514.

Ruzycski S, Yarema M. **Fentanyl misuse.** CMAJ. 2016 Jun 14;188(9):673.

Ryan SA, Ammerman SD; Committee on Substance Use and Prevention. **Counseling Parents and Teens About Marijuana Use** in the Era of Legalization of Marijuana. Pediatrics. 2017 Feb 27.

Ryan SA. Calculating the Real **Costs of the Opioid Crisis.** Pediatrics. 2018 Mar 5.

Sabia S, Elbaz A, Britton A, et al. **Alcohol** consumption and **cognitive decline** in early old age. Neurology. 2014 Jan 15.

Sachdeva A, Chandra M, Deshpande SN. A Comparative Study of Fixed Tapering Dose Regimen versus Symptom-triggered Regimen of **Lorazepam for Alcohol Detoxification.** Alcohol Alcohol. 2014 Jan 8.

Saitz R, Cheng DM, Winter M, et al. **Chronic care management** for dependence on **alcohol and other drugs:** the **AHEAD** randomized trial. JAMA. doi:10.1001/jama.2013.277609.

Saitz R, Palfai TPA, Cheng DM, et al. **Screening and brief intervention for drug use in primary care:** the ASPIRE randomized clinical trial. JAMA. doi:10.1001/jama.2012.9630.

Saloner B, Chang HY, Krawczyk N, et al. **Predictive Modeling of Opioid Overdose** Using Linked Statewide Medical and Criminal Justice Data. JAMA Psychiatry. 2020;10.1001/jamapsychiatry.2020.1689.

Saloner B, Levin J, Chang H, et al. **Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion.** JAMA Netw Open. 2018;1(4):e181588.

Saloner B, Stoller KB, Alexander GC. Moving Addiction Care to the Mainstream -Improving the Quality of Buprenorphine Treatment. N Engl J Med. 2018 Jul 5;379(1):4-6.

Saloner B, Whitley P, LaRue L, et al. **Polysubstance Use** Among Patients Treated With Buprenorphine From a National Urine Drug Test Database. JAMA Netw Open. 2021 Sep 1;4(9):e2123019.

Salisbury-Afshar E. Pharmacotherapy for Adults with **Alcohol Use Disorder.** AmFam Physician. 2016 Jul 15;94(2):155-7.

Samet JH, Botticelli M, Bharel M. **Methadone in Primary Care** - One Small Step for Congress, One Giant Leap for Addiction Treatment. N Engl J Med. 2018 Jul 5;379(1):7-8.

Samet JH, Kertesz SG. Suggested Paths to Fixing the Opioid Crisis: **Directions and Misdirections.** JAMA Netw Open. 2018 Jun 1;1(2):e180218.

Sanderson M, Rowe A. **Kratom.** CMAJ. 2019 Oct 7;191(40):E1105.

Sandhu H, Underwood M, Furlan AD, et al. What interventions are effective to **taper opioids in patients with chronic pain?** BMJ. 2018 Sep 27;362:k2990.

Sanmartin MX, Ali MM, Lynch S, Aktas A. Association Between State-Level Criminal Justice-Focused **Prenatal Substance-Use Policies** in the US and Substance Use-Related Foster Care Admissions and Family Reunification. JAMA Pediatr. 2020;e201027.

Santo T Jr, Clark B, Hickman M, et al. Association of **Opioid Agonist Treatment With All-Cause Mortality** and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021 Jun 2. doi: 10.1001/jamapsychiatry.2021.0976.

Saveland C, Hawker L, Miedema B, et al. **Abuse of family physicians** by patients seeking controlled substances. Can Fam Physician. 2014 Feb;60(2):e131-6.

Sazegar P. **Cannabis Essentials:** Tools for Clinical Practice. Am Fam Physician. 2021 Dec 1;104(6):598-608.

Schaffer AL, Buckley NA, Degenhardt L, et al. Person-level changes in **oxycodone use after the introduction of a tamper-resistant formulation** in Australia. CMAJ. 2018 Mar 26;190(12):E355-E362.

Scheim A, Werb D. **Integrating supervised consumption into a continuum of care for people who use drugs.** CMAJ. 2018 Aug 7;190(31):E921-E922.

Scherer JF, Tucker J, Salas J, et al. Comparison of Opioids Prescribed for Patients at Risk for Opioid Misuse **Before and After Publication** of the Centers for Disease Control and Prevention's **Opioid Prescribing Guidelines.** JAMA Netw Open. 2020 Dec 1;3(12):e2027481

Schieber LZ, Guy GP Jr, Seth P, et al. Trends and Patterns of **Geographic Variation in Opioid Prescribing Practices** by State, United States, 2006-2017. JAMA Netw Open. 2019 Mar 1;2(3):e190665.

Schiff DM, Drainoni ML, Bair-Merritt M, et al. A **Police-Led Addiction Treatment Referral Program** in Massachusetts. N Engl J Med. 2016 Dec 22;375(25):2502-2503.

Schiff DM, Work EC, Foley B, et al. **Perinatal Opioid Use Disorder** Research, Race, and Racism: A Scoping Review. Pediatrics. 2022;149(3):e2021052368

Schmidt EM, Barnes J, Chen C, et al. Patient and Health Care Factors Associated With **Long-term Diabetes Complications Among Adults With and Without Mental Health and Substance Use Disorders.** JAMA Netw Open. 2019 Sep 4;2(9):e1912060.

Schneider JP, Matthews M, Jamison RN. **Abuse-deterrent and tamper-resistant opioid formulations:** what is their role in addressing prescription opioid abuse? CNS Drugs. 2010 Oct 1;24(10):805-10. doi: 10.2165/11584260-000000000-00000.

Schoenfeld AJ, Jiang W, Chaudhary MA, et al. Sustained Prescription Opioid Use Among Previously **Opioid-Naïve** Patients Insured Through TRICARE (2006-2014). JAMA Surg. 2017 Aug 16.

Schroeder AR, Dehghan M, Newman TB, et al. Association of **Opioid Prescriptions From Dental Clinicians** for US Adolescents and Young Adults With Subsequent Opioid Use and Abuse. JAMA Intern Med. 2018 Dec 3.

Schuchat A, Houry D, Guy GP Jr. New Data on **Opioid Use and Prescribing in the United States.** JAMA. 2017 Jul 6.

Schuckit MA. Treatment of **Opioid-Use Disorders.** N Engl J Med. 2016 Jul 28;375(4):357-368.

Schultz JL, Kamholz JA, Moser DJ, et al. **Substance abuse may hasten motor onset of Huntington disease:** Evaluating the Enroll-HD database. Neurology. 2017 Feb 28;88(9):909-915.

Schulze-Döbold C, Ben Denoun M, Dupas B, Paques M, Massin P. **Retinal toxicity in users of "poppers"**. Ann Intern Med. 2012 May 1;156(9):670-2.

Schürer S, Klingel K, Sandri M, et al. Clinical characteristics, histopathological features, and clinical outcome of **methamphetamine-associated cardiomyopathy.** J Am Coll Cardiol HF 2017;5:435-45.

Schuster RM, Gilman J, Schoenfeld D, et al. **One Month of Cannabis Abstinence** in Adolescents and Young Adults Is Associated With **Improved Memory.** J Clin Psychiatry. 2018 Oct 30;79(6).

Schütze Madlen, Boeing Heiner, Pischon Tobias, et al. **Alcohol attributable burden of incidence of cancer** in eight European countries based on results from prospective cohort study. BMJ 2011;342:doi:10.1136/bmj.d1584 (Published 7 April 2011)

Schwab T. US opioid prescribing: the federal government **advisers with recent ties to big pharma.** BMJ. 2019 Aug 22;366:j5167.

Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of **cocaine**. *Circulation*. 2010 Dec 14;122(24):2558-69.

Schwitzer T, Schwan R, Albuissou E, et al. Association Between Regular **Cannabis Use and Ganglion Cell Dysfunction**. *JAMA Ophthalmol*. 2016 Dec 8.

Seamans MJ, Carey TS, Westreich DJ, et al. Association of **Household Opioid Availability** and Prescription Opioid Initiation **Among Household Members**. *JAMA Intern Med*. 2017 Dec 11.

Segura LE, Mauro CM, Levy NS, et al. Association of US Medical **Marijuana Laws With Nonmedical Prescription Opioid Use** and Prescription Opioid Use Disorder. *JAMA Netw Open*. 2019 Jul 3;2(7):e197216.

Sendelweck MA, Bell E, Anderson AM, et al. Associations Between **Indoor Tanning and Substance Use** Among Colorado High School Students. *JAMA Dermatol*. 2016 Jan 20.

Shanahan L, Hill SN, Bechtiger L, et al. Prevalence and **Childhood Precursors of Opioid Use** in the Early Decades of Life. *JAMA Pediatr*. 2020 Dec 28:e205205.

Shapiro B, Coffa D, McCance-Katz EF. **A Primary Care Approach to Substance Misuse**. *Am Fam Physician*. 2013;88(2):113-121.

Sharfstein JM, Olsen Y. **Lessons Learned From the Opioid Epidemic**. *JAMA*. 2019 Aug 5.

Shariff JA, Ahluwalia KP, Papapanou PN. Relationship Between Frequent **Recreational Cannabis (Marijuana and Hashish)** Use and **Periodontitis** in Adults in the United States: National Health and Nutrition Examination Survey 2011 to 2012. *J Periodontol*. 2017 Mar;88(3):273-280.

Sharma U. **Cannabis hyperemesis syndrome**. *BMJ Case Rep*. 2018 Oct 14:2018.

Sheldon T. **Testing of illicit drugs** in the Netherlands could be a model for the UK. *BMJ*. 2019 Apr 18;365:11784.

Shenoi RP, Linakis JG, Bromberg JR, et al. Predictive Validity of the **CRAFT for Substance Use Disorder**. *Pediatrics*. 2019 Jul 24.

Sheron N, Gilmore I. Effect of policy, economics, and the changing **alcohol marketplace** on alcohol related deaths in England and Wales. *BMJ*. 2016 Apr 6

Shiels MS, Berrington de González A, Best AF, et al. **Premature mortality from all causes and drug poisonings** in the USA according to socioeconomic status and rurality: an analysis of death certificate data by county from 2000-15. *Lancet Public Health*. 2019 Feb;4(2):e97-e106.

Shiels MS, Freedman ND, Thomas D, et al. **Trends in U.S. Drug Overdose Deaths** in Non-Hispanic Black, Hispanic, and Non-Hispanic White Persons, 2000-2015. *Ann Intern Med*. 2017 Dec 5.

Shiels MS, Tatalovich Z, Chen Y, et al. Trends in Mortality **From Drug Poisonings, Suicide, and Alcohol-Induced Deaths** in the United States From 2000 to 2017. *JAMA Netw Open*. 2020 Sep 1;3(9):e2016217

Short TD, Stallings EB, Isenberg J, et al. **Gastrochisis Trends and Ecologic Link to Opioid Prescription Rates - United States, 2006-2015**. *MMWR Morb Mortal Wkly Rep*. 2019 Jan 18;68(2):31-36.

Shover CL, Vest NA, Chen D, et al. Association of State Policies Allowing **Medical Cannabis for Opioid Use Disorder** With Dispensary Marketing for This Indication. *JAMA Netw Open*. 2020;3(7):e2010001.

Sigmon SC, Dunn KE, Saulsgiver K, et al. A Randomized, Double-blind Evaluation of **Buprenorphine Taper Duration in Primary Prescription Opioid Abusers**. *JAMA Psychiatry*. 2013 Oct 23.

Sigmon SC, Ochalek TA, Meyer AC, et al. **Interim Buprenorphine vs. Waiting List** for Opioid Dependence. *N Engl J Med*. 2016 Dec 22;375(25):2504-2505.

Silins E, Horwood LJ, Patton GC, et al. Cannabis Cohorts Research Consortium. Young adult **sequelae of adolescent cannabis use**: an integrative analysis. *Lancet Psychiatry*. 2014 Sep;1(4):286-93.

Silver B, Miller D, Jankowski M, et al. Urine toxicology screening in an urban stroke and TIA population. *Neurology*. 2013 Apr 30;80(18):1702-1709. (11% positive for cocaine)

Singer LT, Moore DG, Min MO, et al. One-Year Outcomes of **Prenatal Exposure to MDMA** and Other Recreational Drugs. *Pediatrics*. 2012 Aug 20.

Singh D, Huntwork M, Shetty V, et al. Prolonged **Atrial Fibrillation** Precipitated by New-Onset **Seizures and Marijuana Abuse**. *Pediatrics*. 2014 Jan 13

Singh V, Rodriguez AP, Thakkar B, et al. **Hospital Admissions for Chest Pain Associated with Cocaine Use** in the United States. *Am J Med*. 2017 Jun;130(6):688-698.

Siqueira L, Smith VC; Committee on Substance Abuse. **Binge Drinking**. *Pediatrics*. 2015 Aug 31.

Sites BD, Davis MA. Association of **Length of Time Spent in the United States With Opioid Use** Among First-Generation Immigrants. *JAMA Netw Open*. 2019 Oct 2;2(10):e1913979.

Slavova S, Quesinberry D, Hargrove S, et al. Trends in **Drug Overdose Mortality Rates** in Kentucky, 2019-2020. *JAMA Netw Open*. 2021 Jul 1;4(7):e2116391.

Slomski A. A trip on "**bath salts**" is cheaper than meth or cocaine but much more dangerous. *JAMA*. 2012 Dec 19;308(23):2445-7.

Smedslund G, Berg RC, Hammerstrom KT, et al. **Motivational interviewing** for substance abuse. *Cochrane Database Syst Rev*. 2011 May 11;5:CD008063.

Smith MJ, Cobia DJ, Wang L, et al. **Cannabis-Related Working Memory Deficits** and Associated Subcortical Morphological Differences in Healthy Individuals and Schizophrenia Subjects. *Schizophr Bull*. 2013 Dec 15

Smith Peter C.; Schmidt Susan M.; Allensworth-Davies Donald; et al. **A Single-Question Screening Test** for Drug Use in Primary Care. *Arch Intern Med*. 2010;170(13):1155-1160. How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?"

Smith VC, Wilson CR; Committee on Substance Use and Prevention. **Families Affected by Parental Substance Use**. *Pediatrics*. 2016 Aug;138(2).

Socias ME, Ahamad K. An urgent call to increase access to **evidence-based opioid agonist therapy for prescription opioid use disorders**. *CMAJ*. 2016 Dec 6;188(17-18):1208-1209.

Socias ME, Choi J, Lake S, et al. Cannabis use is associated with **reduced risk of exposure to fentanyl among people on opioid agonist therapy** during a community-wide overdose crisis. *Drug Alcohol Depend*. 2020 Dec 9:108420

**SOGC Clinical Practice Guideline: Substance Use in Pregnancy** No. 256, April 2011 <http://www.sogc.org/guidelines/documents/gui256CPG1104E.pdf>

**SOGC: Ordean A, Wong S, Graves L. No. 349-Substance Use in Pregnancy.** *J Obstet Gynaecol Can*. 2017 Oct;39(10):922-937.e2.

Sohn M, Talbert JC, Huang Z, et al. Association of **Naloxone Coprescription Laws With Naloxone Prescription Dispensing** in the United States. *JAMA Netw Open*. 2019 Jun 5;2(6):e196215.

Sohrabry R, Attridge RL, Hughes DW. Use of **propofol-containing versus benzodiazepine** regimens for **alcohol withdrawal** requiring mechanical ventilation. *Ann Pharmacother*. 2014 Apr;48(4):456-61.

Somoza EC, Winship D, Gorodetzky CW, et al. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of **vigabatrin for treating cocaine dependence**. *JAMA Psychiatry*. 2013 Jun;70(6):630-7.

Song Z. **Mortality Quadrupled Among Opioid-Driven Hospitalizations**, Notably Within Lower-Income And Disabled White Populations. *Health Aff (Millwood)*. 2017 Dec;36(12):2054-2061.

Soprano SE, Hennessy S, Bilker WB, Leonard CE. Assessment of Physician **Prescribing of Muscle Relaxants** in the United States, 2005-2016. *JAMA Netw Open*. 2020;3(6):e207664.

Sordo L, Barrio G, Bravo MJ, et al. **Mortality risk during and after opioid substitution treatment**: systematic review and meta-analysis of cohort studies. *BMJ* 2017;357:j1550

Spirito A, Bromberg JR, Casper TC, et al. Reliability and Validity of a **Two-Question Alcohol Screen** in the **Pediatric Emergency Department**. *Pediatrics*. 2016;138(6):e20160691

Spithoff S, Kahan M. Primary care management of **alcohol use disorder** and at-risk drinking: Part 1: screening and assessment. *Can Fam Physician*. 2015 Jun;61(6):509-514. Review.

Spithoff S, Kahan M. Primary care management of **alcohol use disorder** and at-risk drinking: Part 2: counsel, prescribe, connect. *Can Fam Physician*. 2015 Jun;61(6):515-521. Review.

Srivastava A, Kahan M, Nader M. **Primary care management of opioid use disorders**: Abstinence, methadone, or buprenorphine-naloxone? *Can Fam Physician*. 2017 Mar;63(3):200-205. Review.

Stall N, Godwin J, Juurlink D. **Bupropion abuse and overdose**. *CMAJ*. 2014 Sep 16;186(13):1015.

Staloch DA, Hedley JS. **Pulmonary Foreign-Body Granulomatosis**. *N Engl J Med*. 2017 Sep 28;377(13):1273. (**inject oral opiates**)

Steele DW, Becker SJ, Danko KJ, et al. **Brief Behavioral Interventions** for Substance Use in Adolescents: A Meta-analysis. *Pediatrics*. 2020 Sep 14:e20200351

Steigenwald S, Wong PO, Cohen BE, et al. **Smoking, Vaping, and Use of Edibles and Other Forms of Marijuana Among U.S. Adults**. *Ann Intern Med*. 2018 Dec 18;169(12):890-892.

Stein BD, Sorbero M, Dick AW, Pacula et al. Physician Capacity to Treat Opioid Use Disorder **With Buprenorphine-Assisted Treatment**. *JAMA*. 2016 Sep 20;316(11):1211-1212.

Stein Steinhausen HC, Blattmann B, Pfund F. Developmental outcome in children with intrauterine exposure to substances (**heroin or methadone**). *Eur Addict Res*. 2007;13(2):94-100.

Stelten BM, Post B. Images in Clinical Medicine. **Midline Destructive Lesions in a Cocaine User**. *N Engl J Med*. 2016 Mar 10;374(10):969.

Sterling S, Kline-Simon AH, Satre DD, et al. Implementation of **Screening, Brief Intervention, and Referral to Treatment for Adolescents** in Pediatric Primary Care: A Cluster Randomized Trial. *JAMA Pediatr*. 2015 Nov 2;169(11):e153145.

Stewart C, Fong Y. **Perioperative Cannabis** as a Potential Solution for Reducing Opioid and Benzodiazepine Dependence. *JAMA Surg*. 2020 Dec 2. doi: 10.1001/jamasurg.2020.5545

Stock CJ, Carpenter L, Ying J, Greene T. **Gabapentin versus chlorthalidoxepoxide** for outpatient alcohol detoxification treatment. *Ann Pharmacother*. 2013 Jul;47(7-8):961-9.

Stogner JM, Miller BL. Assessing the Dangers of "**Dabbing**": Mere Marijuana or Harmful New Trend? *Pediatrics*. 2015 Jun 15.

Stonington S, Coffa D. Structural latrogenesis - A 43-Year-Old Man with "Opioid Misuse". *N Engl J Med*. 2019 Feb 21;380(8):701-704.

Strahan AE, Guy GP Jr, Bohm M, et al. **Neonatal Abstinence Syndrome** Incidence and Health Care Costs in the United States, 2016. *JAMA Pediatr*. 2019 Dec 16. doi: 10.1001/jamapediatrics.2019.4791.

Strand MC, Vindenes V, Gjerde H, et al. A clinical trial on the acute effects of **methadone and buprenorphine on actual driving and cognitive function** of healthy volunteers. *Br J Clin Pharmacol*. 2018 Dec 4.

Strand MC, Vindenes V, Gjerde H, et al. **A clinical trial on the acute effects of methadone and buprenorphine** on actual driving and cognitive function of healthy volunteers. *Br J Clin Pharmacol*. 2018 Dec 4.

Strang J, Metrebian N, Lintzeris N, et al. Supervised injectable **heroin** or injectable **methadone** versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. *Lancet*. 2010 May 29;375(9729):1885-95.

Strang J, Bird SM, Dietze P, et al. **Take-home emergency naloxone** to prevent deaths from heroin overdose. *BMJ*. 2014 Nov 4;349:g6580.

Streetz VN, Gildon BL, Thompson DF. Role of **Clonidine in Neonatal Abstinence Syndrome**: A Systematic Review. *Ann Pharmacother*. 2016 Apr;50(4):301-10.

Stucke RS, Kelly JL, Mathis KA, et al. Association of the Use of a **Mandatory Prescription Drug Monitoring Program** With Prescribing Practices for Patients Undergoing Elective Surgery. *JAMA Surg*. 2018 Aug 22.

Substance Abuse and Mental Health Services Administration **SAMHSA**, Center for Behavioral Health Quality and Statistics. (Nov 3, 2011). The DAWN Report: **Drug-Related Emergency Department Visits Attributed to Intentional Poisoning**. Rockville, MD. [http://oas.samhsa.gov/2k11/DAWN040/WEB\\_DAWN\\_040.htm](http://oas.samhsa.gov/2k11/DAWN040/WEB_DAWN_040.htm)

Sullivan K, Capp G, Gilreath TD, et al. **Substance Abuse** and Other Adverse Outcomes for **Military-Connected Youth** in California: Results From a Large-Scale Normative Population Survey. *JAMA Pediatr*. 2015 Aug 17.

Sullivan M, Bisaga A, Pavlicova M, et al. **Long-Acting Injectable Naltrexone Induction**: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. *Am J Psychiatry*. 2017 Jan 10;appiajp201616050548.

Sullivan MA, Bisaga A, Pavlicova M, et al. A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral **Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder**. *Am J Psychiatry*. 2018 Oct 19;appiajp201817070732.

Sullivan MJ, Turner JA, DiLodovico C, et al. **Prescription Opioid Taper Support** for Outpatients With Chronic Pain: A Randomized Controlled Trial. *J Pain*. 2016 Nov 28.

Sun AJ, Eisenberg ML. Association Between **Marijuana Use and Sexual Frequency** in the United States: A Population-Based Study. *J Sex Med*. 2017 Nov;14(11):1342-1347.

Sun EC, Darnall B, Baker LC, et al. Incidence of and Risk Factors for Chronic **Opioid Use** Among Opioid-Naive Patients in the **Postoperative Period**. *JAMA Intern Med*. 2016 Jul 11.

Sundermann AC, Velez Edwards DR, Slaughter JC, et al. Week-by-week **alcohol consumption in early pregnancy** and spontaneous abortion risk: a prospective cohort study. *Am J Obstet Gynecol*. 2020;S0002-9378(20)30725-0.

Sur AH, Loh LC. A 38-year-old man who uses **crack cocaine**. *CMAJ*. 2015 Dec 8;187(18):1383-4.

Svensson PA, Anveden A, Romeo S, et al. **Alcohol consumption and alcohol problems after bariatric surgery** in the Swedish obese subjects study. *Obesity (Silver Spring)*. 2013 Dec;21(12):2444-51.

Swaim RC, Stanley LR. **Substance use among American Indian youths** on reservations compared with a national sample of US adolescents. *JAMA Netw Open*. 2018;1(1):e180382.

Swendsen J, Burstein M, Case B et al. Use and Abuse of **Alcohol and Illicit Drugs in US Adolescents**: Results of the National Comorbidity Survey-Adolescent Supplement. *Arch Gen Psychiatry*. 2012 Apr;69(4):390-8.



Swor DE, Maas MB, Walia SS, et al. Clinical characteristics and **outcomes of methamphetamine-associated intracerebral hemorrhage**. Neurology. 2019 Jul 2;93(1):e1-e7.

Taffe MA et al. Long-lasting reduction in **hippocampal neurogenesis by alcohol consumption** in adolescent nonhuman primates. Proc Natl Acad Sci U S A 2010 Jun 15; 107:11104.

Talbert J, Blumenschein K, Burke A, et al. **Pseudoephedrine sales** and seizures of clandestine **methamphetamine** laboratories in Kentucky. JAMA. 2012 Oct 17;308(15):1524-6.

Tanski SE, McClure AC, Li Z, et al. Cued Recall of **Alcohol Advertising** on Television and Underage Drinking Behavior. JAMA Pediatr. 2015 Jan 19.

Tanum L, Solli KK, Latif ZE, et al. The **Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence**: A Randomized Clinical mNoninferiority Trial. JAMA Psychiatry. 2017 Oct 18

Tardelli VS, Bisaga A, Arcadepani FB, et al. Prescription psychostimulants for the treatment of **stimulant use disorder**: a systematic review and meta-analysis. Psychopharmacology (Berl). 2020;237(8):2233-2255.

Tate M, Dubrey S. What is the diagnosis? (**mule for cocaine drug trafficking**) BMJ. 2016 Apr 29;353:i2394. doi: 10.1136/bmj.i2394

Taylor M, Collin SM, Munafò MR, et al. Patterns of **cannabis use during adolescence** and their association with **harmful substance use behaviour**: findings from a UK birth cohort. J Epidemiol Community Health. 2017 Jun 7

Taylor RG, Budhram A, Lee DH, Mirsattari SM. **Opioid-associated amnesic syndrome** observed with fentanyl patch use. CMAJ. 2019 Mar 25;191(12):E337-E339.

Tedesco D, Asch SM, Curtin C, et al. **Opioid Abuse And Poisoning**: Trends In Inpatient And Emergency Department Discharges. Health Aff (Millwood). 2017 Oct 1;36(10):1748-1753.

Temmingh HS, Williams T, Siegfried N, Stein DJ. **Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse**. Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD011057. There is not sufficient good-quality evidence available to determine the effects of risperidone compared with other antipsychotics in people with a dual diagnosis. Few trials compared risperidone with first-generation agents, leading to limited applicability to settings where access to second-generation agents is limited, such as in low- and middle-income countries. Moreover, heterogeneity in trial design and measurement of outcomes precluded the use of many trials in our analyses.

Teplin LA, Potthoff LM, Aaby DA, et al. **Prevalence, Comorbidity, and Continuity of Psychiatric Disorders** in a 15-Year Longitudinal Study of Youths Involved in the Juvenile Justice System. JAMA Pediatr. 2021 Apr 5:e205807

Terry-McElrath YM, O'Malley PM, Patrick ME. **Solitary Use of Alcohol and Marijuana** by US 12th Grade Students, 1976-2019. JAMA Pediatr. 2020 Dec 21. doi: 10.1001/jamapediatrics.2020.5211

Thayabaran D, Burrage D. **Nitrous oxide induced neurotoxicity**: a case report and literature review. Br J Clin Pharmacol. 2021 Feb 16. doi: 10.1111/bcp.14779

Thiels CA, Habermann EB, Hooten WM, Jeffery MM. **Chronic use of tramadol after acute pain episode**: cohort study. BMJ 2019;365:i1849.

Thienprayoon R, Porter K, Tate M, et al. **Risk Stratification for Opioid Misuse** in Children, Adolescents, and Young Adults: A Quality Improvement Project. Pediatrics. 2016 Dec 15.

Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of **marijuana** inhalation: what cardiologists need to know. Am J Cardiol. 2014 Jan 1;113(1):187-90.

Throckmorton DC, Gottlieb S, Woodcock J. The **FDA and the Next Wave of Drug Abuse - Proactive Pharmacovigilance**. N Engl J Med. 2018 Jul 19;379(3):205-207.

Throckmorton DC, Woodcock J. **Combined Gabapentinoid and Opioid Use**: The Consequences of Shifting Prescribing Trends. Ann Intern Med. 2018 Aug 21.

Tiet QQ, Leyva YE, Moos RH, et al. **Screen of Drug Use**: Diagnostic Accuracy of a New Brief Tool for Primary Care. JAMA Intern Med. 2015 Jun 15.

Tiihonen J et al. **Naltrexone implant** for the treatment of polydrug dependence: A randomized controlled trial. Am J Psychiatry 2012 Feb 17

Tilbrook D, Jacob J, Parsons P, Edwards C, Loewen K, Kelly L. **Opioid use disorder and type 2 diabetes** mellitus: Effect of participation in buprenorphine-naloxone substitution programs on glycemic control. Can Fam Physician. 2017 Jul;63(7):e350-e354.

Toce MS, Michelson K, Hudgins J, et al. Association of State-Level **Opioid-Reduction Policies** With Pediatric Opioid Poisoning. JAMA Pediatr. 2020:e201980.

Tori ME, Larochelle MR, Naimi TS. **Alcohol or Benzodiazepine Co-involvement With Opioid Overdose** Deaths in the United States, 1999-2017. JAMA Netw Open. 2020 Apr 1;3(4):e202361

Torjesen I. Fentanyl misuse in the UK: will we see a surge in deaths? BMJ. 2018 Apr 9;361:k1564. doi: 10.1136/bmj.k1564.

Tormohlen KN, Schneider KE, Johnson RM, et al. Changes in **Prevalence of Marijuana Consumption Modes** Among Colorado High School Students From 2015 to 2017. JAMA Pediatr. 2019 Aug 5.

Tormoehlen LM, Blaisorius AD, Moser EA, et al. Disparities and guideline adherence in **drugs of abuse screening in intracerebral hemorrhage**. Neurology. 2017 Jan 17;88(3):252-258.

Tomaszewski DM, Arbuckle C, Yang S, Linstead E. **Trends in Opioid Use in Pediatric Patients** in US Emergency Departments From 2006 to 2015. JAMA Netw Open. 2018;1(8):e186161.

Towers C, Hyatt BW, Visconti KC, Chernicky L, Chaitin K, Fortner KB. **Neonatal head circumference in newborns with neonatal abstinence syndrome**. Pediatrics. 2019;143(1):e20180541

Townsend T, Kline D, Rivera-Aguirre A, et al. Racial/Ethnic and Geographic **Trends in Combined Stimulant/Opioid Overdoses**, 2007-2019. Am J Epidemiol. 2022 Feb 8:kwab290

Tracy DK, Wood DM, Baumeister D. **Novel psychoactive substances**: types, mechanisms of action, and effects. BMJ. 2017 Jan 25;356:i6848.

Trecki J, Gerona RR, Schwartz MD. **Synthetic Cannabinoid-Related Illnesses and Deaths**. N Engl J Med. 2015 Jul 9;373(2):103-7.

Tremblay M, Baydala L, Khan M, et al. Primary Substance Use **Prevention Programs** for Children and Youth: A Systematic Review. Pediatrics. 2020:e20192747.

Tsai DH, Foster S, Baggio S, et al. Comparison of **Water Pipes vs Other Modes of Cannabis Consumption** and Subsequent Illicit Drug Use in a Longitudinal Cohort of Young Swiss Men. JAMA Netw Open. 2021 Apr 1;4(4):e213220

Tsang TW, Lucas BR, Carmichael Olson H, Pinto RZ, Elliott EJ. **Prenatal Alcohol Exposure, FASD**, and Child Behavior: A Meta-analysis. Pediatrics. 2016 Feb 22.

Tsutaoka BT, Ho RY, Fung SM, et al. Comparative Toxicity of **Tapentadol and Tramadol** Utilizing Data Reported to the National Poison Data System. Ann Pharmacother. 2015 Dec;49(12):1311-6.

Tupper KW, Wood E, Yensen R, et al. **Psychedelic medicine**: a re-emerging therapeutic paradigm. CMAJ. 2015 Sep 8.

Turchi RM, Smith VC: Committee on Substance Use and Prevention. The Role of **Integrated Care in a Medical Home for Patients With a Fetal Alcohol Spectrum Disorder**. Pediatrics. 2018 Sep 10.

Turner SD, Spithoff S, Kahan M. Approach to **cannabis use disorder** in primary care: Focus on youth and other high-risk users. Can Fam Physician. 2014 Sep;60(9):801-808.

Tyndall M. An **emergency response to the opioid overdose crisis in Canada**: a regulated opioid distribution program. CMAJ. 2018 Jan 15;190(2):E35-E36.

Udow SJ, Freitas ME, Fox SH, et al. Exacerbation of **psychosis triggered by a synthetic cannabinoid** in a 70-year-old woman with Parkinson disease. CMAJ. 2018 Jan 15;190(2):E50-E52.

Uebel H, Wright IM, Burns L, et al. Reasons for Rehospitalization in Children Who Had **Neonatal Abstinence Syndrome**. Pediatrics. 2015 Oct;136(4):e811-20.

Uhl S, Bloeschchak A, Moran A, et al. **Telehealth for Substance Use Disorders**: A Rapid Review for the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Substance Use Disorders. Ann Intern Med. 2022 Mar 22. doi: 10.7326/M21-3931.

Urbanoski KA. Need for equity in treatment of **substance use among Indigenous people in Canada**. CMAJ. 2017 Nov 6;189(44):E1350-E1351.

Uscher-Pines L, Huskamp HA, Mehrotra A. **Treating Patients With Opioid Use Disorder in Their Homes**: An Emerging Treatment Model. JAMA. 2020;10.1001/jama.2020.3940

USPSTF- Krist AH, Davidson KW, et al. **Primary Care-Based Interventions** to Prevent Illicit Drug Use in Children, Adolescents, and Young Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323(20):2060-2066

USPSTF- Krist AH, Davidson KW, et al. **Screening for Unhealthy Drug Use**: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323(22):2301-2309

USPSTF- O'Connor E, Thomas R, Robalino S, et al. Interventions to **Prevent Illicit and Nonmedical Drug Use** in Children, Adolescents, and Young Adults: Updated Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020

USPSTF- Patnode CD, Perdue LA, Rushkin M, et al. **Screening for Unhealthy Drug Use**: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020;323(22):2310-2328

Yyei J, Fiellin DA, Buchelli M et al. Effects of **naloxone distribution** alone or in **combination with addiction treatment** with or without **pre-exposure prophylaxis for HIV** prevention in people who inject drugs: a cost-effectiveness modeling study. Lancet Public Health. March 2017;2:e133-40.

VA/DoD: Management of Substance Use Disorders Work Group. **VA/DoD clinical practice guideline for the management of substance use disorders**. Version 3.0. Washington (DC): Department of Veterans Affairs, Department of Defense; 2015 Dec.

VA/DoD: CLINICAL PRACTICE GUIDELINE FOR Management of Substance Use Disorders- 2021. <https://www.healthquality.va.gov/guidelines/MH/sud/VADOdsUDCPG.pdf>

van Donge T, Samiee-Zafarghandy S, Pfister M, et al. **Methadone dosing strategies in preterm neonates** can be simplified. Br J Clin Pharmacol. 2019 Feb 25.

Varner MW, Silver RM, Rowland Hogue CJ, et al: Eunice Kennedy Shriver National Institute of Child Health and Human Development Stillbirth Collaborative Research Network. Association between **stillbirth and illicit drug use and smoking during pregnancy**. Obstet Gynecol. 2014 Jan;123(1):113-25.

Veliz P, Boyd CJ, McCabe SE. **Nonmedical Prescription Opioid and Heroin Use** Among Adolescents Who Engage in Sports and Exercise. Pediatrics. 2016 Jul 25.

Villapiano NL, Winkelman TN, Kozhimannil KB, et al. **Rural and Urban Differences in Neonatal Abstinence Syndrome** and Maternal Opioid Use, 2004 to 2013. JAMA Pediatr. 2016 Dec 12.

Vinson, Daniel C., Manning, Brian K., Galliher, James M., et al. **Alcohol and Sleep Problems** in Primary Care Patients: A Report from the AAFP National Research Network. Ann Fam Med 2010 8: 484-492.

Virtanen M, Jokela M, Nyberg ST, et al. **Long working hours and alcohol use**: systematic review and meta-analysis of published studies and unpublished individual participant data. BMJ. 2015 Jan 13;350:g7772.

Visconti AJ, Sell J, Greenblatt AD. **Primary Care** for Persons Who Inject Drugs. Am Fam Physician. 2019;99(2):109-116.

Voepel-Lewis T, Wagner D, Tait AR. **Leftover Prescription Opioids After Minor Procedures**: An Unwitting Source for Accidental Overdose In Children. JAMA Pediatr. 2015 Mar 23.

Volkow ND, Baler RD, Compton WM, et al. **Adverse health effects of marijuana use**. N Engl J Med. 2014 Jun 5;370(23):2219-27.

Volkow ND, Collins FS. The Role of **Science in Addressing the Opioid Crisis**. N Engl J Med. 2017 May 31.

Volkow ND, Han B, Einstein EB, Compton WM. Prevalence of Substance Use Disorders by Time Since First Substance Use Among Young People in the US. JAMA Pediatr. 2021 Mar 29. doi: 10.1001/jamapediatrics.2020.6981

Volkow ND, Jones EB, Einstein EB, Wargo EM. **Prevention and Treatment of Opioid Misuse and Addiction**: A Review. JAMA Psychiatry. 2018 Dec 5.

Volkow ND, Koob GF, McLellan AT. **Neurobiologic Advances from the Brain Disease Model of Addiction**. N Engl J Med. 2016 Jan 28;374(4):363-71.

Volkow ND, McLellan AT. **Opioid Abuse in Chronic Pain-Misconceptions and Mitigation Strategies**. N Engl J Med. 2016 Mar 31;374(13):1253-63.

Vrijen C, Wiertsema M, Ackermans MA, et al. Childhood and Adolescent **Bullying Perpetration and Later Substance Use**: A Meta-analysis. Pediatrics. 2021 Feb 17:e2020034751

Wachman EM, Schiff DM, Silverstein M. **Neonatal Abstinence Syndrome**: Advances in Diagnosis and Treatment. JAMA. 2018 Apr 3;319(13):1362-1374.

Wakeman S. Shifting Focus to **Evidence-Based Management** of Substance Use Disorders. Ann Intern Med. 2022 Mar 22. doi: 10.7326/M22-0150.

Wakeman SE. Diagnosis and Treatment of **Opioid Use Disorder in 2020**. JAMA. 2020 Apr 24. doi: 10.1001/jama.2020.4104

Wakeman SE, Ghoshhajra BB, Dudzinski DM, Wilens T, Slavin PL. Case records of the Massachusetts General Hospital. Case 35-2014: a 31-year-old woman with fevers, chest pain, and a history of **HCV infection and substance-use disorder**. N Engl J Med. 2014 Nov 13;371(20):1918-26.

Wakeman SE, Ladin K, Brennan T, et al. **Opioid Use Disorder, Stigma, and Transplantation**: A Call to Action. Ann Intern Med. 2018 Jul 10.

Walley AY, et al. **Opioid overdose** rates and implementation of overdose education and nasal **naloxone distribution** in Massachusetts: interrupted time series analysis.BMJ. 2013 Jan 30;346:f174.

Walley AY, Wakeman SE, Eng G. Case 6-2019: A 29-Year-Old Woman with Nausea, Vomiting, and Diarrhea. N Engl J Med. 2019 Feb 21;380(8):772-779

Walsh MC, Crowley M, Wexelblatt S, et al. Ohio Perinatal Quality Collaborative Improves Care of **Neonatal Narcotic Abstinence Syndrome**. Pediatrics. 2018 Mar 7.

Walsh SL, Comer SD, Lofwall MR, et al. Effect of **Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade** in Individuals With Opioid Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Jun 22.

Walton MA, Chermack ST, Shope JT, et al. Effects of a **brief intervention** for reducing violence and alcohol misuse among adolescents: a randomized controlled trial. JAMA. 2010 Aug 4;304(5):527-35.

Wang GS, Roosevelt G, Heard K. **Pediatric marijuana exposures** in a medical marijuana state [published online May 27, 2013]. *JAMA Pediatr*. 2013;167(7):630-633.

Wang GS, Roosevelt G, Le Lai MC, et al. Association of **Unintentional Pediatric Exposures** With Decriminalization of **Marijuana** in the United States. *Ann Emerg Med*. 2014 Feb 3. pii: S0196-0644(14)00079-1.

Wang GS, Severtson SG, Bau GE, et al. Unit-Dose Packaging and Unintentional **Buprenorphine-Naloxone** Exposures. *Pediatrics*. 2018 May 3.

Warner DO, Berge K, Sun H, et al. **Substance use disorder among anesthesiology residents**, 1975-2009. *JAMA*. 2013 Dec 4;310(21):2289-96

Warner M, Trinidad JP, Bastian BA, et al. Drugs Most Frequently Involved in **Drug Overdose Deaths**: United States, 2010-2014. *Natl Vital Stat Rep*. 2016 Dec;65(10):1-15.

Warren EC, Kolodny A. Trends in **Heroin Treatment Admissions** in the United States by Race, Sex, and Age. *JAMA Netw Open*. 2021 Feb 1;4(2):e2036640.

Warren KE, Tay S, Wen LS. Patient and Public Risks of **Powdered Alcohol**: A Citywide Case Study to Prevent Abuse. *Ann Intern Med*. 2016 Feb 16.

Watkins KE, Paddock SM, Hudson TJ, et al. Association between process measures and **mortality in individuals with opioid use disorders**. *Drug Alcohol Depend*. 2017 Jun 27.

Watkins KE, Ober AJ, Lamp K, et al. **Collaborative Care for Opioid and Alcohol Use Disorders in Primary Care**: The **SUMMIT** Randomized Clinical Trial. *JAMA Intern Med*. 2017 Aug 28.

Watson R. Drug trafficking in Europe changes as expertise in synthetic drug production increases (**4-MA illegal** in 10 European countries). *BMJ*. 2013 Feb 6;346:f758.

Webster PC. Canada proposes new legal hurdles for **supervised injection**. *Lancet*. 2013 Nov 2;382(9903):1477-8.

Wei YJ, Chen C, Sarayani A, Winterstein AG. Performance of the Centers for Medicare & Medicaid Services' Opioid **Overutilization Criteria for Classifying Opioid Use Disorder or Overdose**. *JAMA*. 2019 Feb 12;321(6):609-611.

Wei YJ, Zhu Y, Liu W, et al. Prevalence of and Factors Associated With **Long-term Concurrent Use of Stimulants and Opioids Among Adults With Attention-Deficit/Hyperactivity Disorder**. *JAMA Netw Open*. 2018;1(4):e181152.

Weinberger AH, Platt J, Esan H, et al. **Cigarette Smoking Is Associated With Increased Risk of Substance Use Disorder Relapse**: A Nationally Representative, Prospective Longitudinal Investigation. *J Clin Psychiatry*. 2017 Feb;78(2):e152-e160.

Weiner SG, El Ibrahim S, Hendricks MA, et al. Factors Associated With Opioid **Overdose After an Initial Opioid Prescription**. *JAMA Netw Open*. 2022 Jan 4;5(1):e2145691.

Weiner SG, Griggs CA, Mitchell PM, et al. Clinician **impression versus prescription drug monitoring program** criteria in the assessment of drug-seeking behavior in the emergency department. *Ann Emerg Med*. 2013 Oct;62(4):281-9.

Weintraub E, Seneviratne C, Anane J, et al. **Mobile Telemedicine for Buprenorphine Treatment** in Rural Populations With Opioid Use Disorder. *JAMA Netw Open*. 2021 Aug 2;4(8):e2118487

Weir MA, Slater J, Jandoc R, et al. The **risk of infective endocarditis** among people who inject drugs: a retrospective, population-based time series analysis. *CMAJ*. 2019 Jan 28;191(4):E93-E99.

Weisshaar S, Brandt L, Litschauer B, et al. Dose-dependent **naloxone-induced morphine withdrawal symptoms** in opioid-dependent males – a double-blinded, randomized study. *Br J Clin Pharmacol*. 2020 Mar 7. doi:10.1111/bcp.14271.

Weitzman ER, Ziemnik RE, Huang Q, et al. **Alcohol and Marijuana Use** and Treatment Nonadherence Among Medically Vulnerable Youth. *Pediatrics*. 2015 Aug 31.

Wells Daina L, Ott Carol A. **The "New" Marijuana**. Articles Ahead of Print published on 1 March 2011, DOI 10.1345/aph.1P580. *Ann Pharmacother* ;45:414-417. (JWH-018 powder, K2, spice, Mr. Smiley, Red X Dawn, and Blaze )

Wen H, Cummings JR, Hockenberry JM, et al. State Parity Laws and **Access to Treatment for Substance Use Disorder** in the United States: Implications for Federal Parity Legislation. *JAMA Psychiatry*. 2013 Oct 23.

Wen H, Hockenberry JM, Pollack HA. Association of **Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees**. *JAMA Netw Open*. 2018;1(5):e182943.

Werb D, Kerr T, Buxton J, et al. **Crystal methamphetamine and initiation of injection drug use** among street-involved youth in a Canadian setting. *CMAJ*. 2013 Oct 15.

Westover AN, Nakonezny PA. **Aortic dissection** in young adults who abuse **amphetamines**. *Am Heart J* 2010; 160:315-321.

Wetzel M, Hockenberry J, Raval MV. **Interventions for postsurgical opioid prescribing**: a systematic review [online August 15, 2018]. *JAMA Surg*. doi:10.1001/jamasurg.2018.2730

Whitehill JM, Harrington C, Lang CJ, et al. Incidence of **Pediatric Cannabis Exposure** Among Children and Teenagers Aged 0 to 19 Years Before and After Medical Marijuana Legalization in Massachusetts. *JAMA Netw Open*. 2019 Aug 2;2(8):e199456.

Whitehill JM, Rivara FP, Moreno MA. **Marijuana-Using Drivers, Alcohol-Using Drivers, and Their Passengers**: Prevalence and Risk Factors Among Underage College Students. *JAMA Pediatr*. 2014 May 12.

Whiteford HA, Degenhardt L, Rehm J, et al. **Global burden of disease attributable to mental and substance use disorders**: findings from the Global Burden of Disease Study 2010. *Lancet* 2013; online Aug 29.

Whiteside LK, Walton MA, Bohnert AS, et al. **Nonmedical prescription opioid and sedative use** among adolescents in the emergency department. *Pediatrics*. 2013 Nov;132(5):825-32.

Whitman IR, Agarwal V, Nah G, et al. **Alcohol Abuse** and Cardiac Disease. *J Am Coll Cardiol*. 2017 Jan 3;69(1):13-24.

Wiese AD, Griffin MR, Schaffner W et al. **Opioid analgesic use and risk for invasive pneumococcal diseases**. A nested case-control study. *Ann Intern Med*. 2018. [Epub ahead of print]. doi:10.7326/M17-1907

Wilens TE, Biederman J, Martelon M, et al. Further Evidence for **Smoking and Substance Use Disorders in Youth With Bipolar Disorder and Comorbid Conduct Disorder**. *J Clin Psychiatry*. 2016 Aug 30.

Wilkins NJ, Clayton H, Jones CM, Brown M. Current Prescription **Opioid Misuse and Suicide Risk** Behaviors Among High School Students. *Pediatrics*. 2021 Mar 1:e2020030601

Wilkinson ST, D'Souza DC. Problems With the **Medicalization of Marijuana**. *JAMA*. 2014 May 20.

Williams AR, Samples H, Crystal S, Olsson M. Acute Care, Prescription Opioid Use, and Overdose **Following Discontinuation of Long-Term Buprenorphine Treatment** for Opioid Use Disorder. *Am J Psychiatry*. 2019 Dec 2;appiajp.201919060612

Williams JF, Smith VC; AAP: Committee on Substance Abuse. **Fetal Alcohol Spectrum Disorders**. *Pediatrics*. 2015 Nov;136(5):e1395-406.

Williams SD. **If you only have a few minutes with a drug addict**. *BMJ*. 2015 Sep 23;351:h2421.

Williamson J, Huda S, Damodaran D. **Nitrous oxide myelopathy** with functional vitamin B (12) deficiency. *BMJ Case Rep*. 2019 Feb 13;12(2).

Wilson JD, Abebe KZ, Kraemer K, et al. Trajectories of **Opioid Use Following First Opioid Prescription** in Opioid-Naive Youths and Young Adults. *JAMA Netw Open*. 2021 Apr 1;4(4):e214552.

Wilson T, Brar R, Sutherland C, Nolan S. Use of a **primary care and pharmacy-based model for the delivery of injectable opioid agonist treatment** for severe opioid use disorder: a case report. *CMAJ*. 2020 Feb 3;192(5):E115-E117

Wilton J, Abdia Y, Chong M, et al. Prescription opioid treatment for non-cancer pain and **initiation of injection drug use**: large retrospective cohort study. *BMJ*. 2021 Nov 18;375:e066965.

Windle SB, Sequeira C, Filion KB, et al. **Impaired driving and legalization of recreational cannabis**. *CMAJ*. 2021 Apr 6;193(14):E481-E485. doi: 10.1503/cmaj.191032. PMID: 33824147.

Winkelman TNA, Admon LK, Jennings L, et al. **Evaluation of Amphetamine-Related Hospitalizations and Associated Clinical Outcomes and Costs** in the United States. *JAMA Netw Open*. 2018;1(6):e183758.

Winkelman TNA, Villapiano N, Kozhimannil KB, et al. Incidence and Costs of **Neonatal Abstinence Syndrome** Among Infants With Medicaid: 2004-2014. *Pediatrics*. 2018 Mar 23.

Winkelman TN, Chang VW, Binswanger IA. Health, **Polysubstance Use, and Criminal Justice Involvement** Among Adults With Varying Levels of Opioid Use. *JAMA Network Open*. 2018;1(3):e180558.

Winslow BT, Onysko M, Hebert M. Medications for **Alcohol Use Disorder**. *Am Fam Physician*. 2016;93(6):457-465.

Wood DM, Dargan PI. Regional, national and international datasets: How they improve our **understanding of the acute harms** associated with prescription medicine misuse. *Br J Clin Pharmacol*. 2020 Oct 28. doi: 10.1111/bcp.14592.

Wood E, Simel DL, Klimas J. **Pain Management With Opioids** in 2019-2020. *JAMA*. 2019 Oct 10;1-3. doi: 10.1001/jama.2019.15802.

Wood E. Strategies for Reducing Opioid-Overdose Deaths - Lessons from Canada. *N Engl J Med*. 2018 Apr 26;378(17):1565-1567.

Wood KE. Exposure to **Bath Salts** and Synthetic Tetrahydrocannabinol from 2009 to 2012 in the United States. *J Pediatr*. 2013 Feb 4.

Woodward MA, Zhang Y, Tannen B, Behunin N, Niziol LM, Waljee J. Association of Limiting Opioid Prescriptions With **Use of Opioids After Corneal Surgery**. *JAMA Ophthalmol*. 2019 Oct 31. doi: 10.1001/jamaophthalmol.2019.4432.

**World Drug Report 2011 (UNODC)** is at <http://www.unodc.org/unodc/en/data-and-analysis/WDR-2011.html> This year's edition starts with an overview of the illicit drug situation worldwide and regionally, followed by more comprehensive discussions and statistical trends for the key transnational drug markets, namely opium/heroin, coca/cocaine, amphetamine-type stimulants and cannabis.

Wright AP, Becker WC, Schiff GD. Strategies for Flipping the Script on **Opioid Overprescribing**. *JAMA Intern Med*. 2015 Nov 2;1-2.

Wright JD, Huang Y, Melamed A, et al. Use and Misuse of **Opioids After Gynecologic Surgical Procedures**. *Obstet Gynecol*. 2019 Aug;134(2):250-260.

Xu KY, Presnall N, Mintz CM, et al. Association of **Opioid Use Disorder Treatment With Alcohol-Related Acute Events**. *JAMA Netw Open*. 2021 Feb 1;4(2):e210061

Xuan Z, Blanchette JG, Nelson TF, et al. Youth Drinking in the United States: Relationships With **Alcohol** Policies and Adult Drinking. *Pediatrics*. 2015 Jun 1.

Yee LM, Kacanek D, Brightwell C, et al; Pediatric HIV/AIDS Cohort Study. **Marijuana, Opioid, and Alcohol Use** Among Pregnant and Postpartum Individuals Living With HIV in the US. *JAMA Netw Open*. 2021 Dec 1;4(12):e2137162.

Yennurajalingam S, Arthur J, Reddy S, et al. Frequency of and Factors Associated With **Nonmedical Opioid Use Behavior Among Patients With Cancer** Receiving Opioids for Cancer Pain. *JAMA Oncol*. 2021 Jan 7. doi: 10.1001/jamaoncol.2020.6789

Yokell MA, Delgado MK, Zaller ND, et al. Presentation of **Prescription and Nonprescription Opioid Overdoses** to US Emergency Departments. *JAMA Intern Med*. 2014 Oct 27.

Young K. **US opioid epidemic**: it's harder to get the painkillers I legitimately need. *BMJ*. 2017 Feb 15;356;784.

Young LW, Hu Z, Annett RD, et al. Site-Level Variation in the Characteristics and Care of **Infants With Neonatal Opioid Withdrawal**. *Pediatrics*. 2021;147(1):e2020008839

Yuen WS, Chan G, Bruno R, et al. **Adolescent Alcohol Use Trajectories**: Risk Factors and Adult Outcomes. *Pediatrics*. 2020 Sep 23:e20200440

Yuma-Guerrero PJ, Lawson KA, Velasquez MM, et al. Screening, Brief Intervention, and Referral for **Alcohol Use in Adolescents**: A Systematic Review. *Pediatrics*. 2012 Jun 4.

Zamanian RT, Hedlin H, Greuenwald P, et al. Features and Outcomes of **Methamphetamine Associated Pulmonary Arterial Hypertension**. *Am J Respir Crit Care Med*. 2017 Sep 21.

Zaridze D, Lewington S, Boroda A, et al. **Alcohol** and mortality in Russia: prospective observational study of 151 000 adults. *Lancet*. 2014 Jan 30.

Zhang H, Kalluri HV, Bastian JR, et al. **Gestational changes in buprenorphine exposure**: A physiologically-based pharmacokinetic analysis. *Br J Clin Pharmacol*. 2018 Jun 5.

Zhang H, Xie M, Archibald SD, et al. Association of **Marijuana Use With Psychosocial and Quality of Life Outcomes Among Patients With Head and Neck Cancer**. *JAMA Otolaryngol Head Neck Surg*. 2018 Aug 2.

Zhang VS, Olsson M, King M. **Opioid and Benzodiazepine Coprescribing** in the United States Before and After US Food and Drug Administration Boxed Warning. *JAMA Psychiatry*. 2019 Sep 18.

Zhao SX, Deluna A, Kelsey K, et al. Socioeconomic Burden of **Rising Methamphetamine-Associated Heart Failure** Hospitalizations in California From 2008 to 2018. *Circ Cardiovasc Qual Outcomes*. 2021 Jul;14(7):e007638

Zhou H, Rentsch CT, Cheng Z, et al. Association of **OPRM1 Functional Coding Variant With Opioid Use Disorder**: A Genome-Wide Association Study. *JAMA Psychiatry*. 2020;10.1001/jamapsychiatry.2020.1206.

Zhu W, Cherner ME, Sherry TB, Maestas N. **Initial Opioid Prescriptions** among U.S. Commercially Insured Patients, 2012-2017. *N Engl J Med*. 2019 Mar 14;380(11):1043-1052.

Zibbell JE, Aldridge AP, Cauchon D, et al. Association of **Law Enforcement Seizures** of Heroin, Fentanyl, and Carfentanil With Opioid Overdose Deaths in Ohio, 2014-2017. *JAMA Netw Open*. 2019 Nov 1;2(11):e1914666.

Zorob R, Kowalchuk A, Mejia de Grubb M. **Buprenorphine Therapy for Opioid Use Disorder**. *Am Fam Physician*. 2018;97(5):313-320.

1 Centre for Addiction and Mental Health (CAMH): Defining addiction, dependence and abuse. Accessed online at Jan 19, 2010 at [http://www.camh.net/Publications/Resources\\_for\\_Professionals/Pregnancy\\_Lactation/defining\\_addiction.html](http://www.camh.net/Publications/Resources_for_Professionals/Pregnancy_Lactation/defining_addiction.html).  
[Also see CSAM definitions at CAMH Mental Illness and Addiction Index; Accessed online on Apr 06, 2021 at <http://www.camh.ca/en/health-info/mental-illness-and-addiction-index> ]  
2 Jovey RD, Ennis J, Gardner-Nix J, Goldman B, Hays H, Lynch M, Moulin D. Use of **opioid analgesics** for the treatment of chronic noncancer pain—a consensus statement and **guidelines** from the **Canadian Pain Society, 2002**. Pain Res Manag. 2003 Spring;8 Suppl A:3A-28A.  
3 Canadian Tobacco, Alcohol, and Drugs Survey (CTADS): summary of 2017. Accessed online 10 July, 2019 at <https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey/2017-summary.html> ;  
Canadian Alcohol and Drug Use Monitoring Survey (CADUMS). Accessed online Dec 12, 2016 at <http://www.hc-sc.gc.ca/hc-ps/drugs-droques/stat/index-eng.php#s2> Previously accessed online Jan 05, 2010 at <http://www.hc-sc.gc.ca/hc-ps/drugs-droques/stat/index-eng.php> {definition of harm: respondents having experienced at least one of 8 harms during the past year as a result of their drug use. The eight harms that were examined in the CADUMS include respondents feeling that their drug use had a harmful effect on their friendships of social life; physical health; work, studies, or employment opportunities; financial position; or that they felt their drug use led to legal problems; housing problems; or difficult learning things.)  
4 Brands B, Paglia-Boak, Sproule B, Leslie K, Adlaf E. Nonmedical use of opioid analgesics among Ontario students. Can Fam Physician 2010;56:256-62.  
5 Chen CY, Lin KM. Health consequences of illegal drug use. Curr Opin Psychiatry. 2009 May;22(3):287-92.  
6 Council of Ministers of Education. Sexuality and sexual health. In: Canadian Youth, Sexual Health and HIV/AIDS Study: factors influencing knowledge, attitudes and behaviours. Toronto: The Council; 2003. p55-130.  
7 National Institute on Drug Abuse (NIDA). Principles of Drug **Addiction Treatment**: A Research Based Guide. Accessed Dec 29, 2009 at <http://www.drugabuse.gov/PDF/PODAT/PODAT.pdf>  
8 The Sassi Institute. Substance Abuse Subtle Screening Inventory(s). Accessed online 25Mar, 2010 at <http://sassi.com/> .  
9 AUDIT Links: [http://whqlibdoc.who.int/hq/2001/WHO\\_MSD\\_MSB\\_01.6a.pdf](http://whqlibdoc.who.int/hq/2001/WHO_MSD_MSB_01.6a.pdf) ; <https://provider.ghc.org/open/caringForOurMembers/patientHealthEducation/alchoaudit.pdf>  
10 Ballantyne JC, Mao J. **Opioid** therapy for chronic pain. N Engl J Med. 2003 Nov 13;349(20):1943-53.  
11 Portenoy RK. **Opioid** therapy for chronic nonmalignant pain: a review of the critical issues.J Pain Symptom Manage. 1996 Apr;11(4):203-17.  
12 Taha, S. (2018) Best Practices across the Continuum of Care for Treatment of Opioid Use Disorder.Ottawa,Ont.:Canadian Centre on Substance Use and Addiction. Accessed online 18 June 2019 at <https://www.ccsa.ca/sites/default/files/2019-04/CCSA-Best-Practices-Treatment-Opioid-Use-Disorder-2018-en.pdf>  
13 Taha, S. (2018) Best Practices across the Continuum of Care for Treatment of Opioid Use Disorder.Ottawa,Ont.:Canadian Centre on Substance Use and Addiction. Accessed online 18 June 2019 at <https://www.ccsa.ca/sites/default/files/2019-04/CCSA-Best-Practices-Treatment-Opioid-Use-Disorder-2018-en.pdf>  
14 Sur AHW, Loh LC. A 38-year-old man who uses crack cocaine. CMAJ. 2015 Dec 8;187(18):1383-1384. doi: 10.1503/cmaj.150491.  
15 Standridge J, Adams S, Zotos A. Urine Drug Screening: A valuable office procedure. AFP 2010;81:635-40. [See also Jin M, Regier L. **Urine Drug Screening – RxFiles Q&A. March 2011**. Accessed online at <http://www.rxfiles.ca/rxfiles/uploads/documents/members/Urine-Drug-Screening-UDS-QandA.pdf>  
16 Prescription Opioid Analgesics and Stimulants Marketed in Canada. Accessed March 09, 2010 at: [http://www.purdue.ca/pdf/Pill\\_Brochure\\_English.pdf](http://www.purdue.ca/pdf/Pill_Brochure_English.pdf)  
17 Saskatchewan Link: <http://www.health.gov.sk.ca/alcohol-and-drug-services?Anc=bbe26497-3aae-49ff-afdc-fc37c2e4f8f&Pa=35f808e1-f386-4fec-ba90-b5ce33ffd1f0>  
18 Medical Letter. **Acute Reactions to Drugs of Abuse**. 2002;44(1125):21-24.  
19 **UpToDate** 2009. Accessed Dec 30, 2009 @ [www.uptodate.com](http://www.uptodate.com)  
20 Teitelbaum S, DuPont R, Bailey J. Cannabis (**marijuana**) use disorders in adults: Treatment, prognosis, and long-term medical effects. UpToDate 2009.Accessed Dec 30, 2009 @ [www.uptodate.com](http://www.uptodate.com)  
21 **RxFiles Cannabinoids** – An Overview in RxFiles Drug Comparison Charts book. Accessed online Dec 30, 2018 at <http://www.rxfiles.ca/rxfiles/uploads/documents/Pain-QandA-cannabinoids.pdf>  
22 Christie B. Heroin contaminated with anthrax has killed 11 people. BMJ. 2010 Feb 15;340:c937. doi: 10.1136/bmj.c937. Accessed online Feb 22, 2010 at: [http://www.bmj.com/cgi/content/extract/340/feb15\\_1/c937](http://www.bmj.com/cgi/content/extract/340/feb15_1/c937)  
23 Dhalla IA, Mamdani MM, Sivillotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of **opioid** analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009 Dec 8;181:891-6.  
24 Butt P, McLeod M, Becker-Irvine C. Opioid Withdrawal Protocol accessed online 17 Mar, 2010 at: [http://www.quadrant.net/cps/pdf/Opioid\\_Withdrawal\\_Protocol.pdf](http://www.quadrant.net/cps/pdf/Opioid_Withdrawal_Protocol.pdf)  
25 Jones HE, Kallentbach K, Heil SH, et al. Neonatal abstinence syndrome after **methadone** or **buprenorphine exposure**. N Engl J Med. 2010 Dec 9;363(24):2320-31.  
26 Centre for Addiction and Mental Health (CAMH): **Alcohol**; accessed Dec 30, 2009 at: [http://www.camh.net/About\\_Addiction\\_Mental\\_Health/Drug\\_and\\_Addiction\\_Information/alcohol\\_dyk.html](http://www.camh.net/About_Addiction_Mental_Health/Drug_and_Addiction_Information/alcohol_dyk.html)  
27 CDC: **Alcohol** FAQ accessed Dec 30, 2009 at: <http://www.cdc.gov/alcohol/faqs.htm>  
28 Wilson J. In the clinic: Alcohol use. Ann Intern Med. 2009;150:ITC3-1-15; quiz ITC3-16. Access online 03Mar, 2009 at <http://www.annals.org/content/150/5/ITC3-1-full.pdf+html?itacabout>  
Ruidavets Jean-Bernard, Ducimetière Pierre, Evans Alun, et al. Patterns of **alcohol consumption** and ischaemic heart disease in culturally divergent countries: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). BMJ 341:doi:10.1136/bmj.c6077 (Published 23 Nov 2010)  
Rösner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists (**naltrexone**) for alcohol dependence. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD001867. DOI: 10.1002/14651858.CD001867.pub3. Naltrexone appears to be an effective and safe strategy in alcoholism treatment. Even though the sizes of treatment effects might appear moderate in their magnitudes, these should be valued against the background of the relapsing nature of alcoholism and the limited therapeutic options currently available for its treatment.  
McCambridge J, McAlaney J, Rowe R (2011) Adult Consequences of Late **Adolescent Alcohol Consumption**: A Systematic Review of Cohort Studies. PLoS Med 8(2): e1000413. doi:10.1371/journal.pmed.1000413  
Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected **cardiovascular disease** outcomes: a systematic review and meta-analysis. BMJ 2011; DOI:10.1136/bmj.d671.  
Brien SE, Ronksley PE, Turner BJ, et al. Effect of alcohol consumption on biological markers associated with risk of **coronary heart disease**: systematic review and meta-analysis of interventional studies. BMJ 2011; DOI: 10.1136/bmj.d636.  
Sheron N, Hawkey C, Gilmore I. Projections of **alcohol deaths-a wake-up call**. Lancet. 2011 Feb 18.  
28 Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, Randall CL. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009 Sep;33(9):1582-8.  
29 Martinotti G, di Nicola M, Frustaci A, Romanelli R, Tedeschi D, Guglielmo R, et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction. 2010 Feb;105(2):288-99.  
30 Shinn A, Greenfield S. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psych 2010; doi:104088/jcp.08r04062gry.  
Kranzler HR, Covault J, Feinn R, et al. Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism. Am J Psychiatry. 2014 Feb 14.  
31 Urbina A, Jones K. Crystal methamphetamine, its analogues, and HIV-infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis. 2004;38:890-894.  
32 Schifano F, Corkery J, Naidoo V, Oyefeso A, Ghodse H. Overview of **Amphetamine**-Type Stimulant Mortality Data - UK, 1997-2007. Neuropsychobiology. 2010 Jan 29;61(3):122-130.  
33 Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet. 1999;352:1751-1752.  
34 Kish SJ. Pharmacologic mechanisms of **crystal meth**. CMAJ. 2008;178(13):1679-82.  
35 Winslow BT, Voorhees KI, Pehl KA. **Methamphetamine** abuse. Am Fam Physician. 2007 Oct 15;76(8):1169-74.  
36 Centers for Disease Control and Prevention (CDC). Agranulocytosis associated with **cocaine** use - four States, March 2008-November 2009. MMWR Morb Mortal Wkly Rep. 2009 Dec 18;58(49):1381-5.  
Buchanan Jennie A., Heard Kennon, Burbach Cynthia, et al. Prevalence of Levamisole in Urine Toxicology Screens Positive for Cocaine in an Inner-City Hospital. JAMA. 2011;305(16):1657-1658.doi:10.1001/jama.2011.531  
Muirhead Trevor T., Eide Melody J.. Toxic Effects of **Levamisole** in a Cocaine User-Images. N Engl J Med 2011; 364:e52.  
37 Goldstein RA, DesLauriers C, Burda AM. **Cocaine**: history, social implications, and toxicity--a review. Dis Mon. 2009 Jan;55(1):6-38.  
Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of **cocaine**. Circulation. 2010 Dec 14;122(24):2558-69.  
Gardy JL, Johnston JC, Sui SJ, et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med. 2011 Feb 24;364(8):730-9.  
38 **Health Canada: Safe Use of Energy Drinks**. Accessed online at <http://www.hc-sc.gc.ca/hl-vs/vh-vs/food-aliment/boissons-energ-drinks-eng.php> . {Excessive drinking of energy drinks or **mixing them with alcohol** can have serious health effects. Energy drinks are meant to supply mental and physical stimulation for a short period of time. They usually contain **caffeine**, taurine (an amino acid, one of the building blocks of protein), vitamins and glucuronolactone, a carbohydrate. Energy drinks should not be confused with sports drinks such as Gatorade® or Powerade®. Sports drinks re-hydrate the body and provide sugars, which the body burns to create energy and replenish electrolytes.}  
39 **RxFiles: Weight Loss** – Herbal Products Chart from RxFiles Drug Comparison Charts book. Accessed Dec 30, 2018 at: <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-WeightLoss-HerbalProducts.pdf>  
40 Reccoppa L, Malcolm R, Ware M. **Gabapentin abuse** in inmates with prior history of cocaine dependence. Am J Addict. 2004 May-Jun;13(3):321-3.  
41 Pharmacist's Letter/Prescriber's Letter. **Quetiapine** (Seroquel) **Abuse**. Oct 2007;23(23):Number 231008.  
42 **RxFiles: Smoking Cessation** Chart from RxFiles Drug Comparison Charts book. Accessed Dec 30, 2018 at: <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-Smoking-Cessation.pdf>  
43 DeBeck K, Kerr T, Li K, Fischer B, Buxton J, Montaner J, Wood E. Smoking of **crack cocaine** as a risk factor for HIV infection among people who use injection drugs. CMAJ. 2009 Oct 27;181(9):585-9.  
44 Centre for Addiction and Mental Health (CAMH): Exposure to Psychotropic Medications and Other Substances during **Pregnancy** and Lactation: A Handbook for Health Care Providers; accessed Dec 30, 2009 at: [http://www.camh.net/Publications/Resources\\_for\\_Professionals/Pregnancy\\_Lactation/index.html](http://www.camh.net/Publications/Resources_for_Professionals/Pregnancy_Lactation/index.html)  
45 Tenenbein M. Do you really need that **emergency drug screen**? Clin Toxicol (Phila). 2009 Apr;47(4):286-91.  
46 Cork A, Ferns T. Managing alcohol related aggression in the emergency department (Part II). Int Emerg Nurs. 2008 Apr;16(2):88-93.  
47 Wolf L. Considerations in triage for the intoxicated patient. J Emerg Nurs. 2008 Jun;34(3):272-3.  
48 Frithsen IL, Simpson WM Jr. Recognition and management of acute medication poisoning. Am Fam Physician. 2010 Feb 1;81(3):316-23.  
49 Haber PS, Demirkol A, Lange K, Mumion B. Management of **injecting drug users** admitted to hospital. Lancet. 2009 Oct 10;374(9697):1284-93.  
50 Jena AB, Goldman DP, Foster SE, Califano JA Jr. Prescription medication abuse and illegitimate internet-based pharmacies. Ann Intern Med. 2011 Dec 20;155(12):848-50.  
51 Vonghia L, Leggio L, Ferrulli A, Bertini M, Gasbarrini G, Addolorato G; Alcoholism Treatment Study Group. Acute alcohol intoxication. Eur J Intern Med. 2008 Dec;19(8):561-7.  
52 Malone D, Friedman T. Drunken patients in the general hospital: their care and management. Postgrad Med J. 2005 Mar;81(953):161-6.  
53 Beckley I, Ansari NA, Khwaja HA, Mohsen Y. Clinical management of cocaine body packers: the Hillingdon experience. Can J Surg. 2009 Oct;52(5):417-21.  
54 Chen CY, Lin KM. Health consequences of **illegal drug use**. Curr Opin Psychiatry. 2009 May;22(3):287-92.  
55 Flood M, Buckwalter KC. Recommendations for mental health care of older adults: Part 2—an overview of dementia, delirium, and **substance abuse**. J Gerontol Nurs. 2009 Feb;35(2):35-47



---

<sup>56</sup> In: Hoffman RS, Howland M, Lewin NA, Nelson LS, Goldfrank LR. eds. Goldfrank's Toxicologic Emergencies, 10e. McGraw-Hill; Accessed May 25, 2021. <https://accesspharmacy.mhmedical.com/content.aspx?bookid=1163&sectionid=64562562>

<sup>57</sup> Special Advisory Committee on the Epidemic of Opioid Overdoses. **Opioid- and Stimulant-related Harms in Canada**. Ottawa: Public Health Agency of Canada; June 2021. <https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants>